## BLOOD VOLUME DETERMINATIONS

## IN

SURGICAL PATIENTS

# BLOOD VOLUME DETERMINATIONS

## SURGICAL PATIENTS

by

Francis R. Coughlin, Jr., B.Sc., M.D.

Research Assistant, Experimental Surgical Laboratories, McGill University, Montreal. Demonstrator In Anatomy, McGill University, Montreal. Hosmer Teaching Fellow, McGill University, Montreal. Clinical Fellow In Surgery, Royal Victoria Hospital, Montreal.

A McGill University Thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Experimental Surgery.

August, 1955

Faculty of Medicine McGill University, Montreal.

## PREFACE:

The work presented in this manuscript was performed during the tenure of a Hosmer Teaching Fellowship in the Department of Experimental Surgery of McGill University from July, 1954 to June, 1955. Experience with the T-1824 method of blood volume determinations as used at the New York Hospital -Cornell Medical Center in 1952-1953 awakened the author's interest in the potentialities of a Blood Volume Laboratory in a teaching hospital with a surgical service which dealt with complicated problems of water and electrolyte metabolism and blood volume homeostasis in poor-risk patients and patients subjected to extensive operative procedures. Over the past several years, Dr. James R. McCorriston of the Department of Surgery of the Royal Victoria Hospital has been interested in the radioactive iodinated human serum albumin (RIHSA) method of determining blood volume and the application of the method to surgical patients of the Royal Victoria Hospital.

Dr. McCorriston suggested this project as a thesis subject and supervised the details of its execution.

- i -

It has been a pleasure and a beneficial experience to work with Dr. McCorriston over the past year. Dr. McCorriston has been generous in the time which he has allowed to discussing problems of fluid and electrolyte balance and the thesis subject with the author. Dr. McCorriston's enthusiasm and advice have made this project a stimulating introduction to clinical r esearch.

In the summer of 1954, this project was discussed with Dr. Louis Lowenstein of the Hematology Service of the Royal Victoria Hospital. Dr. Lowenstein was interested in initiating a program of radioactive isotope studies of hematologic disorders for the Hematology Service. It was decided to make this investigation and the developement of a Blood Volume Laboratory, a joint project of the Department of Surgery and the Hematology Service. Under the direction of Dr. Lowenstein, Dr. Maurice R. Dufresne, Clinical Fellow in Medicine of the Royal Victoria Hospital, and the author commenced the work presented in this thesis. It was a pleasure to work with Dr. Dufresne throughout the year. The development of the method used, and the results presented are the result as much of Dr. Dufresne's work as the author's. Dr. Dufresne has completed an equal number of blood volume determinations in medical patients and it is hoped that our combined data in 500-600 determinations of blood volume may be the subject of publication in the future under the auspices of the Hematology Service and the Department of Surgery of the Royal Victoria Hospital.

Appreciation is due to Dr. Donald R. Webster, Director of the Department of Experimental Surgery and Surgeon-In-Chief of the Royal Victoria Hospital. This project was commenced with Dr. Webster's approval and encouragement and discussed with him throughout the year.

Dr. Carleton B. Peirce, Chairman of the Department of Radiology of the Royal Victoria Hospital, obtained permission from the Atomic Energy Commission for use of the radioactive iodine, approved the proposed project and encouraged the investigation. Dr. Peirce's guidance was most valuable in suggesting details of safe radiation dosage for adults and children and precautions in the use of the  $I^{131}$ .

Dr. Lloyd Stephens-Newsham, Physicist of the Department of Radiology of the Royal Victoria Hospital, provided the counter used and instructed Dr. Dufresne and the author in use of the scaler and the techniques of standardization of equipment. Dr. Stephens-Newsham was kind enough to order the radioactive iodine as required.

Dr. Darrell D. Munro, Surgeon of the Royal Edward Laurentian Hospital, Montreal, invited the author to study the blood volume of patients with tuberculosis at that hospital. Over one month (May-June, 1955) Dr. Munro supervised the investigation and allowed the pre- and post-operative studies and measurements in the operating room to be made.

Dr. David R. Murphy of the Montreal Children's Hospital was kind enough to allow an investigation of blood volume in childhood to be performed on patients of the Surgical Service. Miss Jeanne M. Wirth, Secretary of the Department of Experimental Surgery, McGill University has typed this manuscript, the tables and the charts. Miss Wirth has been most helpful during the entire year, has facilitated the work of each of the members of the Surgical Diploma Course and has been responsible for scheduling lectures, arranging Seminars, correspondence and innumerable details which have contributed to the value of the year for all of us.

Mr. Paul Roustan has prepared the photographs used and Miss Barbara Heward drew the graphs.

Finally, my appreciation is due to my wife and children who were most patient while the material for this thesis was compiled and the actual writing of the thesis done.

> Francis R. Coughlin, Jr., McGill University, August, 1955.

- V -

PREFACE		i
TABLE OF CONTE	NTS	vi
FIGURES		xi
TABLES	x	iii
CHARTS		xv
PART I IN	TRODUCTION	l
PART II RE	VIEW OF THE LITERATURE	10
1)	Dilution principle	10
2)	Ideal test substance	13
3)	Normal blood volume and its expression in relation to physical measurements.	17
	A- Values reported	17
	B. Relation of blood volume to body type	23
4)	The venous hematocrit and trapped plasma	29

Page

TABLE OF CONTENTS

5)	Body hematocrit concept	35
	A- Definitions	35
	B- Variations in composition of blood in different sized vessels	41
	C- Simultaneous plasma volume- red cell volume dilution measurements	43
	D- Significance of the body-venous hematocrit difference in relation to the plasma dilution hematocrit method of blood volume determin- ation	49
6)	Characteristics of radioactive iodinated serum albumin (RIHSA)	52
	A- Disappearance from serum	53
	B- Urinary excretion	54
	C- Thyroid uptake	55
7)	Blood volume and concentration indices	57
8)	Physiologi <b>cal var</b> iations in blood volume	60
	A- Effect of activity	60
	B- Differences between infants and adults	61
	C- Pregnancy	63

Page

.

9) Medical and surgical conditions affecting blood volume	64
10) Circulatory dynamics	68
ll) Physiological regulation of plasma volume	72
12) Transfusion solutions	77
13) Specific transfusion therapy	82
14) Pathology of blood volume reduction	87
A- Acute blood volume reduction	87
B. Acute plasma volume reduction	92
C- Chronic blood volume reduction	94
15) The spontaneous restitution of normal blood volume occurring in hypovolemic and hypervolemic states	96
16) Compensation for alterations in blood wolume and composition	98
A- Acute total blood volume deficit	99
B- Acute plasma volume deficit 1	.04
17) Tolerance of blood volume definite 1	06

18)	Clinical significance of factors affecting the precision of blood volume measurements	110
19)	Operative blood loss measurements	119
	A- Colorimetric method	119
	B- Gravimetric method	121
	C- Blood volume determinations and estimate of operative blood loss	123
	D- Gravimetric body weight method	126

## PART III MATERIALS AND METHODS

A) Materials 128 1- Laboratory space 128 2- Counting equipment 129 3- Centrifuge 131 4- RIHSA 132 5- Heparin 134 6- Sterile normal saline 134 7- Laboratory glassware and apparatus 135 8- Decontamination and cleaning of 136 equipment 9- Equipment used in performing test 137

#### Page

128

Pa	ØR
	<b>E U</b>
	_

B) Methods			139
		l- Pattern of investigation	139
		2- RIHSA blood volume method	141
		3- RIHSA blood volume calculations	146
		4- Serial RIHSA blood volume determinations	147
		5- Gravimetric measurement of operative blood loss	148
PART	IV	RESULTS	150
PART	v	DISCUSSION OF RESULTS	195
		A) Results in normal subjects	195
		B) Technique and counter standardization	197
		C) Pulmonary tuberculosis series	198
		D) Results of single and serial studies presented in Charts 1 to 4	207
		E) Interpretation of blood volume deter- minations. Estimate of volume deficits	211
PART	VI	SUMMARY	216
PART	VII	CONCLUSIONS	218

- x -

BIBLIOGRAPHY

221

## FIGURES

ļ

FIGURE	1	Normal blood volume values (adult male)	28
FIGURE	2	Body-venous hematocrit difference	33
FIGURE	3	Body-venous hematocrit difference	34
FIGURE	4	Blood volume and hemodynamic response in massive gastrointestinal hemorrhage	67
FIGURE	5	Components of transfusion solutions	76
FIGURE	6	Factors influencing blood volume	86
FIGURE	7	RIHSA blood volume method (Royal Victoria Hospital)	142
FIGURE	8	Replacement of whole blood loss: blood volume changes associated with a major operative procedure	171
FIGURE	9	Replacement of whole blood loss in the surgical treatment of hemorrhage from a duodenal ulcer	172

•

FIGURE 10	Replacement of red cell deficit	173
FIGURE 11	Expansion of plasma volume occurring during ACTH therapy	174

Page

- xii -

•

## TABLES

P	a	g	e
_		_	_

TABLE 1	Composite table of mean values for all groups studied by the RIHSA blood volume method	152
TABLE 2	Normal female subjects studied by RIHSA method	153
TABLE 3	Normal male subjects studied by RIHSA method	154
TABLE 4	RIHSA blood volume measurements of normal male and female subjects in relation to surface area	155
TABLE 5	RIHSA blood volume in normal children	156
TABLE 6	Technique standardization Reproducibility of serial determinations	157
TABLE 7	Technique standardization Syringe precision test	158
TABLE 8	Technique standardization Error due to counter	159
TABLE 9	Technique standardization Variation of replicate sample counts	160

- xiii -

TABLE 10	Technique standardization The comparison of one and two ml. sample counts	161
TABLE 11	Technique standardization Effect of counting geometry on error	162
TABLE 12	Counter standardization Voltage setting	163
TABLE 13	Counter standardization Pulse height selector setting	164
TABLE 14	Pulmonary tuberculosis surgery RIHSA blood volume in pre-operative patients	165
TABLE 15	Pulmonary tuberculosis surgery Summary of blood volume changes associated with pulmonary tuberculosis surgery	166
TABLE 16	Pulmonary tuberculosis surgery Change in total blood volume associated with surgery	167
TABLE 17	Pulmonary tuberculosis surgery Estimate of operative blood loss as calculated from pre- and post-operative RIHSA blood volume measurements	168
TABLE 18	Pulmonary tuberculosis surgery Measurement of operative blood loss and replacement	169
TABLE 19	Pulmonary tuberculosis surgery Post-operative blood volume studies	170

Page

## CHARTS

Page

CHART I	RIHSA blood volume determinations in surgical conditions requiring replacement of total blood volume deficit and red cell volume deficit	175
CHART II	RIHSA blood volume determinations in conditions associated with abnormalities of body water and electrolyte metabolism in geriatric and poor-risk patients	182
CHART III	RIHSA blood volume determinations in miscellaneous surgical conditions	187
CHART IV	RIHSA blood volume determinations in pre- and post-operative cases	191

## PART I INTRODUCTION

The surgical service of a teaching hospital presents an unique opportunity for the study of the physiological and pathological response of individuals to alterations in circulating blood volume. Surgeons are frequently confronted with problems relating to the management of dehydration, massive hemorrhage, thermal and mechanical trauma and the preparation of elderly, malnourished, chronically ill patients for major operative procedures. The hemodynamic response of patients to anaesthesia and operation is an important factor determining operative mortality and morbidity rates.

Progress in the developement of new operative techniques of organ resection, vascular anastomosis and cardiac surgery has been associated pari passu with improved pre- and post-operative care, safer anaesthetic techniques, the use of antibiotics and the availability of whole blood for transfusion. At the same time, extensive operative

- 1 -

procedures have been made available to and have even been designed for patients who are poor operative risks. Massive resection procedures such as radical pelvic exenteration are performed for malignant disease which occurs more commonly in patients of advanced age, many suffering from concurrent chronic cardiovascular, renal or pulmonary disease.

Many operative procedures are potentially associated with operative blood loss and replacement which may amount to exchange transfusion (92, 104). Blood loss and replacement of this magnitude can present a serious challenge to the debilitated patient's ability to maintain circulatory homeostasis and equilibrium of circulatory dynamics. The experience of three major wars in the past forty years has focussed the attention of surgeons on the role of the transfusion of blood and plasma expanders in the treatment of hemorrhage and the prevention of the clinical state of shock (134).

The efficacy of the transfusion of whole human blood in cases of acute hemorrhage was noted in the nineteenth century. Blundell (2,5) in 1829 transfused a patient who had had a post-partum hemorrhage. William Stewart Halsted (185) performed a transfusion using a syringe in 1881. Blum (24) stated in 1876 that "hemorrhage was shock and shock, hemorrhage". However, the measurement of blood volume in the casualties of World War I promoted the idea of shock as a problem of acute blood volume deficiency. This concept has been consistently maintained. Stored plasma became available in large quantities during World War II. Although plasma by expanding the total blood volume was efficacious in the treatment of casualties who had sustained wound trauma and hemorrhage, Churchill (32) was of the opinion that whole blood when available appeared to be preferable in restoring blood volume deficits due to whole blood loss. The availability of large quantites of blood, plasma and synthetic plasma expanders during

- 3 -

the Korean War permitted a comparative trial of these agents in the resuscitation of severely wounded casualties. Though plasma volume expanders were satisfactory and eliminated the problem of homologous serum hepatitis, whole blood in large quantities was recommended by Prentice (129,130), Artz (7,8), and Howard (86,87) for the treatment of blood volume deficits due to wound trauma and hemorrhage.

Since 1915, when Keith, Rowntree and Geraghty (94) described the vital red dye method of the measurement of the blood volume in living human subjects a complex and almost incomprehensible literature has developed on the subject of blood volume measurement, The principle expounded by these authors in 1915 continues to be used today although a variety of test substances, modifications of sampling procedure, and technical methods have subsequently been reported. Practically, surgeons are interested in the blood volume determination as a means of approaching a more rational prescription of transfusion therapy conducive to lowered patient mortality and morbidity. The laboratory determination of blood volume gives information precisely ascertainable in no other way. A laboratory test of blood volume which can be performed simply and provides reliable data in a short period of time can be of great value in guiding transfusion therapy in surgical patients.

Recent reviews (74, 135, 136) of the literature on blood volume determinations emphasize that fairly precise estimates of blood volume can be made with the methods available at present despite the controversy as to which is the better method. However, no ideal method of blood volume determination has yet been developed. The dye T-1824 has been used most widely for the clinical determination of blood volume and has been recommended for the simplicity, rapidity and precision with which determinations may be made.

- 5 -

In 1950 Storaasli, Krieger, Freidell and Holden (166) described the use of radioactive iodinated human serum albumin, known as RIHSA, for the measurement of blood volume clinically. This method offers simplicity, rapidity and precision in the performance of routine blood volume studies. The scintillation counting technique permits tracer doses of radioactivity to be used. Successive determinations are not affected by increasing concentrations of the radio-isotope in the patient's blood, hemolysis or lipemia. Moreover the blue discoloration of the skin which occurs when serial T-1824 studies are performed is eliminated. Time consuming in vitro labeling of blood elements such as is done with the recent red cell tagging methods is eliminated. Thus the RIHSA method was chosen for use in this investigation of blood volume in surgical patients.

It was desired to study the RIHSA method itself initially in order to develop a practical technique applicable for routine use in a hospital such as the Royal Victoria Hospital, Montreal, Quebec,

- 6 -

where it was intended to establish a Blood Volume Laboratory which would be at the disposal of the clinical staff. This necessitated an appraisal of the various methods described for the performance of the RIHSA determination and modification of the procedure to the available scintillation counting apparatus. Following a standardization of the equipment and technique used, it was then proposed to study the blood volume in various groups of patients.

Normal adult male and female subjects were found amoung personnel and patients of the Royal Victoria Hospital. These subjects provided a basis for the comparison of the blood volumes of subjects who had clinical evidence of abnormal hemodynamics or abnormal blood volume. Individual and serial blood volume determinations were performed on subjects who had abnormalities of electrolyte balance or who had large blood losses and were being treated for these conditions. Emphasis was placed on elderly and poor-risk patients.

- 7 -

In order to ascertain the relationship of age to blood volume a group of normal subjects in early childhood was studied at the Montreal Children's Hospital.

The effect of chronic illness on blood volume was studied in a group of preoperative patients with tuberculosis at the Royal Edward Laurentian Hospital, Montreal, Quebec. A detailed study of the measurement of operative blood loss in the surgery of pulmonary tuberculosis was conducted at this institution.

In general, it was hoped to learn something about: the general principles of the measurement of blood volume by the RIHSA method; the factors involved in the maintenance of the blood volume hemostasis in surgical patients; the rational rules of transfusion therapy in surgical patients.

During the period from the summer of 1954 until late spring of 1955 a method for the

- 8 -

performance of RIHSA blood volume determinations was evolved and over 300 determinations performed on human subjects,

#### PART II REVIEW OF THE LITERATURE

#### 1 - DILUTION PRINCIPLE:

The measurement of blood volume in living human beings has since 1915 been performed by the injection of test substances into the circulating blood, allowing a period of time to elapse for mixing and then measuring the concentration of test substance in the plasma or red cells (94). From the dilution of the test substance can be calculated the plasma volume or the red cell volume. Total blood volume is measured by the simultaneous performance of plasma volume and red cell volume determinations or by the performance of either plasma volume or red cell volume determination and the venous hematocrit. (The venous hematocrit is considered as an indicator of the ratio of plasma or red cell volume to whole blood volume). Gregersen (75) has commented that the techniques devised for

blood volume determination in living man depend on the volume distribution of a known amount of some suitable test substance in the volume to be measured. This dilution principle has been phrased in other words by Edelman (48): "the extent to which a substance is diluted in a solvent constitutes a measure of the volume of the solvent". The method assumes that a definite compartment is measured in the case of plasma volume measurements. This compartment is really the circulating albumin pool - which Fox (61) states may be larger than the true plasma volume, and in the case of red cell volume measurements the compartment is that of the active circulating red cell mass which may or may not represent the true red cell volume. The test substances used, then, are divided into two categories: the substances used to measure plasma volume directly and the substances used to measure red cell volume directly. The test substances

most widely used clinically have been the dye vital red (94), T-1824 (67), radioactive iodinated human serum albumin (166), and labelled red cells. The red cells may be labelled in vivo by the inhalation of CO (6), or labelled in vitro by the isotopes,  $P^{32}$  (84),  $Cr^{51}$  (163), (using the patient's own cells), or labelled in a donor by his ingestion of  $Fe^{59}$  (79), or labelled by being of a different serological type (Ashby technique (9) --depending upon differential agglutination).

#### 2 - IDEAL TEST SUBSTANCE:

For clinical use the characteristics of an ideal test substance for blood volume determination must be considered under the classifications of:

- 1) precision desired
- convenience and rapidity with which the determination may be performed and results known
- 3) the expense of having the laboratory facilities for the test available.

Test substances must, of course, be non-toxic in the dosage used, have no pharmacological action on the circulatory system for a long enough period to allow thorough mixing and representative sampling, must mix readily with the normal constituents of the blood and must be easily identified and measured (136). For practical clinical purposes a method which is precise within two units of blood (1000 cc.)

is a minimum standard; actually a method of blood volume measurement precise within one unit if blood is desired. Beling (15) states that the outside limits of error of routine T-1824 blood volume determinations is probably 10%, that is, 500-600 cc. in a normal 70 Kgm male adult, but that a reproducibility within 5% error, an entirely satisfactory standard of biological measurement, is claimed for successive T-1824 blood volume determinations. Brady (27) found a reproducibility of 3% for serial I<sup>131</sup> -RIHSA blood volume measurements. Royster (145) found that T-1824 method of determining plasma volume plus the hematocrit was accurate to plus or minus 250 cc. in estimating changes in blood volume associated with operative blood loss and transfusion replacement. Frank (62) found  $Cr^{51}$  measurements to be reproducible within 3%. Thus it appears that clinically satisfactory measurements can be obtained with care in the technique using the T-1824, I<sup>131</sup>, Cr<sup>51</sup>, or P<sup>32</sup> methods. The reproducibility does

- 14 -

not mean that the true blood volume is measured, but that the volume in which the test substance has mixed, the active circulatory volume, has been measured with precision.

Serial samples with the Cr<sup>51</sup> method can vary less than 5% over a one hour period according to Prentice (129) and the mixing curve of I<sup>131</sup> RIHSA according to Storaasli (166) is logarithmic at a rate not inconsistent with simple removal of the tagged albumin from the circulatory system rather than "slow mixing" with a non-actively circulating volume of blood. These facts provide good evidence that the  $I^{131}$  -RIHSA measurement approximates the plasma volume or at least the albumin pool and depots of plasma or cells do not exist under normal circulatory conditions. For surgical purposes, when rapid measurements may be necessary, the dye (T-1824) or I<sup>131</sup> - RIHSA methods are inherently less complicated, more rapid, less elaborate, requiring only one injection and a blood sample. The removal of blood, tagging of cells at room temperature

- 15 -

with isotope  $(P^{32} \text{ or } Cr^{51})$  and reinjection and sampling do not commend themselves for use when part of the value of results consist in the rapidity and simplicity with which the results may be obtained. At such times, accurate rapid information may be required in the interests of the patient's well-being and, in general, greater simplicity of performance of a laboratory test may be rewarded with fewer errors. If blood volume determinations were as readily performed, facilities for performing the determination would undoubtedly be present wherever hemoglobinometry is performed. Blood volume determinations are reported by McInnes (104) as being of great value in instances of radical pelvic exenteration when a complete change of circulatory blood volume may occur during the operative period. Berlin (20), McInnes (104), Beling (15) have established blood volume laboratories for the performance of these determinations on a routine basis in chest surgery (20), radical pelvic surgery (104) and general surgery (15).

- 16 -

## 3 - NORMAL BLOOD VOLUME AND ITS EXPRESSION IN RELATION TO PHYSICAL MEASUREMENTS:

## A) - Values reported:

Blood volume has been related to weight, height and surface area. Blood volume has been stated in percentage of body weight; cubic centimeters per kilogram of body weight, per centimeter of height, per square meter of surface area. Average normal values for the various methods may be found in Wintrobe's textbook (192). Average normal values have varied with the method used but there is fairly good agreement. Hence Bischoff's (23) direct method of exsanguination gave a normal value of 7.7% of the body weight or 73 cc/Kgm. In 1915, Keith, Rowntree and Geraghty (94), using vital red in 18 males, reported: Plasma volume 49 cc/Kgm, 1764 cc/m<sup>2</sup>; total blood volume 85.8 cc/Kgm. In 1937, Gibson and Evans (68) using T-1824 in 41 females reported: plasma volume

41.5 cc/Kgm, 1520 cc/m<sup>2</sup>; total blood volume 46.1 cc/Kgm, 2523 cc/m<sup>2</sup>; cell volume 24.6 cc/Kgm. In 1950, Berlin (18) using P<sup>32</sup> - tagged red cells reported values in 71 males; total blood volume 69.0 cc/Kgm; red cell volume 29.9 cc/Kgm; plasma volume 38.7 cc/Kgm. In 1951, Berlin (16) using P<sup>32</sup> - tagged red cells reported values in 16 females: total blood volume 64.4 cc/Kgm; red cell volume 27.0 cc/Kgm; plasma volume 37.0 cc/Kgm. In 1950, Storaasli, (166) using RIHSA reported values in 31 males: plasma volume 40.3 cc/Kgm; total blood volume 73.0 cc/Kgm. In 1953, Brady (27) in a comparative study of the RIHSA, P<sup>32</sup> and T-1824 methods reported in 25 subjects: RIHSA plasma volume 43.6 cc/Kgm; RIHSA total blood volume 71.8 cc/Kgm; T-1824 plasma volume 45.4 cc/Kgm; T-1824 total blood volume 81.3 cc/Kgm; P<sup>32</sup> red cell volume 30.1 cc/Kgm. In 1953, Gray and Frank (72) in a comparative study of radioactive chromic chloride and radioactive sodium chromate in 10 adults

performance of routine blood volume determinations.

The values reported by various means of blood volume determination as stated in terms of the relation of blood volume to body weight, height and surface area, do not completely agree. When the same parameter of physical measurement is used ( e.g. weight in kilograms), some variation in the reported values for blood volume may be attributed to such factors as:

- Differences in test substances employed. Specifically, the volume distribution of the test substances employed differs during the period allowed for mixing. Thus Mollison (107) states that the carbon monoxide red cell method may give an artifactitiously higher value for red cell mass than the later isotope methods of tagging red cells.
- Differences in time of collection of the post-injection blood sample. If, for example, dye has begun to leave the circulation

- 20 -
in significant amounts, collection of a "delayed" blood sample will result in over-estimate of the plasma volume because the volume distribution of the dye is larger.

- 3) Differences in the criteria for sampling of the normal population. For example, the inclusion of values obtained from individuals recovering from acute illness as done by Schreiber (50), may introduce a bias so that the mean value is not truly representative of the normal.
- 4) Differences in the mode of calculation of total blood volume when the dilution - hematocrit method is used. Systematic error may occur in the calculation when trapped plasma differs from the factor used and when body-venous hematocrit difference is neglected as pointed out by Mollison (107).
- 5) Individual physiological variation in intravascular volume. Though the average volumes

generally agree well when calculated in the same manner and when a satisfactory test substance is used, there is a wide range of values in normal individuals listed by various authors, which may in part be due to individual physiological variation.

### B) - Relation of blood volume to body type:

Most commonly and most con-

viently (107) the blood volume is expressed in terms of cubic centimeters per kilogram of body weight. It is recognized that the average values cannot be rigidly applied in the estimation of deficits because of the wide range of normal values. However, some authors have satisfactorily applied arbitrary standards of excess or deficit based on average normal values for the method which they are using. For example see Berlin's (19) article on blood volume in pulmonary tuberculosis.

Ravdin (135) in a review of the literature on the problem of blood volume maintanence and regulation concludes that effective circulating blood volume is correlated closely with the mass of active metabolizing tissue and that an approximation sufficiently accurate for

- 23 -

average clinical use may be derived by measurement of the patient's height, and the calculation of a theoretically normal blood volume for an individual of average normal weight for the patient's height.

Gibson and Evans (68) in 1937

related estimates of blood volume determinations to weight, height, and surface area. On the whole, plasma volume was more closely related to height and surface area than to weight. They found that predominately muscular individuals tended to have plasma volume above the average for their height and that tall thin individuals had plasma volumes below the average for their height.

Perera (122) reported the effect of significant weight change on predicted plasma volume. A significant volume increase was noted only with an increase in lean body mass.

Gregersen and Nickersen (76) in 1950 studied the relation of blood volume to body type. They noted the satisfactory agreement as far as average normal values were concerned, but that the spread of data on which the average is based is so wide that the average normal value cannot be applied to all cases. In an attempt to place the relationship of body size to blood volume on a more quantative basis they followed Sheldon's (155) classification of somatotypes. Their results under rigidly standardized determinations, were that computations made in terms of square meters of surface area showed the smallest variation, particularly in the group of extreme body types. It appeared that plasma volume is a function of body type. They found values for plasma volume as follows:

extreme endomophs - 36.9 cc/kgm student endomophs - 40.5 cc/kgm student ectomophs - 50.1 cc/kgm extreme ectomophs - 56.5 cc/kgm

Thus, in general, it has been noted that: the obese have a lower blood volume and the thin a higher blood volume when expressed as cubic centimeters per kilogram body weight (76); the muscular individuals

have a higher blood volume and the thin individuals a lower blood volume when expressed as cubic centimeters per centimeter of height (68). Blood volume correlates best with active metabolic mass (135) and this may be reflected in the somatotype (76). There is a good correlation of blood volume with surface area (68, 76, 91). Reeve (136) and Gregersen (74) have both indicated that it is fortunate that the majority of methods of blood volume estimation in common use do give values sufficiently accurate for clinical use. Expression of normal blood volume in cubic centimeters per kilogram is convenient (107), but one must be aware of wide range of values from which the average is derived in order that rigid application of normal values be avoided in individuals who might represent extremes of the normal. Serial blood volume changes may accurately indicate the trend of change in the blood volume of an abnormal individual. When a single blood volume determination is performed on a patient with an abnormal blood volume (e.g. after hemorrhage or massive transfusion)

- 26 -

one requires a knowledge of the limitation of average values plus some arbitrary standard of normal extremes of blood volume to interpret adequately the laboratory findings.





### FIGURE 1

÷

Normal blood volume values (male adult) . Values obtained from RIHSA blood volume determination in a normal male subject. Total blood volume, plasma volume and red cell volume are stated in absolute amounts (ML.) and relative to weight (ML/KGM). Venous hematocrit is corrected for 4% trapped plasma.

#### 4 - THE VENOUS HEMATOCRIT AND TRAPPED PLASMA:

The precision with which the hematocrit determination can be performed enters into a consideration of the precision with which total blood volume can be calculated from direct measurements of plasma volume or red cell volume. First, it is of interest to note that several investigators have reported that, whith repeated withdrawal of small samples of blood, the venous hematocrit decreases out of proportion to the quantity of red cells removed. A hemodilution of 3% may occur (29, 67, 82, 115, 175). Rydin and Verney (147) considered this to be due to secretion of the antidiuretic hormone and this view is shared by other investigators interested in the problem of the regulation of oncotic pressure (125).

The term "trapped plasma" refers to the amount of plasma remaining in the packed red cell mass after centrifugation of whole blood. In 1953 Owen and Power (119) reviewed the extensive literature on the subject and performed studies of

- 29 -

their own, using radioactive iodinatedalbumin as an indicator of the amount of plasma remaining in packed red cells after centrifugation. They tested heparinized venous samples from 39 human subjects. They concluded that 3.79% plus or minus 0.70%, that is, slightly less than 4% of the cell volume as determined by centrifugation, consists of trapped plasma.

In 1952, Chaplin and Mollison

(31) studied the problem using T-1824 as an indicator of the amount of plasma trapped. They concluded that over a range of venous hematocrits from 15-85%, trapped plasma values increased from 1.5 to 5%. Trapped plasma varied inversely with total centrifugal force applied (speed, time, radius of centrifugation) and directly with the magnitude of the hematocrit value. They have a useful chart in their paper, permitting their results to be applied by reference to this chart. In 1953, Schlenker (149), in a paper on the determination of packed cell volume, states that the completeness of packing depends upon:

> a) centrifugal force applied, speed and effective radius

b) duration of centrifugal spin

- c) volume concentration of cells in sample
- d) anticoagulant used
- e) secondary factors, such as bore of tube, state of aggregation, etc.

Centrifugal force may be calculated from the formula CF = RPM X RADIUS X  $2/10^6$ . Schlenker (149) states that with normal bloods CF 187 (2500 RPM, radius 15 cm) for 15-20 minutes is sufficient to obtain complete packing; a value within 5% of the minimum can be obtained after 10 minutes. When the erythrocyte count is 2.0 to 4.0 million per cubic millimeter CF 120 (2000 RPM, radius 15 cm) for 10 minutes is sufficient. Berlin (17) does not use any correction for trapped plasma. Beling (15) and Storaasli (166) also omit use of this correction factor. Vazquez (174) corrects all venous hematocrits spun at 3000 RPM for 30 minutes for 2% trapped plasma. Brady (27) corrects all venous hematocrits spun at 3000 RPM for 30 minutes for 4% trapped plasma. Reeve, Gregersen and co-workers (139) routinely correct for 4% trapped plasma. In 1951, Mollison (107) interprets the "hematocrit" to refer to the red cell column only and ignored the layer of white cells on top of the column, correcting for 5% trapped plasma routinely.



ERROR	IN	TOT		BLOOI	D	VOLU	ME,	WHEN
PLASMA -	– DIL	UTI	<u>on</u> —	нст	· (	CALCU	LAT	ION
IS UNCOF	RECT	ED	FOR	BO	DY	HCT	-	0.9
				VEN	ous	HCT		1.0
ERROR (c.c.	kgm)	IS	SHOWN	IN	REL	ATION	то	
PLASMA \	OLUM/	ES	(10,20,	40, 60	, 100	c.c. kg	m)	AND
	VENC	OUS	НСТ	(10	% -	80%)		
		VALUE HCT - PV - RCV -	S LIMITIN 10% - 6 10 - 1 4 - 6	IG CU 30 % 00 cc / 93 cc /	kgm kgm			
		TBV -	20 - 1	50 cc/	kĝm	J		P.V.
	+ 30	<sup></sup> 7					P.V. 20	cç∕kgrn
	+ 25	.0-				40	lcc∕kgm	/
T.B.V. (R.C.V.) ERROR c.c./kgm	+ 20	.0-		F	P. V.	P.V 60 cc∕kgm	/	
	+ 15	.0-		100 c	c / kgm		/10 0	PV. cç/kgm
	+ 10	».o-			/ /		[ ]	/
	+ 5	.0-						
		0	10 20	30	40 5	50 60	70	т 80
← ANEMIA - <del>×</del> AVERAGE <del>-×</del> PLETHOR A							<b>→</b>	
			VENOU	IS HE	EMATO	CRIT	%	
							-	·· · ,

### FIGURE 2

Body-venous hematocrit difference. Effect of body-venous hematocrit difference on calculation of total blood volume when using RIHSA method. Error increases as hematocrit % and plasma volume per kilogram increase.





#### FIGURE 3

Body-venous hematocrit difference. Effect of body-venous hematocrit difference on calculation of total blood volume when using RIHSA method. Error increases as hematocrit % and plasma volume in absolute amounts (ML) increase.

#### 5 - BODY HEMATOCRIT CONCEPT:

The use of a substance such as T-1824 or RIHSA to estimate total blood volume by the dilution hematocrit method assumes:

- a) that plasma dilution methods measure absolute plasma volume;
- b) that the venous hematocrit is a representative sample of the absolute total blood volume;
- c) that the measured plasma volume and venous hematocrit may be used to calculate absolute total blood volume.

#### A) Definitions:

١.

Absolute plasma volume is the true volume of plasma in the body. Gregersen (75) states that the volume distribution of T-1824 is identical with that of various antigens (77) of albumin (152) tagged with  $I^{131}$  and of hemoglobin (4), constituting strong evidence that the dye method measures the true plasma volume. T-1824 combines with albumin by linkage with the epsilon ammonium radical of lysine (95),  $I^{131}$  combines with albumin by linkage with the tyrosyl groups (90). Therefore, T-1824 and RIHSA measure at least the circulating albumin pool which, though slightly larger than the true plasma volume, is at least in rapid equilibrium with it (151). The question of the volume distribution of T-1824 and RIHSA is discussed by Freinkel (63).

Absolute red cell volume is the true volume of red blood cells in the body. Gregersen (75) states that  $P^{32}$  and  $Fe^{55}$  agree (114) as to the measurement of red cell volume, but that the carbon monoxide method over-estimates red cell volume due to loss of the gas in tissues. Mollison (107) concurs with this statement concerning carbon monoxide.

<u>Absolute total blood volume</u> is the true volume of blood in the body, the sum of the

plasma volume and red cell volume. The sum of the plasma volume by the dilution method (e.g. RIHSA) plus the red cell volume by the dilution method (e.g.  $Cr^{51}$  tagged red cells) would be a measurement of the true blood volume within the limits of those methods.

<u>Venous hematocrit</u> is the ratio of red cells to whole blood in the venous blood. A hematocrit of 45% indicates that the blood sample contains 45% red cells and 55% plasma.

<u>Body hematocrit</u> is the ratio of red cells to whole blood in a statistically representative sample of the absolute total blood volume. To obtain this sample one would have to drain all of the blood of the body into a container, agitate the blood well and centrifuge a sample. Practically, the body hematocrit is calculated by simultaneously performed measurement of the plasma volume (e.g. by RIHSA) and the red cell volume (e.g. by Cr<sup>51</sup> tagged red cells). The calculation is as follows:

> Body hematocrit =  $\frac{(Cr^{51}) \text{ red cell volume}}{(Cr^{51}) \text{ red cell volume plus}}$ (RIHSA) plasma volume

The importance of an understanding of the body hematocrit and venous hematocrit is this: if the body hematocrit is the same as the venous hematocrit, one may calculate total blood volume from the equation:

If the body hematocrit is smaller than the venous hematocrit the above calculation will result in over-estimating total blood volume (and red cell volume). If the body hematocrit and venous hematocrit differ constantly under all conditions of circulation when using accurate means of simultaneous measurement of plasma volume and red cell volume a correction factor, K, may be used to overcome the error, so that the equation becomes:

RIHSA plasma volume (ml.) TBV = 1.00 - <u>Venous hematocrit (%) X K</u> 100 Interest in the concept of body venous hematocrit difference has arisen from a comparison of total blood volumes calculated from the simultaneous determination of plasma volume using plasma diluents (especially T-1824) and labelled red cells (17). Differences have been noted for example when total blood volume was:

- a) calculated from T-1824 plasma volume plus venous hematocrit
- b) calculated from P<sup>32</sup> red cell volume plus venous hematocrit
- c) calculated by adding T-1824 plasma volume and P<sup>32</sup> red cell volume.

To account for these differences, a difference between venous hematocrit and body hematocrit is postulated.

Evaluation of the body - venous hematocrit question involves a review of the opinions regarding:

a) variations in the composition of blood in different sized vessels in the body;  b) the findings of investigators who have employed simultaneous plasma diluent and tagged red cell methods of calculating total blood volume;

c) the opinion of investigators as to the practical significance, the magnitude and nature of the error in calculation of total blood volume from the plasma diluent - hematocrit method, with special reference to the errors which might occur in the RIHSA hematocrit blood volume measurement.

## B) Variations in composition of blood in different sized wessels:

Blood is a suspension of finely particulate matter in a fluid medium, hence cannot be expected from the point of view of viscosity to obey the physical laws governing the behavior of simple fluids such as homogenous solutions (107).

Krogh (97) has described the flow of blood in capillaries with red cells having an axial flow and the plasma forming a cuff about the red cells. Fahraeus (55) demonstrated that the hematocrit of blood passed through fine glass tubes varied with the diameter of the tubes. Thus when the tube diameter was 1.0 mm. the hematocrit was 40%, when the diameter was 0.1 mm. the hematocrit was 34%, when the diameter was 0.05 mm. the hematocrit was 28%. In the smaller vessels, then, the red cell to plasma ratio was 28:72 and in the larger tubes the ratio was 40:60. Mollison (107) states that it is now accepted that "the blood vessels are lined with

a layer of relatively slowly moving plasma and the red cells form an axial stream". Green (73) estimates that in a dog with a total blood volume of 1150 ml. the total capacity of the venous system is about 870 ml. (76% of total); the total capacity of the aorta, arteries and arterioles is of the order of 220 ml. (19%); the capacity of the capillaries is roughly 60 cc. (5%). Bazett (14) estimated that the smaller vessels (arterioles, capillaries, venules) held, at most, only 15% of the blood of the body. From the estimates of Green (73) and Bazett (14) one would conclude that the capacity of the smaller vessels is not large enough to account for the reported differences in body - venous hematocrit. However, Gregersen and co-workers are convinced from studies of the proportion of red cells and plasma to whole blood in various organs (5) and in the eviscerated animal (78) that the "extra plasma" is probably distributed throughout the body and not present as a single large pool in some organ or tissue.

# <u>C) Simultaneous plasma volume - red cell</u> volume dilution measurements:

Smith, Arnold and Whipple (159)

in 1921 insisted that the true blood volume could be determined only by estimating plasma volume and red cell volume seperately and then adding them together. For the estimation of red cell volume they used the carbon monoxide method and for measuring the plasma volume they used the red dye method. Although both of the methods which they used lead to positive errors which should have negated each other (107, 75), these investigators found a discrepancy between the total blood volume as calculated seperately by the dye - hematocrit and tagged cell - hematocrit methods.

Gregersen (75) in 1953 reported

measurements of plasma volume with T-1824 and red cell volume with  $P^{32}$  in splenectomized dogs. These studies were intended to elucidate the problem of body - venous hematocrit difference. He states that in normal human subjects the total blood volume as calculated from the red cell tag substances and the venous cell percentage (i.e. venous hematocrit) has been on the average (137) 10% lower than the total blood volume determined from the sum of the dye dilution plasma volume and the tagged cell dilution red cell volume. On the other hand, the total blood volume as calculated from the dye dilution plasma volume and the venous cell percentage has been higher than the sum of the separate measurements. References cited are: for the T-1824 -  $P^{32}$  comparison (83, 140, 111, 21); for the T-1824 - Fe<sup>55</sup> comparison (70); and for the T-1824 - Ashby marked cell comparison (12).

Gregersen (75) considers that the T-1824 dye method accurately measures the true plasma volume (because of the characteristics of its volume distribution) but over-estimates the total blood volume (because of the body - venous hematocrit difference); the isotopic red cell tag methods

accurately measures the true red cell volume, but under-estimates total blood volume. In splenectomized dogs the ratio of body hematocrit to venous hematocrit was 0.87 to 1.00. Hence in the splenectomized dog the underestimation of total blood volume by the isotopic red cell tag method would be about 13%; the over-estimation of total blood volume by the plasma dilution method would range from about 2% at venous hematocrit 10% to about 30% overestimation at venous hematocrit 70%. In other words when using a plasma dilution method (e.g. T-1824 or RIHSA) the larger the venous hematocrit, the larger will be the absolute and relative over-estimation of total blood volume (and red cell volume). Thus use of the equation:

would result in an error of 3 - 30% over the 10 - 70% hematocrit range in splenectomized dogs,

- 45 -

whereas use of the equation:

would result in the same estimate for total blood volume as would the sum of the plasma dilution plasma volume plus the red cell dilution red cell volume.

The validity of the correction factor 0.87 in the splenectomized dog was substantiated under the following experimental conditions:

- 1 conscious dogs in a normal circulatory
  state;
- 2 immediately after severe hemorrhage and at intervals of days thereafter;
- 3 after infusions of dextran into dogs with normal blood volume;
- 4 after infusions of concentrated cell suspensions into dogs with normal blood volumes;

5 - after three weeks acclimatization to low oxygen tension;

6 - after "dehydration" with intraperitoneal
 dialysis or with intravenous infusions
 of 50% sucrose and again after "rehydration".

However in dogs after hemorrhage followed immediately by infusions of dextran, for unknown reasons, the ratio was not 0.87 but 0.80.

These findings of Gregersen are detailed in the series of papers in the American Journal of Physiology, November, 1953, and present a sound pattern of experimental surgical approach to the clarification of the body - venous hematocrit difference. An outstanding finding was that the 0.87 correction factor could be applied with confidence except in the cases of hemorrhage immediately treated with dextran. As mentioned by Gregersen (75), this latter finding should be studied more intensively.

In the case of the human being Chaplin and Mollison (31), using T-1824 and  $P^{12}$ , conclude that the body - venous hematocrit difference was real, relatively constant and that a correction factor of 0.91 could be applied with confidence. Gray and Frank (72), using radioactive chromic chloride and radioactive sodium chromate, found that a correction factor, of 0.91 could be applied in normal adults. Schreiber (150) using RIHSA and radioactive sodium chromate tagged red cells found that a correction factor of 0.937 was applicable in normal adults but that the body - venous hematocrit ratio was less than 0.937 in congestive failure and altered when cardiac compensation occurred. D) Significance of the body - venous hematocrit
 difference in relation to the plasma dilution
 hematocrit method of blood volume determination:

From the foregoing paragraphs it is probable that a real difference exists in man between the body and venous hematocrits. The correction factor is probably about 0.9 when the RIHSA method is used. If this correction factor is a constant, an overestimate of total blood volume (and red cell volume) will occur when the correction factor is not used. The following are the opinions regarding the significance, magnitude and nature of this error of overestimation.

Berlin (17) omits the use of any correction for body - venous hematocrit difference when using the P<sup>32</sup> method, stating: "This concept (i.e. body - venous hematocrit difference) is based upon the use of Evans blue for the measurement of plasma volume, which we do not regard as satisfactory, and, since theoretical considerations of the hydro-

dynamics of blood flow seem to indicate that a significant change in the hematocrit does not occur in the smallest vessels, we do not believe that the total body hematocrit differs significantly from the venous hematocrit! If Berlin's position is incorrect and the correction factor is constant at about 0.9 as suggested by Mollison (107), Berlin's calculations of total blood volume would result in under-estimates of total blood volume by about 10%. Berlin (15), Whiting and Hotz (188), McInnes (104) using the T-1824 method; Storaasli (166), Brady (27), Siler and Fultz (157) using the RIHSA method -- have omitted use of the body venous hematocrit correction factors when reporting use of blood volume determinations. These reports were all made in surgical publications within the past five years and the authors all claimed satisfaction with their particular method of blood volume determination.

Mollison (107) is of the opinion that a correction factor of 0.9 should be used whenever the dilution hematocrit method is used in the estimation of total blood volume. He points out the magnitude of the error which may occur when the hematocrit is elevated and cites examples of serial blood volume determinations where transfused blood was accurately accounted for when the correction factor was used and unsatisfactorily accounted for when the factor was omitted. He illustrated mathematically the large errors which may occur when the hematocrit is elevated and hence is in substantial agreement with Gregersen (75).

# <u>6 - CHARACTERISTICS OF RADIOACTIVE IODINATED</u> <u>HUMAN SERUM ALBUMIN (RIHSA):</u>

The period during which detectable amounts of RIHSA remain in the circulatory and lymphatic systems has not been determined precisely, This time has been reported to be perhaps 6 days (141), after intravenous injection, and the time is probably longer. Complete mixing with the circulating blood occurs within 10 minutes according to Aust (10). Within a few minutes after injection radio-activity is detectable in the thoracic duct. This is negligible and amounted to less than 2% in 10 minutes according to Storaasli and co-workers (166, 96). Equilibrium of the activity between blood and lymphatic systems is complete within 7 to 13 hours (182). No activity is found in the spinal fluid up to five days after injection (166, 182). Negligible amounts are found in the bile after intravenous administration (166).

#### A) Disappearance from serum:

In dogs 91.5% of the activity is located in the plasma one hour after injection, 80% remains at 5 hours, 45% at 24 hours, and 32% at 72 hours (182). In man, Storaasli (166) found that on the basis of 100% being present at 10 minutes, 96% remains at 15 minutes, 95% at 30 minutes, 90% at one hour, 86% at two hours, 81% at three hours, 78% at four hours, 74% at six hours, 69% at eight hours. The five minute sample contains 106% of the activity of the 10 minute sample.
# B) Urinary excretion:

The urine is the chief route of elimination of  $I^{131}$  following the administration of RIHSA. At the end of the first day after injection, the total urinary excretion may reach from 5 to 20% of the total amount given (10, 166, 161). Apparently RIHSA is gradually metabolized by the body, with the liberation of free  $I^{131}$ . Most of the free  $I^{131}$  is excreted in the urine ( as Na  $I^{131}$ ), the remainder being taken up by the thyroid gland. Another factor in the disappearance of the RIHSA from the vascular system is due to the diffusion of the iodinated protein from the vascular bed to the extra-vascular spaces as demonstrated in the studies of thoracic duct lymph (166).

- 54 -

# C) Thyroid uptake:

Approximately 5% of the injected radioactivity has been found in the thyroid gland within the first 24 hours (166).

Absence of activity in the bile

(166) would indicate that the liver does not participate in the excretion of RIHSA. However, it is of interest to note that Sterling (161, 162) has reported that in the hypoalbuminemia associated with Laennec's cirrhosis there is a slower turnover and longer half-time of intravenously administered RIHSA than in other hypoalbuminemic states.

Tyor (173) has studied the serum disappearance rate and urinary excretion rate of  $I^{131}$  after RIHSA injection in patients with cirrhosis and has compared it with findings in other diseases. Disappearance from serum was similar, but urinary excretion of  $I^{131}$  (inorganic) was decreased, during the first 24 hours in patients with cirrhosis. Stirrett (165) has successfully employed RIHSA in 300 microcurrie doses in the diagnosis and localization of liver metastases. Chou (34, 34, 126), Farmer (56), Yuhl (194) and Dunbar (45) have employed RIHSA in the diagnosis and localization of intracranial tumours.

### 7 - BLOOD VOLUME AND CONCENTRATION INDICES:

Performance of the hemoglobin, red blood cell count and hematocrit determinations permits the calculation of volume, color and saturation indices (192) expressed in absolute terms as the mean corpuscular volume, mean corpuscular hemoglobin and the mean corpuscular hemoglobin concentration. These are called the corpuscular constants and are of value in the classification and treatment of anemia. Consideration of the constants in a particular case permits of a diagnosis, e.g., of normocytic, normochromic anemia (in acute hemorrhage), or hypochromic microcytic anemia (iron deficiency or chronic blood loss). Several authors have effectively shown the lack of correlation between laboratory tests of concentration (HGB, RBC and HCT determinations) and the findings of blood volume determinations (192, 36). A moment's

reflection will show that it is possible to have a 90% HGB, 43% HCT and 4.5 million RBC count in a normal male immediately after a hemorrhage of 1000 cc. before fluid shifts into or out of the vascular space have occurred. Hemodilution would occur if fluid shifted into the vascular space and hemoconcentration if fluid shifts out of the vascular space. The stability of circulatory dynamics depends more upon the volume of total blood than upon the composition of the blood as far as red cells or plasma is concerned within wide limits. Howard (87) has stated than an acute 50% deficit in red cell volume is tolerated better than an acute 50% deficit in total blood volume. Moreover, as Mollison (107) points out, a patient with aplastic anemia (chronic red cell volume deficit) may be ambulatory with five gms. % hemoglobin. Also profound hypotension and circulatory depression may occur in severe dehydration due to generalized peritonitis (acute plasma volume -

and total blood volume deficit) in the presence of a higher hematocrit which represents a suprious or relative polycythemia (assuming normal red cell volume).

Recognizing the limitations of

concentration indices, but maintaining their value in the absence of blood volume determinations and measurements of operative blood loss in surgery, Thomas (170) has studied the blood changes after intrathoracic operations. Thomas (170) felt that the hematocrit (and hemoglobin) determination was better than the red cell count since the latter often gave erratic results.

## 8 - PHYSIOLOGICAL VARIATIONS IN BLOOD VOLUME:

Physiological variations in normal individuals may explain some of the discrepancies between different published estimates of normal blood volume (107).

## A) Effect of activity:

Plasma volume is affected by posture, exercise and rest in bed (107). Thompson (171) found that 20-30 minutes of standing after 30 minutes in the recumbent position produces a decrease in plasma volume of approximately 300 ml. Conversely, Walters (179) and Widdowson and McCance (189) found that lying down for one to two hours produces a fall in hemoglobin and hematocrit of about 5%. Taylor (169) found that lying in bed for three weeks produces a fall in plasma volume of about 500 ml. in males. This is accompanied by a scarcely significant fall in red cell volume and thus the hematocrit rises.

### B) Differences between infants and adults:

Normal newborn infants have a larger blood volume per kilogram than normal adults, the difference depending almost entirely upon the different levels of the venous hematocrit. Mollison (107) using T-1824 and P<sup>32</sup> tagged red cells, separately found that newborns having a venous hematocrit of 63% had a total blood volume of 84.7 ml/Kgm. Normal adults with a venous hematocrit of 44.7% had a blood volume of 76.6 ml/Kgm. Russell (146) studied a group of 64 infants and young children weighing 10-30 Kgm. Recalculation of his data by Mollison (107) revealed an average blood volume of 75.4 ml/Kgm.

Ely and Sutow (52) studied the growth of thiocyanate space in infancy and childhood and performed T-1824 blood volume determinations on infants and children up to the age of 8 years and weighing 2 to 25 Kgms. They found an increase in blood volume in absolute amounts with age. The

- 61 -

increase was directly related to weight, height, and surface area. The best correlation appeared to be with weight. In 50 subjects, aged 0-9 years, the mean total blood volume was 81.1 ml/Kgm, with a venous hematocrit of 40%. No correction was made for trapped plasma or venous hematocrit-body hematocrit difference. (When recalculated after the manner used by Mollison (107), the total blood volume in this series of 50 children is found to be 74. ml/gm).

Robinow and Hamilton (143), using vital red dye, concluded that the blood volume of children was about 90 ml/gm. The size of the volume may be attributed to: inaccuracy of the vital red method and lack of appropriate correction for trapped plasma and venous hematocrit-body hematocrit difference.

- 62 -

# C) Pregnancy:

Mollison (107) remarks on the magnitude of the increase in plasma volume during normal pregnancy while accounting for the observed decrease in venous hematocrit. Berlin (17) using the  $P^{32}$  red cell tag method agrees with the findings of increased plasma volume, but maintains that a decrease in red cell volume occurs too, contributing to the fall in hematocrit. The decrease in red cell volume, according to Berlin (17) is apparently due to a failure of production of red cells rather than due to excessive destruction of cells or decreased red cell survival time.

# 9 - MEDICAL AND SURGICAL CONDITIONS AFFECTING BLOOD VOLUME:

Numerous reports have been made on various medical and surgical conditions affecting blood volume. Berlin's review (17) mentions congestive heart failure, uremia, pulmonary tuberculosis, cirrhosis, cancer, leukemia, polycythemia and pregnancy. Berlin (20) and Albritten (2) have studied changes in blood volume with thoracic surgery; Bonica and Lyter (26) have summarized much of the pertinent literature on blood loss in general surgery.

There has been a great deal of controversy over the findings in specific disease conditions with different results being found by different investigators of the same disease with the same or different methods. In general, congestive heart failure appears to increase the total blood volume, red cell volume and plasma volume and, with compensation, the volumes approach normal.

- 64 -

Uremia, according to Berlin (17) decreases the red cell volume and the plasma volume may be normal, smaller or larger than normal. In pulmonary tuberculosis, blood volume is usually reduced by 15% or so. In hepatic cirrhosis, plasma volume is usually large and red cell volume is usually small, that is, a true anemia exists and hemodilution may be present. In cancer, red cell volume may be small (33) or variable (17). In chronic leukemia, when the spleen is palpable, the plasma volume is usually enlarged but this is variable. With treatment of chronic myelogenous leukemia, the plasma volume may decrease, if previously enlarged. In primary and secondary polycythemia the blood volume is usually enlarged due to an increased red cell volume. Relative polycythemia occurs in patients with obvious fluid loss or shock, an elevated hematocrit being present when there is a normal red cell volume.

In normal pregnancy, using the  $P^{32}$  red cell labelling method, Berlin (17) found that

- 65 -

there is a decrease in red cell volume during the first trimester. An increase in total blood volume, red cell volume and plasma volume occurs in the 2nd and 3rd trimesters. Low hematocrit values may be due to a disproportionate increase of plasma volume over red cell volume in the 2nd and 3rd trimesters.

The state of knowledge of the influence of specific disease states on blood volume continues to be in a state of flux pending further knowledge and agreement on the method of determination (e.g.  $I^{131}$ , RIHSA or  $Cr^{51}$  - tagged red cells), which is best for demonstrating true changes in blood volume in specific conditions, the limitations of each method and the proper mode of expression of results obtained (e.g. on basis of surface area, true body mass, ideal weight, etc). In the interim, serial determinations by the same method and mode of calculation at least reflects changes in blood volume in the same patient.







Blood volume and hemodynamic response in massive gastrointestinal hemorrhage. Hypotension and tachycardia are not early indices of oligemia. Partial replenishment of deficient blood volume pre-operatively reverted blood pressure to normal. 3500 ML of blood given from 4pm until 11pm. Death was due to hemorrhage post-operatively.

## 10 - CIRCULATORY DYNAMICS:

Patients who are to undergo anaesthesia and stress of surgery require careful evaluation of the adequacy of their circulatory dynamics. The relationship of the total blood volume to circulatory homeostasis would appear to be more important than the relative volume of the plasma or red cell mass. Three considerations make this apparent:

- 1) On the basis of a study of 4500 casualties Howard (87) concluded that a rapid loss of 50% of the red cell mass can be tolerated if the total blood volume is maintained, whereas, a 50% reduction of the total blood volume is usually accompanied by hypotension and other signs of decompensation of circulatory dynamics.
- Profound hypotension and circulatory depression may occur in patients with a normal red cell volume but a low

total blood volume. This occurs in cases of acute peritonitis with internal fluid loss and no concomitant red cell volume loss. Hence, a patient with peritonitis may have a blood pressure of 80 systolic and a hematocrit of 55%.

3) In subjects with chronic anemia, such as permicious anemia, the hemoglobin may fall as low as 3 gm % before the patient is admitted to hospital. Normal non-strenuous activity may be performed by patients with a hemoglobin level of only 5 gm %.

These facts indicate that the red cell mass is important for its space-occupying function and oxygen transport as emphasized by Moore (109) but that total blood volume is of greater importance when acute stress is applied to the circulatory system.

The following discussion is taken from Elkinton (50). The peripheral arterial blood pressure is a function of the peripheral vascular (mainly arteriolar) resistance, the cardiac output and, to a lesser degree, the elasticity of the larger arteries. Cardiac output is a function of the heart rate, force of systole and the venous return. The venous return is a function of the total circulating blood volume, the propulsive forces (muscle contraction, gravity, changes in thoracic and abdominal body cavity pressure and differences in capillary venous pressure) applied to the blood in the venous system and the tonus of the veins and capillaries. Peripheral resistance is a resultant of local factors (external thermal change, chemical influences) and central regulation by the vasomotor center which is situated in the floor on the fourth ventricle at the level of the calamus scriptorius. Reflex activity of the vasomotor center is under regulation of higher centers (cerebral cortex and hypothalamus), radiation from the respiratory center, afferents from

- 70 -

the pressoreceptors, other afferents, hypercapnia and oxygen lack. (50)

Although a normal blood volume is only one of the variables which determine the adequacy of the circulation, reduction in blood volume or plasma volume always results in impairment of the circulatory dynamics (50). For this reason changes in the volume of blood and plasma associated with various types of dehydration and traumatic shock are of intense practical interest.

## 11 - PHYSIOLOGICAL REGULATION OF PLASMA VOLUME:

From an analysis of his own and other authors' work, Mollison (107) concluded that:

- The plasma volume and venous hematocrit have a substantially rectilinear inverse relationship with plasma volume decreasing from 60 to 35 c.c./Kgm over the hematocrit range 10-70% (107, 65, 66, 70, 115, 140, 146, 108).
- 2) The red cell volume and venous hematocrit have a substantially rectilinear direct relationship with red cell volume increasing from 5 to 40 c.c./Kgm over the hematocrit range 10-55% (140, 108). Above a venous hematocrit of 55% the red cell volume increases disproportionately and above a venous hematocrit of 75%, in congenital heart disease (117), the disproportionate red cell volume increase is even more striking.

3) The total blood volume appears to increase throughout the range of hematocrit values from 10 to 70%, especially above a venous hematocrit of 55% (107, 66, 70, 140, 146, 108).

It should be noted that these conclusions were reached as a result of direct-dilution plasma volume or red cell volume measurements and with the elimination of the error which may be introduced by the difference between venous hematocrit and body hematocrit.

The plasma volume can be altered far more rapidly than the red cell volume. The body has no normal mechanism for destroying excess red cells and red cell volume can be reduced very slowly by diminishing production and waiting for the excess red cells to reach the end of their normal life span (107). By contrast, plasma volume can be rapidly altered and until venous hematocrit values of 55% are exceeded, plasma volume is readjusted so as to keep the sum (plasma volume plus red cell volume) approximately constant (107). In Mollison's (107) opinion, the factors controlling plasma volume are:

- 1) red cell volume;
- 2) serum protein concentration (a reduction in the total amount of circulating protein tends to be accompanied by a reduction in plasma volume and an increase in circulating protein tends to be accompanied by an increase in plasma volume);
- 3) salt balance (in the presence of deficits of the principal extracellular cation, sodium, extracellular volume decreases. Since plasma cation is in equilibrium with interstitial cation, plasma volume decreases correspondingly).

Mollison (107) is of the opinion that intravascular hydrostatic pressure, protein concentration of the plasma and body salt balance are adequate to explain control of plasma volume and that it is not necessary to postulate a center for control of the body fluid volume. However, one wonders, in view of the remarkable control of the blood volume, if a center is not present perhaps in the bone marrow similar to the oncorceptors, postulated by Verney (176) which are concerned with the regulation of oncotic pressure or the chemoreceptors and pressoreceptors described by Comroe (37, 38) and Schmidt (38) which reflexly affect respiration, heart rate and blood pressure.







#### FIGURE 5

Components of transfusion solutions. An approximation is shown of the red cell, plasma and anticoagulant composition of whole blood, stored plasma and packed red blood cells as supplied by the Royal Victoria Hospital Blood Bank.

## 12 - TRANSFUSION SOLUTIONS:

Transfusion therapy and the use of plasma expanders are indicated for the immediate  $\overset{{}_{\mathcal{A}}}{\text{connection}}$  of quantitative and qualitative blood deficits. The substances generally used consist of whole banked blood, concentrated red cell suspensions, plasma, concentrated human serum albumin, synthetic large molecule polysaccharide solutions (PVP or Dextran). Whole blood is stored for a maximum of 21 days under refrigeration, heparinized, citrated or in siliconed containers. Concentrated red cell suspensions are prepared from whole banked blood by removal of supernatant plasma following sedimentation or centrifugation. Red cells may be suspended in a minimum volume of plasma or washed with saline solution and resuspended in saline solution. Plasma is prepared by separation from whole banked blood and may be stored under refrigeration, dehydrated or stored at room temperature, for six months or more. Plasma contains plasma proteins

- 77 -

and electrolytes and has nutritional as well as osmotic properties. The value of the plasma expanders consists mainly in the osmotic properties of their large molecule colloids. Whole blood contains red cells which have space occupying and oxygen carrying capacities (109). Packed red cells contain a larger mass of red cells per unit volume than whole blood. Specific transfusion therapy is always desirable (6). For deficits in total blood volume - whole banked blood; for deficits in plasma volume - plasma; for deficits in red cell volume - packed red cells are indicated. In emergencies, when whole blood is not immediately available, correction of acute total blood volume deficits may be made with plasma or a plasma expander. Artz and Howard (7) were entirely satisfied with these agents in resuscitation of the severely wounded in Korea during 1953. However, it was found that the use of pooled, refrigerated, irradiated plasma was accompanied by a serum hepatitis incidence of 20%. Hence

- 79 -

plasma expanders were used in place of plasma. The most widely used plasma expanders are dextran and PVP. Dextran may be accompanied by evidence of interference with the normal coagulation mechanism (28); as much as 30% of administered PVP is stored in the reticulo-endothelial system, the last being excreted over one week in the urine. Examination 10 years later of German soldiers who received PVP during World War II showed no evidence of abnormality referable to the incomplete excretion of PVP (184). The characteristics of a satisfactory plasma volume expander (49) are : maintenance of satisfactory colloidal osmotic pressure, constant molecular composition, adequate viscosity, stability within a fairly wide range of temperature change, stability in storage for long periods of time, ease of sterilization. It must be non-pyogenic, non-allergenic, non-toxic to tissues (early or delayed), inexpensive and reproducible in adequate quantities for stockpiling. To these qualities might be added non-interference with proper typing and cross-matching of blood and non-interference with normal hemostatic mechanisms.

The use of whole blood or plasma purely for nutritional purposes is inefficient and not economical (158, 3). In 500 cc of donor blood there are but 19 gms of plasma protein. For restoration of the nutrition of malnourished patients quantities of blood would be required of the order sufficient to cause hemosiderosis from deposition of broken-down hemoglobin. The transfusion of whole blood has been recommended in cases of so-called medical (i.e. non-hemorrhagic) shock as may occur in acute infections, myocardial infarction or diabetic acidosis. In the absence of pre-existing red cell volume deficit the hypovolemia which may occur in these conditions is on the basis of a concentrated plasma volume. Plasma volume expansion is effective in restoring circulatory blood volume and circulatory dynamics (107). Sayen (148) has reported success with the vasopressor nor-adrenalin in myocardial infarction. Peters (123) maintains that when hypotension is

- 80 -

present in diabetic acidosis, blood may be indicated and feels that blood has a specific activity in improving circulatory efficiency lacking in plasma or plasma expanders. Peters states (124) that he has not seen complications (thrombosis or dehydration) referable to increasing the red cell volume in patients with diabetic acidosis by whole blood transfusions and notes furthermore that, following reversion of the acidosis, red blood cell counts, hemoglobin and hematocrit determinations are usually reduced. (This may be interpreted not only as a pre-existing red cell volume deficit, but as over-expansion of plasma volume due to therapy).

### 13 - SPECIFIC TRANSFUSION THERAPY:

Specific transfusion therapy is predicated upon the qualitative and quantitative replacement of blood volume to replace existing deficits (158). The route of administration of transfusion solutions is ordinarily intravenously, although intra-arterial transfusion has been recommended under certain circumstances. Intraperitoneal transfusion of blood has been found to result in some increment of the blood volume as cells and plasma are transported by the abdominal lymphatics and thoracic duct to the systemic circulation (107). The subcutaneous administration of blood has no merits to recommend it (107). The rate of administration of transfusion is conditioned by the severity of the deficit and the rapidity with which the deficit was incurred. In general, in the replacement of acute total blood volume deficits the rate of administration

- 82 -

should be rapid. Replacement of chronic deficits should be undertaken over several days in order to minimize disturbance of compensated circulatory dynamics. The rate of administration of a transfusion appears to be as important as the route of administration (7). The amount of transfusion solution required for the correction of deficits is a matter of controversy. In severe acute blood volume deficits there is an agreement that transfusion should proceed until there is evidence of restoration of normal circulatory dynamics. Specifically, replacement should be titrated against pulse and blood pressure until the latter have been established at normal levels. One authority on the subject of trauma, Sir Reginald Watson-Jones (183), states that transfusion should proceed further until there is no longer evidence of peripheral compensatory vasoconstriction; that is, pallor and coolness of skin should be absent. He suggests that the warmth at the tip of the nose is a reliable clinical indicator of the degree of

peripheral vasoconstriction. Artz (7), Prentice (129), and Howard (87) were more vigorous in the treatment of acute hemorrhagic blood volume deficits. These authors felt that the greatest single difference between the therapy of wounded men in the Korean war and those in World War II was the use of massive quantities of blood administered throughout different treatment periods. They noticed that the greatest single factor in judging the prognosis of the wounded was not the blood pressure on commencement of therapy but the number of transfusions required for resuscitation. (In patients requiring 5-10 pints, the group mortality was 1.6%; inpatients requiring 20-56 pints, the group mortality was 53%). The overall mortality of 138 wounded persons, studied in the last six months of the Korean War was 14.5%. These were patients who required from 5 to 56 pints of blood in the first 24 hours of injury. Evidently as

a minimum standard of adequate treatment Artz (7) states "unless hemorrhage is uncontrolled, the patient should be restored until the systolic blood pressure is 110 mm. of mercury or more and the pulse rate 120 per minute or less before the operation".





## FIGURE 6

Factors influencing blood volume. Volume replacement and loss are shown as being algebraically related. With certain reservations this concept is the basis for the practical management of quantitative and qualitative therapy of circulatory volume abnormalities.

- 86 -
## 14 - PATHOLOGY OF BLOOD VOLUME REDUCTION:

With respect to circulatory

efficiency three entities are of interest surgically:

A) the acute blood volume reduction
 occurring in the presence of massive
 hemorrhage or unreplaced operative
 blood loss;

B) acute plasma volume reduction;

C) the chronic reduction of blood volume occurring in debilitated malnourished individuals with chronic benign or malignant disease.

## A) Acute blood volume reduction:

The term shock is ill-defined and in the minds of surgeons has generally been associated with hemorrhage. The statement made by Blum (24)

in 1876, that "hemorrhage is shock and shock, hemorrhage", has played a significant role in the therapy of hemorrhage. Since 1915 (94) blood volume studies have promoted the association of the term shock with hypovolemia according to Ravdin (134). Wiggers (190) has studied the problem of shock intensively in dogs and has standardized a method of producing hemorrhagic shock by reduction of blood volume to such a degree that the arterial systolic pressure is lowered to 50 mm. of mercury. He divides the reactions into oligemic and normovolemic shock. Oligemic shock (following hemorrhage) is described as having three phases: the initial period of stabilized hemorrhagic hypotension, impending or progressive stage of shock and the critical stage. Normovolemic shock (following re-infusion of all of the withdrawn blood) is described as having a compensatory stage, a progressive stage and a terminal stage. He is of the opinion that vasoconstriction has only a negligible effect in maintaining arterial blood

pressure and may actually be detrimental to the survival of the animal by decreasing blood flow when hypotension exists. He is of the opinion that dibenamine and hexamethonium have therefore possible advantages in certain stages of shock. Howard (88) is of the opinion that vasoconstrictors have little or no place in the treatment of shock, but that their place is limited to meeting a deficiency in the autonomic nervous system. In the presence of adequate transfusion, vasoconstrictors were of no value in the treatment of hypotensive shock resulting from traumatic hemorrhage.

Essentially, the results described in Wigger's experiments are those of failure of compensation of circulatory dynamics: reduction in venous pressure, arterial blood pressure, cardiac output, tachycardia (decreased cardiac rate occurring terminally) and increasing peripheral vasoconstriction. That is, if the hemorrhage (blood volume reduction) is of sufficient magnitude a satisfactory equilibrium of circulatory dynamics is impossible.

The question arises: what must be the magnitude of blood loss in order to produce a new, compensated, equilibrium of circulatory dynamics in a previously normal individual? (Considered from the aspect of blood volume determinations - the residual volume after bleeding as well as the volume of hemorrhage regulates the circulatory response.) In dogs a 40% reduction of blood volume was necessary to lower the arterial pressure to 50 mm. Hg. by Wigger's method (190); a 48% reduction of blood volume was necessary to produce fatal shock by bleeding in Walcott's series (177), Howard (87) and Prentice (130) have reported that 15-25% blood volume reduction in man by hemorrhage and wound trauma may be associated with no hypotension, but that after a loss of 25-30% of the blood volume hypotension will develop pre-operatively (that is, before the emergency surgery necessitated by significant wound trauma).

An interesting reaction to injury is the hypertensive response. Howard (88) studied 52 men who had a sustained systoic blood pressure above 140 mm. Hg. These were individuals who had non-critical wounds associated with a loss of one liter of blood or less and had no previous history of hypertension. The hypertension disappeared following the induction of general or spinal anaesthesia. Hexamethonium abolished and regitine depressed the hypertensive response. The response seemed to be an over-compensation for blood loss and trauma and appeared to be mediated through the sympathetic nervous system. The authors quote the findings of Grant and Reeves (71) who reported similar observations in patients with limb injuries and small or medium sized wounds and blood volumes within 20% of the predicted normal.

#### B) Acute plasma volume reduction:

Acute plasma volume reduction may result from inadequate salt and water intake; internal redistribution of plasma volume as may occur in burns, paralytic ileus, peritonitis the third space effect described by Randall. (133); excessive gastrointestinal fluid loss from the body by diarrhea, vomiting or nasogastric secretion. Plasma volume reduction results in an increase in the concentration of red blood cells, increased blood viscosity and may be attended by the features of oligemia as described under acute hemorrhage. In addition, compensation for decreased plasma volume cannot proceed effectively when the specific problem features the passage of fluid from the vascular into the interstitial space (i.e., in dehydration and third space effect). When spontaneous restitution of plasma volume is impossible, expansion of plasma volume by fluid

- 92 -

and electrolyte therapy is a prerequisite for survival. Burns are complicated by the fact that there is initial red cell destruction and by the anemia which may occur in the early postinjury period.

## <u>C)</u> Chronic blood volume reduction:

Clark (33) studied the blood volumes of chronically-ill patients, using T-1824. They found that, when the blood volume was expressed on the basis of the standard or usual weight prior to illness, marked deficits in total blood volume, total circulatory protein, hemoglobin and red cell mass were present. They maintained that in these patients the operative risk could be reduced by restoration of the blood volume toward normal. Large transfusions were tolerated well and no evidence of hemoconcentration occurred, indicating that the transfusions had replaced a real deficit. Furthermore, serial blood volume studies showed the expected increment due to transfusion. Patients so treated withstood operations well without marked change in blood pressure and pulse rate. These authors considered that the deficiency of hemoglobin was a factor of primary importance

in the problems engendered by depletion of body proteins. They agreed with Whipple and others (186, 103) that in the presence of a deficiency of both hemoglobin and tissue protein, priority is assigned to the fabrication of new hemoglobin.

# 15 - THE SPONTANEOUS RESTITUTION OF NORMAL BLOOD VOLUME OCCURRING IN HYPOVOLEMIC AND HYPERVOLEMIC STATES:

The immediate effects of hypo-

velemia due to acute deficits in total blood volume (oligemia) or of hypervolemia due to acute excesses in total blood volume (transfusion hypervolemia) may be reflected in changes in the circulatory dynamics as evidenced by changes in peripheral vascular tonus, venous pressure, heart rate, blood pressure and cardiac output. The restoration of circulatory homeostasis depends largely upon the lability of the plasma volume with fluid shift occurring across the capillary membrane. Starling's hypothesis is the basis of the current concepts on the control of the volume of blood and the distribution of water and electrolytes across capillary and cell membranes (73). The direction of flow between the intravascular and interstitial space depends upon the effective filtration pressure. The latter is determined by four variables: the intracapillary hydrostatic pressure, the intracapillary colloid osmotic pressure, the interstitial hydrostatic pressure and the interstitial colloid osmotic pressure. Equilibrium is present when there is no net shift of water in either direction.

## <u>16 - COMPENSATION FOR ALTERATIONS IN BLOOD VOLUME</u> <u>AND COMPOSITION:</u>

Compensation, that is, reversion toward a normal blood volume, may occur in certain pathological states which decrease a normal blood volume or following therapy which increases a normal blood volume. The compensation referred to is alteration in the abnormal blood volume so that it approaches normal. Confining the discussion to hypovolemia which affects circulatory dynamics, as manifested by a tendency toward hypotension or tachycardia or lowered venous pressure, the usual causes are acute total blood volume deficit or acute plasma volume deficit. Acute red cell volume deficit in massive hemolysis may be found in certain conditions.

## A) Acute total blood volume deficit:

Acute total blood volume deficit is encountered in patients with massive hemorrhage (e.g. gastrointestinal tract bleeding) or with unreplaced operative blood loss. Physiological compensation occurs by fluid shift across the vascular membrane from the interstitial space into the vascular space, thus augmenting the plasma volume (51). Removal of 430 cc. of blood in four minutes was observed to decrease venous pressure for thirty minutes without hypotension or, tachycardia (101). Removal of 1050-1150 cc. of blood rapidly, results in no hypotension in some individuals when lying in the supine position but may result in unconsciousness where there is a sudden change of position (178). Removal of 1500-2000 cc. of blood rapidly results in low right auricular pressure and low cardiac output despite some tachycardia (89). These individuals exhibited signs of

pallor, cold, clammy extremities and sometimes, air hunger.

Ebert, Stead and Gibson (47) studied the rate at which restoration of the blood volume occurred spontaneously. After hemorrhage of 1000 cc. adults were found to require 36 hours to restore blood volume. This was judged by noting the rate of fall of the hematocrit, assuming no significant red cell formation within 36 hours.

Berlin (20) noted that, following thoracoplasty procedures in patients studied 2-6 days post-operatively, the average post-operative blood volume deficit was only 865 cc., in contrast to a deficit of 1250 cc. calculated from the change in pre- and post-operative red cell volume measurements. Hence an average of approximately 400 cc. was spontaneously added to the circulation by an increase in plasma volume supplementary to incomplete transfusion replacement of blood of patients subjected to stress of operation, anaesthesia and blood loss.

Royster (145) in comparing estimates of change in pre- and post-operative blood volume with operative blood loss measured by the gravimetric technique of Baronofsky (13) in patients undergoing radical operations for cancer of the head and neck, noted that in 8 out of 17 cases the post-operative blood volume ranged from 0 to 2000 cc. more than expected on the basis of measured loss and replacement. In their interpretation of their results they referred to "changes of an unpredictable nature in the fluid shift and blood constituents following large operations with profuse bleeding". Undoubtedly a shift of fluid into the vascular compartment with expansion of the plasma volume played a significant role in the change noted.

Wiggers' (190) conclusions on the repletion of blood volume following hemorrhage in

the dog are that contraction of the spleen may replace at least 10% of the blood withdrawn, when the hemorrhage was adequate to produce shock. (The hemorrhage usually amounted to 2000 ml. and the splenic contraction increased the circulatory volume 200 ml.) If the spleen of the dog has an open circulation as described by Machenzie, Whipple and Wintersteiner (102) it would seem that contraction of the spleen would result in a relocation of the contained blood rather than an actual increase of the blood volume. However, this relocation of blood would efficiently contribute to the active circulating blood volume by its redistribution to areas of more active metabolism than the spleen. Wiggers (190) notes the present tendency to question the importance of the spleen as a blood reservoir even in dogs. Wiggers (190) states that a shunting mechanism may be present relocating blood from the capillary bed into larger vessels containing the active circulation. Wiggers' (190) opinion is that fluid

- 102 -

migration into the blood stream through the capillaries is simple and based on reduction of intracapillary hydrostatic pressure while colloid osmotic pressure remains the same. The effective filtration pressure becomes higher in tissue spaces than within the capillaries, hence water and electrolytes enter the blood stream. The rates of plasma replenishment in hemorrhage experiments have been given as 0.25 cc/Kgm/min. (1), 0.154 cc/Kgm/min. (100), 0.101 cc/Kgm/min. (132).

Shortly after hemorrhage the reexpansion of plasma volume is from interstitial fluid only (51). The interstitial fluid is apparently replaced from exogenous sources provided that the intake of water is adequate (101) rather than from intracellular water as concluded earlier by Stewart and Rourke (164) and Lands and Johnson (99).

#### B) Acute plasma volume deficit:

Acute plasma volume deficit

is encountered in states of dehydration (salt and water deficit) which may be due to inadequate fluid and electrolyte intake, or excessive abnormal loss. A normal loss of fluid and electrolytes may be: internal - 3rd space effect described by Randall (133) occurring in burns, ileus, peritonitis, ascities or hydrothorax, or external- with abnormal gastrointestinal tract losses due to vomiting, nasogastric suction, enterocutaneous fistulae or diarrhea.

In fact, in war wounds of the abdomen usually accompanied by peritonitis as opposed to wounds of the extremities where whole blood loss occurs predominately, it has become an axiom that "abdominal wounds hemoconcentrate, extremity wounds hemodilute" (87). Abdominal wounds are accompanied by a much higher

- 104 -

mortality rate than wounds of the extremities (87). This may be partially related to the plasma loss of peritonitis plus whole blood loss and injury to viscera such as the kidneys and liver. In specific deficits of plasma volume one of the factors in compensation for the lowered total blood volume, is absent: The spontaneous restitution of plasma volume by shift of interstitial fluid into the vascular space. Hence, in support of failing hemodynamics (lowered blood pressure, elevated pulse, lowered venous pressure) vasopressors have little value in resuscitation of the patient with hemorrhagic or traumatic shock (86) and prompt fluid, electrolyte or transfusion therapy must be supplied.

#### 17 - TOLERANCE OF BLOOD VOLUME DEFICITS:

Blood volume deficits may be incurred rapidly or slowly. Massive hemorrhage results in the rapid depletion of circulating blood volume. A chronic anemia may gradually decrease the red cell volume when there is interference with the production of red cells and a normal duration of red cell survival (43) or when there is normal production of red cells and decreased duration of red cell survival (41). Clark (33) drew attention to the significance of existing circulating blood volume deficits in debilitated, malnourished patients with chronic benign or malignant disease. These workers considered that the surgically significant feature of reduced blood volume is an increased susceptibility to shock, correctable by transfusion. Clark (33) recommended that debilitated patients in a state of "chronic shock" should have deficits of total blood volume, circulating hemoglobin and red cell volume corrected pre-operatively by transfusion to the standard value, (T-1824 method) for their usual weight in health. By doing so, it was found that poor-risk patients tolerated major operative procedures better as regards circulatory dynamics and wound healing.

It has been observed that 1000 cc. of blood may be rapidly withdrawn from healthy young adults without ill effects (47) but that occasionally withdrawal of less than 500 cc. of blood from blood donors may result in fainting or a "vaso-vagal response" (107). An individual's hemodynamic response to blood volume depletion is apparently a function of:

1. - the volume removed; Wiggers
(190) defines the maximal amount
of blood which may be removed
from an individual without death
resulting the "sublethal bleeding
volume");

- 107 -

- the volume remaining in the circulatory system;
- 3. the functional capacity of the individual to compensate for the discrepancy between the actual remaining and the usual blood volume.

Paquin (121), who has studied 60-80 year old patients with carcinoma who were candidates for radical pelvic surgery, is of the opinion that in such adults the physiological limit of deficit for operative blood loss lies somewhere about 1000 cc. Recalculation of some of Berlin's (20) data on blood volume in thoracic surgery indicates that post-operatively 3 of 27 patients had deficits of 1000 cc. or more and none was in shock at the time of the blood volume study.

Regarding the pre-operative correction

of blood volume deficits several empirical rules

have been established for transfusion. Crehan (39) states that 40 ML. per pound of weight loss pre-operatively is a useful "rule of thumb". Crehan (39), in discussing restoration of blood volume in gastrointestinal bleeders, stated a preference for whole blood rather than plasma volume expanders, commenting that his choice is influenced by the superiority of red blood cells in regard to their persistent space-occupying function and oxygen-carrying capacity (109, 153,). Beling (15), using T-1824 and calculating normal values on the basis of normal weight in health, stated that any deficit in total blood volume of 500 cc. or more should be corrected pre-operatively by transfusion. Mollison (107) states that patients should not be subjected to operation with a hemoglobin level of less than 10 gm.%, and quotes the statement of Grant and Reeve (71), that, in patients who have trauma associated with blood loss, the blood volume should be raised to at least 80% of normal before operation is begun.

## <u>18 - CLINICAL SIGNIFICANCE OF FACTORS AFFECTING</u> THE PRECISION OF BLOOD VOLUME MEASUREMENTS:

The question of the degree of accuracy with which an estimate of the blood volume can be made is of particular interest to the surgeon. As stated by Fox and Lasker (60), the objective of fluid therapy in surgical emergencies, including hemorrhage, loss of gastrointestinal fluids and thermal burns, is "to restore cardiac and renal output and the function of other vital organs so that essential surgical procedures can be performed". Using the terminology of Fox and Lasker (60), there may occur: vascular fluid loss (e.g. hemorrhage), extravascular fluid loss (e.g. vomiting, nasogastric suction, diarrhea, fistulas or intraabdominal fluid extravasation due to peritonitis or pancreatitis) or fluid loss primarily as an

internal redistribution caused by tissue trauma (e.g. thermal burns, extensive crushing injury, fractures). These fluid losses decrease the volume of circulating blood and maintenance of circulatory dynamics ( as reflected in venous pressure, blood pressure, pulse, state of tonus of skin vessels) is dependent upon the mobilization of physiological mechanisms to compensate for decreased blood volume. Decrease in blood pressure and rise in pulse rate with associated decline in venous pressure and evidence of peripheral vasoconstriction are frequently indications of marked decrease in circulating blood volume. Artz (7) states that hypotension in an individual who has been subjected to trauma or hemorrhage is almost always an indication of the need of further therapy to expand the blood volume. One author (118) recently stated that he used operative hypotension as an indication for blood volume expansion in a study of the

efficacy of plasma volume expanders. The physiologic and biochemical response of the patient are effective guides to therapy (60) and are the usual basis for a practical decision on rates, quantity and type of therapy to be employed when confronted with surgical emergency such as oligemic hypotension. Blood volume determinations, then, should provide the clinician responsible for the management of such an emergency with data which will allow a more exact prescription of transfusion solutions so that the patient's compensatory mechanisms may function more adequately. The precision of blood volume determinations depends upon: the method used, the condition of the patient (with reference to circulatory dynamics and integrity of the vascular membrane enclosing the vascular space) and familiarity with the technique of the method by the technician performing the determination.

When dilution methods of performing blood volume determinations are used it is assumed that a rather well-defined compartment of body fluid is being measured, namely, the intravascular (or blood volume) compartment. However, the vascular compartment consists not of rigid inanimate tubing but of tubing which is capable of contraction, dilatation and distension and which is really a semipermeable protoplasmic membrane separating the intravascular and extravascular fluid spaces of the extracellular fluid space. This concept, as it pertains to distribution of fluid after trauma and the measurement of blood volume, is discussed by Fox (60, 61). RIHSA or T-1824 have the volume distribution of albumin and hence measure the "circulating albumin pool" which may be slightly larger (63) yet in rapid equilibrium with the plasma volume during the 10-15 minutes mixing time usually allowed for a blood volume determination. In hemorrhage fluid shifts occur

into the plasma (51), mixing of the test substance may be altered by an abnormal circulation time and loss of the test substance from an open vessel may increase its apparent distribution. Test substances measure only the volume in which they are mixed hence will not measure stagnant blood in the body. In short, the dilution method measures only circulating blood volume. Prentice (129), Artz and Howard (7) have postulated sequestration of blood as a reason for the deficits existing in casualties treated with massive transfusion. These authors point to damaged muscle as a place where blood may be lost from the active circulation. Alternatively, they suggest hemolysis or bleeding between blood volume studies are responsible for an expansion of the discrepancies.

T-1824 may stain tissues and be taken up by reticulo-endothelial cells (193,

- 114 -

43, 105), thus giving an artifactitiously high blood volume. Inaccuracies of colorimetry are present (107) in higher dye concentration ranges and limit the accuracy of the method.

Under normal conditions of circulation, T-1824 has been reported to give results which are serially reproducible within 3.5-10.0%(15, 27); radioactive chromium - 3% (62, 72), RIHSA - 3% (27). These estimates are for studies done within two hours of each other.

Experiments involving transfusion and hemorrhage of measured amounts of blood have been done in conjunction with blood volume determinations (72, 62) (157). In general, an increase in blood volume has been shown with transfusion and a decrease with hemorrhage. Use of a factor to correct for body-venous hematocrit difference will affect the calculation of the magnitude of blood volume and red cell volume changes when plasma diluent test substances are used. Clark (33),

and McInnes (104) in serial studies of blood volumes of patients noted increases in blood volume when the patients were transfused pre-operatively but did not express any quantitative comparison of the measured amount given and the blood volume increase. Fox (60, 61) notes that not all of the volume of transfusion can be accounted for by blood volume measurements and attributes this to shifts of cells and plasma occuring within the patient rather than to the methods (RIHSA and  $Cr^{51}$ ) or calculations used. Berlin (20), in calculating "blood turnover" during operations, assumes that satisfactory precision is present in his measurement. (i.e. "turnover" equals difference between post and pre-operative blood volumes plus transfusion.) Correlation of the blood volume "turnover" with gravimetrically measured operative blood loss would have provided a basis for practical evaluation of the assumption which is probably correct since such a correlation has been made (145) using T-1824 for the same purpose. Siler and Fultz (157) using RIHSA in studying measured hemorrhage in dogs could account for 65% of the measured blood loss. However, there is no mention of their paper as to the circulatory state of the animals when measurements were made and apparently the dogs were not previously splenectomized. Gregersen (75) points out that blood volume measurement is not reproducible precisely in nonsplenectomized dogs.

Realizing the inherent limitations of the dilution methods, clinically precise data may nevertheless be obtained. RIHSA has a satisfactory volume distribution (63) during the normal mixing time (10-15 minutes) and reproducible measurements are obtained under normal circulatory conditions (27). A three sample technique (27) may be used to minimize the effect of abnormal mixing in abnormal circulatory states such as congestive heart failure or shock. In patients subjected to trauma, blood loss and transfusion, Prentice and coworkers (129, 130), using Cr<sup>51</sup> tagged red cells, obtain multiple blood samples until the samples differ by less than 5% indicating complete mixing. Red cell tag methods, especially those using injected isotopically labelled red cells, have the advantage that the volume distribution of the cells cannot be greater than the vascular compartment unless the vascular membrane is broken (e.g. as in hemorrhage from an open vessel) or injured (permitting diapedesis).

## 19 - OPERATIVE BLOOD LOSS MEASUREMENT:

The quantitative determination of operation blood loss has been approached in four ways: by the colorimetric method, by the gravimetric method, by blood volume determinations and by measuring changes in weight of the patient.

## A) Colorimetric method:

Gatch and Little (64) introduced the acid hematin colorimetric method in 1924. This involves washing all the sponges, linen and instruments free of blood, then adding hydrochloric acid to these washings to make an 0.1 N solution. The acid hematin preparation is then compared colorimeterically with a sample of acid hematin prepared from the blood of the patient before surgery. These authors considered the estimate thus obtained to be a minimum because of the inability to recover all of the

hemoglobin by washing. The error was stated to be at least 5%. Modifications of the procedure have been described (127, 112, 187, 154). Results of the determination are not available until completion of the operation except in the case of transurethral prostatic resection, where blood is washed directly into a container. Transfusion requirements during operation are supplied on the basis of the surgeon's estimate or routine policy for specific procedures. Such estimates based on clinical impression of the amount of blood loss may be seriously in error (36). Dingman (44) used the colorimetric method in a study of blood loss in infant cleft lip and cleft palate surgery. Pre-operative blood volumes of the children were not measured, but estimated at approximately 90 cc/Kgm as given by Robinow (143). The cleft lip patients weighed from 2.5 to 9.2 kilograms and lost from 3 to 13% of their estimated blood volume; the cleft palate patients ranged from 7.6 to 20.1 kilograms and lost from 4 to 7% of their estimated blood volume at operation. The value of a method

of operative blood loss measurement in children is commended by these authors.

## B) Gravimetric method:

Wangensteen (180) described the

gravimetric method in 1942. The method consists of: the use of dry sponges throughout the operation; blood soaked sponges are weighed frequently during the operation, minimizing loss of weight by evaporation; the gain in weight of the sponges is regarded as blood loss, each gram being considered equivalent to one ml. Moist sponges may be used to cover viscera and minimize fibrin formation; these sponges are not weighed. The gravimetric method (13) was found to give 10% higher values for blood loss than the colorimetric method, and to provide the advantage of a record of the measurement contemporaneous with the loss so that transfusion may be quantitative during operation. Average values for blood loss by the gravimetric method reported in Wangensteen's paper of 1946 (13) were:

Operation	ML.
appendectomy	25.8
hernia	82.9
gall bladder	179•4
subtotal gastrectomy for ulcer	499.8
subtotal gastrectomy for cancer	455•6
thyroidectomy	405.6
radical mastectomy	415.4
pneumonectomy, lobectomy	1399.

Royster (145) studied operative blood

loss in head and neck surgery. Their gravimetric measurement showed the following average losses:

Operation: radical maxillary resection	<u>ML</u> 1505
bilateral jaw - upper neck dissection	1849.
jaw - tongue - neck dis- section	2473.
radical neck dissection 2483. jaw - neck dissection 4068.

Average blood losses for the various groups of operations ranged from 376 to 770 ML. per hour.

Ladd and Gross (98) use this method routinely in operations on children. Barononfsky(13) states that for blood losses of 500 ML. or less, an equivalent amount of plasma is usually adequate; for blood losses in excess of 500 ML. it is best to replace them with an equivalent amount of blood.

# <u>C) Blood volume determinations and estimate of</u> <u>operative blood loss</u>:

The performance of blood volume determinations before and after surgery allows an estimate of operative blood loss when the extent of transfusion is known. Royster (145) used the T-1824 method. Correlation with the gravimetric measurement averaged plus or minus 250 ML. when the difference between pre- and postoperative total blood volume determinations was compared with the measured (gravimetric) loss, the loss on dressings and transfusion.

Berlin (20) used the P<sup>32</sup> method. Blood turnover was calculated by adding the red cell volume of transfusion (assumed to be 200 ML. per 500 ML. transfusion) to the difference between preand post-operative red cell volume measurements. It was noted that the apparent turnover (i.e. loss) of whole blood during operation was less than expected from a calculation of the whole blood loss represented by the red cell loss. This was accounted for by the spontaneous restitution of plasma volume which occurs due to shift of fluid into the vascular compartment from the extravascular fluid compartment.

McInnes (104) used the T-1824 method. Blood volume determinations were performed in four patients before and after radical surgery. All patients had cancer, were deficient in red cell volume and received transfusions pre-operatively. Low post-operative red cell and total blood volumes were restored to normal values by transfusion.

In an attempt to permit a con-

tinuous estimate of the volume of circulating blood during radical surgery Plentl and Gelfand (128) described a method of serial determinations of blood volume using T-1824. A dilute solution of dye was introduced in 3-4 mgm. amounts during operation and repeated determinations made. These authors found satisfactory results with the small concentrations of dye permitting several serial determinations to be performed within the period of operation.

### D) Gravimetric body weight method:

Paquin (121) described a method of determining operative blood loss by measuring the weight of the patient immediately before and immediately after operation. The difference in weight is due to the net difference between the weights of materials added or removed during operation. Contributing to weight gain are: transfusion of blood, intravenous fluids; contributing to weight loss are: blood loss, water loss (insensible water loss, urine, intestinal contents, bronchial secretions, ascitic fluid, etc.), specimen removed. Routinely the patient is weighed by the intern on a special scale in the operating suite; the weight of the specimen is measured by the circulating nurse, the volume of blood and water administered are recorded accurately by the anaesthetist. Insensible loss is calculated on the basis on 0.75 gm/Kgm/hour. These data permit calculation of post-operative blood

- 126 -

requirements. Paquin comments that in pelvic exenteration procedures, urine collected in a suction bottle may be measured as blood loss and insinuate an error in the direction of greater loss. The loss of blood in the pelvis may constitute a third space effect in Randall's (133) terminology, and cause an error in the direction of lesser loss. In pelvic exenterations this third space effect may cause a large decrease in circulating blood volume which was illustrated in one case in which the loss amounted to 1500-1700 cc. (The change in circulating blood volume was based on T-1824 determinations pre-operatively and post-operatively and knowledge of transfusion and operative blood loss by the gravimetric method).

- 127 -

### PART III MATERIALS AND METHODS

#### A) MATERIALS:

In this section are described the requirements for a hospital blood volume laboratory in which an average of ten RIHSA blood volume determinations per day may be performed. The description is based on experience in equipping and establishing such a laboratory at the Royal Victoria Hospital, Montreal.

#### <u>1 - Laboratory space:</u>

Running water, sinks, electrical outlets, vacuumline, water bath and equipment storage space were present in a laboratory which had stainless steel tables. Special shielding is not necessary under ordinary conditions of background radio-activity. Since tracer quantities of radioactivity are used, waste may be poured down drains which connect with main sewage outlets and further diluted by running water. Contamination of the laboratory would be indicated by an elevation of background count, but should not occur with ordinary care in the handling of RIHSA.

#### 2 - Counting equipment:

A well-type scintillation counter was provided by Dr. Lloyd Stephens-Newsham of the Department of Radiology, of the Royal Victoria Hospital. Similar scintillation counting apparatus is commercially available (e.g. Model D S -3 Scintillation Well Counter, Nuclear Chicago, 223 W. Erie Street, Chicago 10, Illinois). The counter used had an efficiency of 35-40% for gamma disintegrations. The counter consists essentially of a sodium iodide crystal, phototube and preamplifier surrounded by a lead housing. Well counting permits the immediate counting of liquid specimens (e.g. plasma, urine, gastric aspirate) with maximum sensitivity and favorable background rates so that counting errors of less than 1% may be obtained when using 0.01 microcuries of radioactive iodine.

A scaler with an automatic timing device was used. (Atomic Instrument Company Model 1030A). The background was approximately 500 counts per minute at voltage 800, pulse height selector plus 40, attenuator 2. Two ml. samples of plasma or other solution containing approximately 0.01 µc gave more than 10 times the background activity. Counting was performed for 5 minutes. The scaler, being connected with the counter, automatically registered the counts. The counting apparatus should be turned on at least 15 minutes before counting, as some variation in counting may occur immediately after the counter is turned on. Each counter should be tested periodically for variability in counting. The optimum setting for voltage, pulse height, and attenuation can be determined by altering these settings and noting the range over which successive counts differ least. For example, by altering the voltage a curve may be constructed with a constant slope, a plateau, and a further slope. Counting should be done at a voltage situated on the plateau of the curve in order to minimize effects on counting due to voltage fluctation occurring in the source of the current.

#### 3 - Centrifuge:

For the determination of the hematocrit a satisfactory centrifuge is absolutely necessary. An angle centrifuge cannot be used. A small laboratory centrifuge (3000 r.p.m.; 15 cm radius) with a mounting for four tubes is satisfactory. A larger centrifuge with a timer (greater than 3000 r.p.m.; 22 cm radius) is superior. Centrifugation must be standard (e.g. 3000 r.p.m.; 15 cm; 30 minutes) as variation in the packing of red cells due to different durations and amounts of centrifugal force may introduce errors beyond those due to trapped plasma and body-venous hematocrit difference. For a rough estimate of the ratio of red cells to whole blood, 15-20 minutes of spinning (3000 r.p.m.; 15 cm) will probably be within 5 divisions of the final hematocrit reading. For precise results, the importance of standardization of centrifugation conditions cannot be over-emphasized when using the RIHSAhematocrit method.

## 4 - RIHSA:

Radioactive Iodinated Human Serum Albumin ("RISA") was obtained from Abbott Laboratories, Department of Radioactive Pharmaceuticals, North Chicago, Illinois. An allocation number and a certificate of compliance was first obtained from the Atomic Energy Commission by Dr. Carleton B. Peirce, Department of Radiology, Royal Victoria Hospital. The RISA was shipped by air express directly from Oak Ridge, Tennessee. Approximately 5 millicuries per month were used. The RISA, in 10 cc. sterile rubber-capped bottles, contained approximately 10 mgm of human serum albumin and from 0.4 to 1.0 millicuries of  $I^{131}$  per cubic centimeter. Not more than one atom of iodine per 6000 molecular weight of albumin is introduced in the preparation of the RISA (141).

The RISA should be stored under refrigeration ( $2^{\circ} - 10^{\circ}$  C,) and should be used within four weeks after the date of preparation. An assay of the radioactivity at time of shipment is included with each lot.  $I^{\frac{1}{2}}$  has a half-life of eight days. A chart of factors from day 1 to 30 based on the half life is useful in calculating the activity on a specific day.

#### <u>5 - Heparin:</u>

Five cc. ampules of heparin solution, 10000 u per ML (Connaught Laboratories) were used. Heparin was drawn into the syringe for a blood sample, allowed to thinly coat the barrel and the excess discharged into the ampoule. Actually only 0.25 to 0.5 mgm of heparin is needed to prevent coagulation of 5 ml of blood. Sequestrene (disodium ethylene diamine tetraacetic acid) 5 mgm per 5 ml of blood (80) or evaporated oxalate (81), is suggested as a cheaper alternate and neither anticoagulant should effect the hematocrit determination.

#### 6 - Sterile normal saline:

Sterile normal saline in 100 ml. rubbercapped containers is required for preparation of dilute RIHSA for injection. One bottle is sufficient for 15 determinations on the average.

# 7 - Laboratory glassware and apparatus:

- a) 2000 ml volumetric flask with glass
   stoppers (2)
- b) 1000 ml volumetric flask with glass stoppers (2)
- c) 2 ml volumetric pipettes (24)
- d) 1 ml volumetric pipettes (12)
- e) Wintrobe hematocrit tubes (12)
- f) Wintrobe pipettes (12)
- g) Round bottom glass test tubes for counting 16 x 75 mm (36)
- h) centrifuge tubes, glass (36)
- i) suction trap bottle

#### 8 - Decontamination and cleaning of equipment:

- a) enameled tray (14" x 18" x 3") (1 or 2)
- b) beakers 1500 ml (3)
- c) Kodak automatic tray siphon, (Canadian Kodak Co., Toronto, Ont.) (1)
- d) Clay-Adams hematocrit tube cleaner (1)
- e) sodium iodide (1 pound) (Merck and Co, Montreal, Quebec)
- f) detergent powder
- g) Versene (Ethylenediaminetetraautic acid)
   ( 5 pounds) (Bersworth Chemical Co.,
   Framingham, Massachusetts)
- h) test tube brushes
- i) tongs for handling warm glassware
- j) rubber gloves

#### 9 - Equipment used in performing test:

- a) basket for carrying equipment to patient
- b) forms on which to record data pertaining
  to patient (date, weight, height, diagnosis,
  reason for examination, time and amount of
  injection, time of sample) (space for recording results and interpretation)
- - 20 ml (20)
  - 1 ml tuberculin (3)
- d) covers for syringes
- e) needles #20 gauge (36)
  #25 gauge (6)
- f) containers, glass, 30 ml for blood samples
- g) glass marking pencils
- h) parafilm for covering sample containers
  - 25 20" size (Fisher Scientific, Montreal)

i) alcohol for cleansing skin before veni-puncture

.

j) sponges (2" x 2")

### B) METHODS:

#### 1 - Pattern of investigation:

Isolated single determinations were performed on normal individuals and individuals with conditions thought to affect the volume of circulating blood (e.g. carcinoma, portal cirrhosis, intestinal obstruction, burns, ulcerative colitis, hemorrhage). The majority of the patients studied were from the Royal Victoria Hospital.

Serial studies during treatment were performed on patients of the Royal Victoria Hospital (surgery service) who presented interesting electrolyte and blood volume problems.

Operative blood loss in general surgical and thoracic surgical patients was estimated by pre- and post-operative blood volume determinations plus a record of transfusion at operation. An intensive investigation over a period of one month was conducted at the Royal Edward Laurentian Hospital. Correlation between gravimetric and RIHSA estimate operative blood loss was studied and determinations were performed on 35 pre-operative patients on the surgical service of the hospital during that month. This study was undertaken to evaluate the adequacy of operative transfusion routing, to ascertain the influence of chronic disease on the blood volume of patients with tuberculosis, and to determine the practicability and usefulness of the RIHSA method in such an institution.

The effect of age on blood volume was the subject of an investigation of the blood volume in early childhood conducted largely at the Montreal Children's Hospital.

The problems related to the establishment of a blood volume laboratory were investigated by a trial in the Royal Victoria Hospital of various methods of RIHSA blood volume determinations. Associated problems of decontamination and re-use of glassware, evaluation of errors in technique, and the reproducibility of test results were studied.

#### 2 - RIHSA blood volume method:

The method diagrammed in

Figure 7 is that evolved in the Blood Volume Laboratory of the Royal Victoria Hospital and is recommended for the performance of routine blood volume studies. The steps in the figure are outlined below:

> a) <u>RIHSA solution</u> containing 500-1000 microcuries per milliliter is received from the supplier by air express.

b) <u>Preparation of dilute (2 uc/ml.)</u> <u>RIHSA solution</u>: 200 uc (approximately) is withdrawn (tuberculin syringe; #25 needle) from the concentrated solution and injected into the rubber-capped 100 ml. bottle of sterile normal saline. This dilute solution may be used up to one week after preparation but must be kept under refrigeration.





### FIGURE 7

RIHSA blood volume method. Diagram illustrates the method employed at the Royal Victoria Hospital, Montreal. c) <u>Injection</u>: Exactly 5 ml. (Multi-Fit syringe; #20 needle) is withdrawn from the dilute RIHSA solution after the bottle has been shaken well. The 5 ml. are injected into a peripheral vein of the patient; the syringe is not rinsed out with blood. The injection may be made into the rubber tubing of an intravenous infusion set already in place with the solution running.

d) Equilibration time; sampling: Between 10 and 15 minutes are allowed for equilibration under normal circulatory conditions when only a single post-injection sample is to be withdrawn. Under abnormal conditions 10, 20 and 30 minute samples may be used to calculate the RIHSA volume distribution. A 10 ml. blood sample is withdrawn with minimal tourniquet stasis from another vein using a lightly heparinized needle-syringe. When venous pressure is low and peripheral veins are in collapse the blood sample may be obtained from the femoral vein or artery. - 144 -

e) <u>Preparation of standard</u>: Exactly 5 ml. of dilute RIHSA is placed in a volumetric flask which is filled with tap water up to the 2000 ml. mark. (The volume of dilute RIHSA taken for the standard is critical; it must be exactly 5 ml., the amount injected into the patient.) The flask is inverted ten times for uniform mixing. Tap water may be used in the preparation of the standard as gamma radiation is being counted in the well counter. Beta counting may be affected by the phenomenon of "self-absorption" of radiation in protein solutions. Hence for beta counting, plasma of the same protein concentration as that of the patient's plasma should be used.

f) <u>Hematocrit determination</u>: The patient's blood sample is mixed well and 1 ml. placed in a Wintrobe hematocrit tube. This is spun under standard conditions (i.e. 3000 RPM; 15 cm; 30 minutes) of 167 G. for 30 minutes. Under these conditions the venous hematocrit is multiplied by 0.96 to correct for trapped plasma. Pending an accurate definition of body-venous hematocrit difference when RIHSA is used, no correction is made for this difference. It must be remembered that such a policy may lead to an over-estimate of red cell mass of 2 to 20% (75). For an appreciation of the magnitude of this error see Figures 2 and 3 of this thesis. The error is partially nullified by noting changes in serial determinations and the accuracy of the RIHSA plasma volume is not affected by the hematocrit. The hematocrit is read to the top of the red cell volume; buffy coat is not included.

g) <u>Preparation of plasma for counting</u>: The remaining whole blood is rapidly centrifuged to obtain the supernatant plasma. Exactly 2 ml. of plasma (2 ml. T.D. volumetric pipette) are placed in a glass counting tube which has already been counted for at least one minute. Background count equals count of empty tube for 5 minutes. Sample plus background count equals count of the same tube containing 2 ml. plasma for 5 minutes.

h) <u>Standard counting</u>: From the well mixed standard exactly 2 ml. are taken and placed in a glass counting tube similar to that used to hold the plasma. Background counting is done with the tube empty. Standard plus background count equals count of tube containing 2 ml. of standard for 5 minutes. Counting of the empty tube eliminatæs contamination of the counting tube as a source of counting error.

#### 3 - RIHSA Blood volume calculations:

The calculation is predicated upon the assumption that the same total amount (5ml.) of dilute RIHSA is injected a)into the patient, and b)into the 2000 ml. flask. Thus, the concentration in the plasma (plasma counts minus background counts) times the volume of plasma equals the concentration in the standard (standard counts minus background counts) times the volume of the standard (2000 ml.). Solving the equation for Plasma Volume:

PV = (Plasma Counts - Background Counts) X 2000 (Standard Counts - Background Counts)

The Total Blood Volume is calculated from the Plasma Volume and the venous hematocrit times 0.96:

$$\frac{PV}{HCT\% X 0.96}$$

Red Cell Volume is the difference between the Total Blood Volume and the Plasma Volume:

#### 4 - Serial RIHSA blood volume determinations:

In order to perform a second determination, the residual radioactivity from the previous determination must be taken into account. An initial blood sample is taken and the plasma radioactivity determined. More RIHSA is injected and then the usual postinjection sample is taken. The increment in plasma radioactivity of the second sample is accepted as being due to the RIHSA injected for the second determination. This increment in radioactivity then reflects the volume distribution of the RIHSA during the second determination. Calculation of the second RIHSA blood volume is then similar to the calculations described above. For examples of serial determinations and the protocol of these experiments see Table 6 - Technique Standardization.

#### 5 - Gravimetric measurement of operative blood loss:

The method used was essentially that described by Wangensteen in 1946 (180), in which each gram of weight gain of dry sponges was taken as one ml. of blood loss. In addition the volume of suction was noted during the procedure. At the close of the operation the four to six towels used to drape the operative area were removed and weighed. The large drape was not weighed but blood on it was estimated. Large sponges weighed 26 gms., small (2" x 2") sponges weighed 6.5 gms., towels (14" x 26") weighed 75 gms. The procedure was simplified and arithmetical errors minimized by:

- a) counterbalancing sponges to be weighed
   with an equal number of dry sponges;
- b) placing the sponges in a paper bag immediately after they were discarded from the sterile field. Groups of sponges were then weighed: 6 large sponges in a paper bag (counter-balanced with 6 large dry sponges and a paper bag) or 10-20 small sponges in a paper bag (counterbalanced with an equal number of small sponges in a paper bag).

# PART IV RESULTS

The experimental and clinical invest-

igative results are presented in Tables 1 to 19 inclusive; Figures 8 to 11 inclusive; and Charts 1 to 4 inclusive.

Tables 1 to 5 present the data on normal adults and children; Tables 6 to 11 are on technique standardization; Tables 12 and 13 are on counter standardization; Tables 14 to 19 review the data obtained from the investigation of blood volume changes associated with the surgery of pulmonary tuberculosis.

Figures 8 to 11 graphically illustrate representative blood volume problems studied by serial determinations.

Charts 1 to 4 present data obtained by single and serial RIHSA blood volume determinations in patients presenting problems of abnormal blood volume, fluid and electrolyte abnormalities in elderly and poor-risk patients and a miscellaneous group of patients. Clinical data are appended to the results of the RIHSA blood volume determinations.



CLASSIFICATION AND MORESER	XEAN AGE	AGE RANGE	PLASHA WOLDKE NL/XOH	RED CELL VOLUME HL/KOM	TOTAL BLOCD VCLURE	HOT S	SURPACE AREA	TOTAL BLOOD VOLUNE	
BORNAL ADULT HALES (25)	27	15-49	40.8 \$ 6.0	52.0 ± 5.4	72.7 2 8.5	45.8 2 5.0			
FORMAL ADULT VALES (15)	27	21-41				45.2 - 3.5	1.91 <sup>4</sup> 0.14	2764 \$ 258	•
BORNAL ADULT PERALES (18)	50	14-46	43.5 ± 7.3	27.2 - 5.7	70.7 = 10.2	40.5 ± 5.5			
BORGAL ADULT FERALES (11)	28	14.44				40.2 = 2.7	1.58 ± 0.21	2518 1 205	
BORMAL CHILDREN (27)	6	2-11	49.6 = 4.5	28.7 - 2.4	78.3 - 6.1	58.2 ± 1.9	0.00 \$ 0.16	1974 ± 186	
FULNCHARY THE HALES-PHE-OP (16)	38	26-60	41.4 ± 7.0	31.9 = 4.7	73.5 ± 10.4	45.4 ± 5.4			
PULNCRARY THE PRIMALES - PRE-OP (16)	55	24-55	40.1 \$ 5.5	24.1 \$ 2.6	64.2 ± 7.1	39.3 ± 3.3			
PULNORARY THE MALE- POST-OP (9)	56	26-60	36.4 ± 5.9	26.2 - 6.6	62.6 ± 11.0	43.2 - 5.3		•	
FULHORARY THE FEMALE- ROST-OF (6)	36	29-41	57.9 - 2.4	22.0 - 3.2	59-9 - 5-3	58.0 - 2.4			

# RIBSA BLOOD VOLUNE DETERMINATIONS

# TABLE 1

Composite table of mean values for all groups studied by the RIHSA blood volume method. Ţ



							IODINATE	HIMAN SERVICE	ALBUNCTI NORMAL P			,		
ŧ	TANE	DATE	DIAGNOSIS	AOS	нт (сн.)	*7	нот	HOT X 0,96	PLASNA VOLUMS NL	IPV NCL/KDX:	RED CELL YOLAS	NCT HL/KOK	TOTAL BLOOD VOLUME	19V 11/101
1	0.7.	9/25	NONAL (O.P.D.)	23	150	<del>3</del> 9.4	38.0	36.5	2132	54.1	1226	51.1	5598	85,2
2	D.P.	9/29	BREAST CYST	17		58.2	56.0	54.6	3018	51.9	1597	27.4	461 5	79.5
•	L.B.	10/6	NORMAL (R.V.H.)	28	_	60.5	59.5	37.9	2257	57.5	1577	22.8	565A	60.1
4	5.L.	10/14	PSTCHONEUROSIS	46		80.5	42.0	40.5	2650	32.7	1776	55*0	4406	54.7
5	J.T.	12/15	LAB. TECH.	28	157	50.5	58.3	36.8	2203	43.8	1285	25.5	5468	60.5
6	R.B.	12/15	LAD. TECH.	57	178	84.0	45.5	43.7	2672	51.8	2074	24.7	4746	56.5
7	J.B.	12/16	LAB. TSOR.	29	173	61.2	59.5	37.9	5485	56.9	2126	5 <b>4.</b> 8	5609	91.7
8	0.B.	12/16	PHYSICIAN	30	179	72.6	35.5	34.1	555 <del>4</del>	49.0	1859 .	25.5	<b>97</b> 95	74.5
9	B.B.	12/16	LAD. TRUE.	22	158	51.2	57.0	33-5	2395	46.8	1518	25.7	5715	72.5
10	Ŧ.J.	12/28	PSTCHCHEUROS IS	19	155	45.4	41.5	<del>39</del> .8	2244	49.4	1484	52.7	5726	82.1
n	A.C.	-	NORMAL (R.V.R.)	40	155	45.4	42.0	40.3	1929	42.5	1502	28.7	5251	71.7
12	J.4.	1/18	APREDECTORY (P.O.#6)	14	165	59.5	41.5	<del>5</del> 9.8	2190	56.8	1448	24.5	5638	1.1
13	V.S.	3/4	BORAL (R.V.E.)	44	165	58.0	42.0	40.3	2519	40.0	1565	27.0	5004	57.0
14	L.O.	<b>9/1</b> 2	BREAST OTST	42	-	41.8	44.0	42.2	1960	46.9	1408	55.7	5565	A0.0
15	£.¥.	5/25	LAB. 7808.	29		61.4	56.0	34.6	2960	48.2	1566	25.5	4926	75.7
16	v. <b>c.</b>	5/25	: LAD. 200E.	29		75.0	47.5	45.6	2480	55.1	2079	27.7	<b>6779</b>	60 <b>.</b> e
17	£.8.	2/27	SECRETARY	<del>39</del>		62.3	58.0	36.5	2405	38.6	1582	25.5	5767	60,8
18	1.7.	5/27	SECRETART	25	179	43.6	41.0	<del>39</del> .4	1900	45.6	1255	28.5	5155	71.c
ATEN	ME (18 P	DULE SUBJ	icts)				HOT 40.5%			45.5		27.2		19V 70-7
5.	P.						±3.5			17.5		25.7		\$10.7

#### PLASMA VOLUME. MED CELL VOLUME. TOTAL MLOOD VOLUME DETAINIDIATION

:

# TABLE 2

Normal female subjects studied by RIHSA method. Plasma volume 45.5 ML/KGM, red cell volume 27.2 ML/KGM, total blood volume 70.7 ML/KGM. (HCT 40.3%)



_															
•	KANE	DATE	DIAGNOSIS	AGE	н	WT	HCT	HCT x 0.96	PLASMA VOLUME NL	PLASMA VOLUME NL/KOM	NUT Kuri Critt Aothinr	RED CELL VOLUME	TOTAL BLOOD VOLUME HL	TOTAL BLOOD VOLUME BL/KGM	
1	K.C.	9/15	BIL. HARMOPLASTY ( P.O. #4 )	19		73.0	43.5	41.8	3610	49.5	2593	35.5	6203	85.0	
2	A. B.	9/16	DUODENAL ULCER	33		65.7	49.5	47.5	2261	34.7	2064	31.4	4345	66.1	
3	A.S.	10/12	HEMPIOPLASTY ( P.O. # 7 )	29	72	66.4	37.5	36.0	3123	47.0	1757	26.5	4580	73.5	
4	R.N.	10/13	APPENDECTORY ( P.O. # 6 )	29		65.0	43.0	41.3	3440	52.9	24,20	37.2	5860	90+2	
5	R.D.	10/23	SCAR	20		78.2	46.0	44.2	3420	43.7	2705	34.6	6129	78.1	
6	¥.H.	10/29	HERITA	30	-	90.0	47.5	45.6	2960	32.9	2461	27.6	5441	60.5	
7	J.P.	12/1	MED. STUDENT ( R.V.H. )	24		79.4	47.0	45.1	3312	41.7	2721	34.3	6033	76.0	
8	N.d.	12/8	MORMAL ( R.V.H. )	35		· 102.0	46.3	44.4	3727	36.5	2976	29.2	6703	65.7	
9	1.3.	1/26	NED. STUMBAT ( R.V.H. )	22	68	70.1	45.6	43.8	2508	35.8	1955	27.9	4463	63.7	
10	K. B.	2/1	PRACT. HALLUX ( 6 DAYS )	30	66	R0.8	45.0	43.2	2700	33-4	2054	25.4	4754	58.6	
ш	P.G.	2/3	MASTOIDECTONT ( P.O. # 4 )	22	76	72.6	42.2	40.5	3790	52.2	2580	35.5	6370	87.8	
12	4.D.	2/3	MASTOIDECTORY ( P.O. # 3 )	41	61	57.7	45.0	43.2	2340	40.6	1760	30.8	4120	71.4	
13	J.J.	2/3	MED. STUDENT	24	74	85.0	42.5	40.8	4160	47.5	2861	32.7	7061	60.2	
ц	D.L.	2/3	PILONIDAL SINUS	24	70	80.0	42.7	41.0	2990	37.4	2359	29.5	5349	66.9	
15	×. 8.	3/2	APPENDECTONY ( P.O. #7 )	21	69	63.0	17.0	45.1	2750	43.7	2259	35.9	5009	79.5	
16	B.K.	3/12	MORMAL ( B.V.H. )	15		57.2	51.0	49-0	2055	35.9	1974	34.5	4029	70.4	
17	м.н.	3/25	VARICUSE VEINS	45		100.0	46.5	44.6	3660	36.6	2946	29.5	6606	66.1	
78	I.M.	5/25	PHYSICIAN	25		77.2	45.0	43.2	3670	47.5	2791	36.2	0461	e3.7	
19	F.C.	5/25	PHTSICIAN	28	71	77.2	51.0	49.0	2840	36.8	2729	35-3	5569	72.1	
20	J.M.	5/25	PHYSICIAN	36	72	<b>81.0</b>	45.5	43.7	3160	39-0	2453	30.3	5613	69.3	
21	K.S.	5/27	MED. STUDENT	24	74	88.6	48.5	46.6	3020	34-1	2635	29.7	5655	63.8	
22	<b>#.</b> S.	5/27	NED. STUURNT	23	68	70.4	46.0	44.2	2700	34.4	2139	30.4	4839	68.7	
23	B.P.	5/27	MED. STUDENT	23	70	75.0	48.7	46.8	3010	40.2	2648	35.3	5658	75.4	
									~~~						

#### PLASHA VOLUNE CALL VOLUME. TOTAL BLOOD VOLUME DETAINATIONS SITH IOUINATED HURAN SERUM ALBURIN MORMAL MALES - AGES 15-45

TABLE 3

Ċ

Normal male subjects studied by RIHSA method. Plasma volume 40.8+6.0 ML/KGM, red cell volume 32.0+3.4 ML/KGM. Total blood volume 72.7+8.5 ML/KGM (HCT 54.8%).

1 154 -


TOTAL BLOOD VOLUME IN RELATION TO SURFACE AREA AND HEMATOORIT:

#### NORMAL FEMALE AND MALE SUBJECTS

NO.	AGE	<b>x</b> ²	TBV-ML.	TBV-ML./W2	HOT K
71	23	1.29	5558	2603	58.0
	28	1.49	3468	2328	58.5
<b>P</b> 6	57	2.00	4746	2373	45.5
¥ 7	29	1.72	5609	3261	59.5
<b>F</b> 8	30	1.90	5593	2638	35.5
<b>F</b> 9	22	1,50	3713	2475	37.0
<b>F</b> 10	19	1.41	3728	2643	41.5
<b>F</b> 11	40	1.41	5251	2299	* 42.0
<b>F</b> 12	14	1.62	5658	2245	41.5
<b>F</b> 15	44	1.61	3884	2412	42.0
<b>F 18</b>	25	1.41	3135	2223	41.0
FEMALE AD	ULT MEAN :	1.58 м <sup>2</sup>		2518 ML.	40.2 %
S.D.	1	0.21		± 295	± 2.7

M 3	29	1.87	4880	2610	37-5	
¥ 9	22	1.83	4463	2439	45.6	
M 10	30	1.90	4754	2502	45.0	
и 11	22	1.96	6370	3250	42.2	
M 12	41	1.55	4120	2658	45.0	
M 13	24	2.12	7061	3330	42.5	
м 14	24	1.97	5349	2715	42.7	
M 15	21	1.77	5009	2830	47.0	
M 19	28	1,95	5569	2856	51.0	
и 20	36	2.01	5613	2793	45.5	
M 21	24	2.12	5655	2668	48.5	
M 22	23	1.85	4839	2644	46.0	
<u>H 23</u>		1.92	5658	2947	48.7	
MALE AS	DULT MEAN :	1.91 M <sup>2</sup>		2788 ML.	45.2%	
5	3.9.	± 0.14		± 255	- 3.5	

# TABLE 4

RIHSA blood volume measurements of normal male and female subjects in relation to surface area. Male subjects averaged 2788  $ML/M^2$ ; female subjects averaged 2518  $ML/M^2$ .



										-															¥. u		1				
	NA Na Na Na	16.5	18.0	1,,1	2*71	13.6	16.6	P	1.61	9"71	14.2	14.2	15,8	13.7	1).2	17.3	1	4.4	12.5	12.5	12.)	12.7	11.7	10.2	7.0	<b>5.</b> 6		£		ŧ.	
	5	6.7	6.4	5.5	5.1	ĩ	6.1	3	5 3	5.6	5.6	5.6	5.9	6*7	°.	٠,	3 3		3	3	1	53	717	52	2	2.9		5		Į	
	r a/ca	8.6	311.6	9*6	1.6	7*8	10.5	9.6	<b>7*6</b>		8.6	9.6	6.9	8°9	8.2	<b>n.</b> 0	8.9 0.1		3	72	7.9	<b>3</b> "0	5	6.5		<b>6.6</b>		Ĕ	Ĭ	<b>, ,</b>	
	∧2 kr/v	1977	2246	1921	<b>%</b> 61	1912	21.17	2103	2110	2013	1906	2065	2176	1961	1928	<b>%</b>	2128		2	1905	1906	1996	200	1629	ž	92 92		ť			
	u∕n5 u∕n5	24	54 63	ій 8	66 66	17	۶ ۲	8	5 5 7 5	8 8 8	я 75	8 ¥	3	5 8	<b>1</b> 2	20 21	9 1 9 1			29 7L	8	22	4 4	¥ 5	8	й 9		5	7 X	!. <del>?</del>	
	T.N.	11 6.19	76.3 14	69.3 12	74.3 12	17 9-72	61 6.97	62.7 1)	82.5 IJ	81.3 IS	11 1.69	76.2 1)	81.5 13	21 7"84	7.9 12	<b>60.4</b> 15	(I 0.69		62.6 13	79.9 12	51.5 12	<b>86.6</b> 12	W.3 11	69°2	6 0.89			ł		1.7	
	121 121	26.1	1"12	2.3	26.7	29.0	<b>28.1</b>	9°62	д.9	0.3	27.6	28.1	5.0	20.02	29.2	¥.6	2°2		3.62	3 <b>4</b> ~5	29.2	7"2	ý°¢	24.9	¥.4	53.9		5		1	
	MT/TO	8.X	49.2	44.0	4.74	45.6	8-87	1.6	97.6 1.2	19.3	2.1	1.84	51.0	10	1.81	9°9	\$°-7		53.0	7765	52.3	<b>X.</b> 2	1.9.7	4.6	41.2	7*65	İ	Ł	9.61	3	
	븉끹	272	2356	2017	1620	1441	2022	166T			16.79	711	1764	1607	1542	6961	1575		1205	1236	1239	662T	9111	945	8	<b>X</b>			•		
	2a	816	637	*	<b>6</b> 33	\$	R.	5	2	1	5	ц,	5	24	Ē	289	5	5	5	3	ŧ	ŝ	ş	R	ñ	ŝ					
	k y	146	1521	1921	2911	1096	1264	1215	<b>6</b>	5	066	1063	1117	(COL	\$	1911	* 1		đ	12	ř	813	5	601	3	64					
	1 0.%	to.3	3.5	ž	<b>X</b> *0	6 <b>.</b> N	X.5	3.6	74	74	<b>39.6</b>	<b>3.</b> .8	74	5.7	74	×.×	23		2	141	X*0	7-16	1" <b>X</b>	35.8	7.6	- R					
	5	0.1	0.7	6.0	7.5	<b>0.5</b>	0"0	2	2	1 9	1.2	•••	0"6	7.2	0.	3	3:		2.5	5	7.5	9			0.1	2*2		5	×.×	1.9	
	-		•	•	•	•	•	_	<b>.</b> .			<b>^</b>	- -	<b>_</b>	-	-				-		-	-	_		~		_		.,	
L CHIL	~ <b>.</b> *	1	1.05	1.05	<b>X</b> '0	<b>X</b> -0	6.9	<b>8</b> .0	8 8		<b>96</b> °0	0.61	0.6	0.8	5	5	2 6		20	3	9*0	3	5	6°0	0			4	13		
2	i:	6.12	9.0	29.1	24.5	1-12	ŝ	<b>6</b> °2	2 1 1	л Я И	23.5	2.5	21.9	20.5	9.6	6.8			1	13.5	15.2	15.0	13.9	1).6	12.5						
1	8	3	R1	ž	2	130	8	121	<u>1</u>	4 X	115	ŝ	â	111	111	ş	3 ș	1	ğ	8	Ħ	102	<b>8</b> ·	8	5	R			1		
	2		4		a	*	a	а	a s		5	2	*	4	2	3	<b>x</b> s		1 8	=	*	8	\$	8	<b>a</b> :	R					
	83	7   	-	×	я	ŗ	а	-			-	•	•-																		
	Abilission - biachouts	BAR DEPONENTS	T. 404 4.	APPENDICTOR (P.0.5)	T. and J.	MICTAL FOLD.	T. and J.	T. and A.	7. end 4.	T. 1964. T. 1944.	1	T	T. and 4.	CLAST CRANKER ( P.J. NGO )	T. and A.	T. and A.	T. and J.			EPORNULAS	CLEFT MARTS	THE	1. <del>m</del> .i.	2111 (MURANE - 140)	CIERT MARK ( 7.0. AL )	T. and J.					
Sec.	Ę	11/2	27	\$	ŝ	\$	61.7	۶Ľ	25	4 S	92 A	4/23	61,3	or V	414	ц Х	67,53		*	R 🗡	A'N	Ş	\$	5	Ş.	R >					
2 - 11 - 71 - 71 - 71 - 71 - 71 - 71 - 7	1	-		1.0			ę	ė					;	ł	•	1	5			1	4	1	.e.	j.		-					
					-		¥ •			• •		2	2	7	13	2	2 2			=	#	8	*	2	*	6					

RIHSA blood volume in normal children

•

•



REPRODUCIBILITY OF CLOSELY SPLOED RIESA BLOOD VOLUME DETERMINATIONS :

¥0.	RANE	DATE	7D4	PROOFDURE	PLASKA AOTIVITY 0.p. 5 =.	PLASMA ACTIVITY INCREMENT	STANDARD ACTIVITY 0.p. 5 M.	YOLUKE KL	DV COSPICIENT OF VARIATION \$	HCT \$ X0.96	TOTAL BLCOD VOLUME HL	THY DESPFICIENT OF VARIATION \$	ROURES
1.	1.8.	12/4	1490	DUROT 5 ML									RESTING TH
	0	-	1707	SAMPLE 1	2279	5259	3×37×	200	2.70	42.2	2400	2.60	SED
_	R.V.I.		1517	SAMPLE 2	62949	30600	52552	2115		42.2			
2.	A.B.	12/6	1420	SAMPLE 1	16939								RESTING IN
	GA. STOK.		1432	SANCELE 2	65285	46584	49567	2150		45.4	5901		TRUTS WHOLE
	R.V.S.		1455	TRUBOT 5 ML					0.00		,,	0.24	BLOOD OVER
			1445	MARFLE 3	109621	46358	49367	2151		1.1	5882		PRICECING 45 ER
3.	D.R.	12/7	1146	SAMPLE 1	9549								RESTING IN
	TT N. DUGD. ULOBR		1147	INJECT 5 ML									850
			1196	SAMPLE 2	<del>59257</del>	29000	46019	5100		55.5	4791		
_			1210	SAMPLE 3	67020	27765	46019	5515	. 3.52	56.0	5177	7+51	
4.	J.G.	\$/12	1505	SAMPLE 1	1965								DEMINTELY
	20 K. 790		1506	SANPLE 2	27494	25551	35376 *	2615		58.6	4259		FOST-OP (LT.
	MELA		1519	INJECT 5 ML	-				1.17		1	1.17	NOT IN SHOOK
			1590	SARPLE 5	2420	2952		2677		50,6	4560		
۶.	1.P.	5/13	1807	SAMPLE 1	1805								DO EDIATELY
	51 8.		1806	INJECT 5 RL	21185	10550	20050	8000		44.9	ssa		POST-OF (LT.
	MEL		1827	DURT 5 ML	,,		277 Ju	244	4.25		,,,,,	4.25	NOT IN SCOR
			1899	SANDLE 5		17757	29970	5575		44.2	6045		
6.	A.P.	5/19	1526	SAMPLE 1	2879								5 NOURS POST-OP
	56 P.		1927	INJECT 5 HL									(PRECHONECTORY)
	THO		1557	SAKPLE 2	79977	20994	43500	1712	2.87	50.0	2709		HTPOTEKSTVE
			1999	SUCTA 3	114219	54366	45500	1795		36.5	2827	2.1.3	(BF 00/071 F 90 )
7.	L.N.	· 67	1027	DEVENT 5 KL									Breetwo tu
	30 7.	<b>.</b>	1042	SANDLE 1	26504	25304	55515	2510		54.6	5658		NED IN
	110		1045	DUROT 5 KL	- (1-1-				0.48			0.99	
_			1075	SANTLE 2		20169	59515	2466		36.5	5915		

MEAN COMPTIGLARY - SCEAL BLCC. VLIDE + 2.20%

# TABLE 6

Technique standardization. The reproducibility of RIHSA blood volume measurements was  $\pm 2.2\%$ .

í.



TECHNIQUE STANDARDIZATION

#### THEOISICE OF STRINGE NEASUREDURITS

( AUGUST 26, 1954 )

STRINGE MUNDER	2 HL VOLUHB	CORFFICIENT OF VARIATION \$	5 HL VOLUNE ON	CORFFICIENT OF VARIATION \$
1	1,996	1.09	5.002	0,30
2	2.054	0.79	5-047	0.60
2	2.046	1.39		
3	2.011	0.55	5.028	0,22
4	2.051	0.64	5.025	0.16
5	2.042	1.19	5.043	0,52
5			5.041	0,46
6	2.015	0.15	5.006	0,22
7	2,002	0.79	5.011	0.12
8	2.027	0.45	5.033	0.52
9	2.025	0.35	5.027	0,20
10	1.989	1.44	4.979	0.76
11	2.015	0.15	5.014	0.06
12	2.034	0 <b>.7</b> 9	5.041	0.28
15	2.011	0.35	4.994	0.46
14	2,000	0.89	5.013	0.08
15	2.010	0.40	5.025	0.16
15			5.004	0.26
16	2.005	0.74	4.992	0.50
17	2.019	0.05	5.009	0.16
17	2.006	0.59		
18	2.012	0.50	5.013	0,08
19	2,020	0.10	5.020	0.06
20	2.037	0.94	5.025	0.16
	2.018	0.63 %	5.017	0.28 \$
.D.	1 0.015		20.015	
	1.989	1.44 %	4.979	0.76 \$
ATRIDUES .	2.046	1.39 🛠	5.047	0.60 \$
LINGIE	0.057		0,068	

TABLE	7	

Technique standardization. Syringe precision test. When 5 ml. volume was delivered, mean coefficient of variation was 0.28%.



#### COUNTING ERROR

### SANFLE HORE THAN TEN TIMES BACKGROUND.

SUCCESSIVE 5 MINUTE COUNTS OF 2ML. SAMPLE OF PLASKA CONTAINING LESS THAN 0.01 pc  $1^{151}$ . BACKGROUND EQUALSLESS THAN 2500 COUNTS PER 5 MINUTES. RADIOACTIVE DECAY IS NEGLECTED.

DATE	FEBRUARY 7. 1955	FEBRUARY 25, 1955	FEBRUARY 26, 1955
PERIODS	COUNTS/5 MIN.	COUNTS/ 5 MIN.	COUNTS/5 MIN.
1	29051	43590	39403
2	28838	43457	39328
3	28829	43656	39205
4	28920	43548	3894 <del>9</del>
5	28779	43649	38957
6	29082	43679	39240
7 ,	29086	45808	39219
8	29179	43522	39235
9	28878	43535	<b>58</b> 984
10		43542	39116
11		43183	39068
12		45435	39104
13		43550	39104
14			39104
15			39109
EAN	28958	43550	39147
.D.	- 140	± 142	± 151
.D. <b>%</b>	± 0.48%	± 0.33%	± 0.33%
xtremes	28779 29179	45808 45183	- <u>58949</u> <u>59405</u>
ANGE	400	625	454
\$3 <b>73</b>	9	13	15

### TABLE 8

Technique standardization. Counting error due to variation in counting apparatus is less than 1% (S.D.O. 48 - 0.33%).

.



•	NAKE AG	E PL. _HL.	DATE	PLASMA + TUBE BACKGROUND	TUBE BACKGROUND	PLASMA ACTIVITY	MEAN FLASHA ACTIVITY	% VARIATION FROM MEAN
1	CORBETT	2	2/1	55141 52598	1965 1965	51176 50633	50904.5	0.53%
2	OORBETT	2	2/1	49624 50163	2040 1905	47584 48258	47921	0.63%
3	HAWKINS	2 2	1/21	17689 17603	1745 1785	15944 15818	15881	0.40%
<b>h</b>	AUKETICH	2	1/31	4881 4819	1845 1735	5036 5084	3060	0.78%
5	VUKELICH	2 2	1/51	17670 17554	1865 1715	15805 15819	15812	0.04%
6	VUKELICH	2 2	1/24	677 <b>4</b> 6611	2160 2150	4614 4481	45475	1.47%
7	VUKELICH	2 2	1/24	22451 22571	1895 2160	20556 20211	20583.5	0.85%
8	MANDELOORN 5	9 <u>2</u> 2	12/15	28455 28624	1935 1855	26 <b>5</b> 20 26769	26644.5	0.47%
9	MANDELOORN 5	9 2	12/15	27969 27955	1840 1870	26129 26085	26107	0.08%
				1	MEAN COEFFIC	IENT OF V	ARIATION	0.58%

VARIATION IN COUNTING REPLICATE PLASMA SAMPLES.

NET VARIATION DUE TO:

VOLUMETRIC TECHNIQUE (FIPETTING 2 ML.; PIPETTE DIFFERENCES)

BACKGROUND VARIATION

COUNTING (COUNTER. TIMER. GEOMETRY).

# TABLE 9

Technique standardization. Replicate plasma samples showed a mean coefficient of variation of 0.58%.



	•		1				
NAME	DATE	VOLUME	FLASMA + TUBE BACKGROUND	TUBE BGD	PLASMA ACTIVITY	PLASMA ACTIVITY CORRECTED TO 2 MI	MEAN PLASMA ACTIVITY
GIROUX	11/22	2 1	65160 33752	1960 1830	63200 31922	63200 6 <del>3</del> 844	99.0% 100%
GIROUX	11/22	2	7040 4482	2010 1923	5030 2559	5030 5118	98•3% 100%
GIROUX	11/22	2 1	28153 15522	1880 1826	2627 <del>3</del> 13696	262 <b>7</b> 3 27392	95•9% 100%
DURELLE	11/18	2 1	44280 23342	1770 189 <b>7</b>	42510 21445	42510 42890	99•1% 100%

VARIATION BETWEEN COUNTS OF UNEQUAL PLASMA SAMPLE VOLUMES.

NET VARIATION DUE TO:

÷,

DIFFERENT GEOMETRY OF 1 ML. AND 2 ML. SAMPLES, VOLUMETRIC TECHNIQUE, BACKGROUND VARIATION, COUNTING ERRORS.

# TABLE 10

Technique standardization . The comparison of one and two ML. Sample counts shows the lack of counter variation when counting these volumes.



	DATE	Volume ML.	c.p.m. 0.01 UC TUBE + BGD	c.p.m. BGD	c.p.m. O.01 µO ACTIVITY	
PPROXIMATELY 0.01 HO	<b>2</b> /24	2	9732	450	9282 <sup>.</sup>	100%
131	2/24	3	9597	450	9147	99%
L <sup>-&gt;-</sup> RISA IN TAP	2/24	4	9031	450	8581	92%
VATER.	2/24	5	8516	450	8066	87%
	2/24	6	7856	450	7406	80%

BFFECT OF DILUTING VOLUME OF SAMPLE CONTAINING 0.01 UC RIHSA.

NET VARIATION DUE TO:

ALTERATION IN GEOMETRY OF 2ML TEST SOLUTION BY FURTHER DILUTION

VOLUMETRIC TECHNIQUE ERRORS IN ADDITION OF DILUENT

BACKGROUND VARIATION, COUNTING ERROR.

### TABLE 11

Technique standardization. Precision of counting is relatively independent of geometrical relationship of crystal to solution when 2 ml. is counted but changes with dilution.



### COUNTER STANDARDIZATION

### SFFECT OF VOLTAGE VARIATIONS

# PEBRUARY 23, 1955

<b>FOLTAGE</b>	С.Р.М. I <sup>131</sup> + вдр	C.P.M. BGD	С.Р.И. 1 <sup>131</sup>						
400	16								
450	16								
500	.31								
550	140	111	29						
600	2750	214	2536						
650	11164	322	10842						
700	13682	394	13288						
750	15564	466	15098						
800	<b>*</b> 16272	600	15672						
850	17755	1002	16755						
900	33029	13503	19526						
INUATOR S BE HEIGHT	ETTING : 2 SELECTOR : +40								
TOACTTVR	DEGAY NEGLECTED.	-							

# TABLE 12

Counter standardization. Optimal voltage (800) setting was chosen by variation of voltage over a wide range. Fluctuations in counter input voltage result in minimal counting variation when voltage is set at 800.



#### COUNTER STANDARDIZATION

### EFFECT OF VOLTAGE AND FULSE HEIGHT SELECTOR VARIATIONS FEBRUARY 23, 1955

	VOLTAGE: 600		VOLTAGE : 70	0	VOLTAGE: 800	
P.H.S.	C. P.m.	C.F.D.	G.F.D.	C.F.m.	C.P.B.	c.p.m.
	1 <sup>151</sup> + BOD	BGD	1 <sup>151</sup> + BOD	BGD	131 + BGD	
0	_					
+5	17925	456	21347	908	_	
<b>+10</b>	14745	545	19728	455	29752	6714
<b>+</b> 15	12615	272	18825	455	21961	1452
<del>4</del> 20	9132	252	17861	452	20679	601
<del>4</del> 25	1429	155	16164	416	19919	552
<del>1</del> 30	681		15962	576	19452	465
+35			15270	544	18777	478
<b>+4</b> 0			14148	321	•18 <i>6</i> 91	447
<b>↓</b> 45			13307	<del>3</del> 01	18225	431
<b>∔</b> 50			12059	265	17954	440
+55			12046	229	17247	
<b>∔6</b> 0			10824	251	16822	382
+65			6818	223	16474	
<b>+</b> 70			1920	195	15479	<b>34</b> 8
+75			806	158	14959	
<del>1</del> 80					15895	288
<del>1</del> 85					12756	
<b>4</b> 90					1474	178
ATTENUAT	CE SETTING: 2.					······································
TEST SUE	STANOS: 2ML.	- Less than O	.2yc 1131 (RIHSA).			
OOUNTING	PERIODS: CNE	MINUTE.	-			
RADICACI	IVE DECAY NEGLE	CTED.				

• SETTING CHOSEN: ATTENTUATOR. 2 - PULSE HEIGHT SELECTOR. + 40.

÷

۰.

### TABLE 13

Counter standardization. Optimal pulse height selector (+40) - Setting was chosen from settings for voltage (800) and attenuator (2) settings.

.



	AGE	WT. Kon	P.V. ML/KGM	ROV ML/KGM	tev ML/KGM	HOT \$	NO.	AGE	WT KGł.	PV ML/KGM	ROV HL/KGH	TBV ML/KOM	ROT \$
	27	64.5	44.8	39.7	84.5	49.0	*17 ELL	29	52.7	40.7	24.9	65.6	59.5
	32	57.5	41.9	34.4	76.3	47.0	•18 PAT	39	46.8	44.4	23.9	68.3	56.5
	26	75.0	39•7	28.4	68,1	43.5	*19 CAM	36	48.2	41.8	26.1	67.9	40.0
POD	31	76.8	41.4	36.1	77.5	48.5	•20 CAL	41	47.7	42.4	23.4	65.8	57.0
(AC	60	71.8	34.5	28.9	63.4	47.5	*21 DUP	38	56.8	48.6	26.8	75.4	57.0
lOF	<b>3</b> 5	69.1	52.5	27.9	60.4	48.0	*22 PAL	30	51.8	37•5	26.5	63.8	45.5
POR	41	58.2	42,1	52.1	74.2	45.0	*23 BIC	53	65.0	33.6	23.1	56.7	42.5
ruc	57	73.6	33+3	24.9	58.2	44.6	*24 DES	24	55.5	36.4	23.9	60.3	41.2
PR3	36	64.5	35.5	<del>3</del> 0.8	66.3	48.3	•25 SHA	26	63.0	34.8	21.7	56.5	40.0
LAW	60	47+7	49.4	<del>3</del> 2•5	81.9	41.3	*26 PAR	26	55.2	37.7	24.5	62.2	41.0
OTT	<b>35</b>	107.	<del>3</del> 0.3	26.4	56.7	48.5	*27 BAR	37	56.4	39.5	24.9	64.4	40.3
TAL	<u>72</u>	50.0	48.9	<del>3</del> 0•2	79.1	39•7	*28 LIV	34	58.4	50.2	<del>3</del> 0.0	80.2	<del>3</del> 9 <b>.</b> 0
WRI	<del>3</del> 9	59.8	49.1	<del>3</del> 9.0	88.1	46.0	•29 DIZ	43	63.6	44.7	18.9	63.6	51.0
DUC	<del>3</del> 2	63.6	55.8	<b>51.</b> 0	86.8	37.2	*30 LIE	27	64.5	28.4	22.1	50.5	45.5
DAL	50	40.8	45.7	40.6	86.3	49.0	•31 KSN	47	58.2	36.6	20.5	57,1	57.5
CRO	44	79•3	<b>38.</b> 1	26.8	64.9	43.0	*32 WHI	32	56.1	44.5	24.5	69.0	57.0
AVERAGE THO ( 16 MALES )			PV	ROV	ŤBV	нст	AVERAGE	TBC		FV 40.1	RCV 24.1	TBV 64.2	HOT 59.5%
			41.4	31.9	73.3	45.4%	(16 FE	VALES • )		<b>±5.</b> 5	±2.6	±7.1	±3.3
			47.0	14.7	-10.4	23.4				43.5	27.2	70.7	40.5%
AL AVI 3 MALI	erage Es )		40.8	32.0	72•7	45.8%	( 18 P	AVERAGE DALES )		±7.3	±3.7	-10.2	13.5
	EL ED SEN VOD CAO POR COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3 COC FR3	A08 EL 27 ED 32 MEN 26 00D 31 A00 60 10P 35 NOR 41 10C 57 PR3 36 A07 57 PR3 36 PR3 46 PR3	AGE         WT. EUDH           SEL         27         64.5           SED         32         57.5           SED         31         76.8           SAO         60         71.8           SOR         41         58.2           TOC         57         73.6           FR3         36         64.5           SAW         60         47.7           STT         33         107.           TAL         32         50.0           GRI         39         59.8           SDUC         32         63.6           OAL         50         40.8           STRO         44         79.3           STRO         44         79.3           STRO         5         MALES	AGE         WT. NON         P.V. ML/XGH           EL         27         64.5         44.8           ED         32         57.5         41.9           ME         26         75.0         39.7           NOD         31         76.8         41.4           60         60         71.8         34.5           NOR         41         58.2         42.1           NOR         41         58.2         42.1           NOR         57         75.6         35.5           NA         60         47.7         49.4           DTT         33         107.50.5         54.5           NA         60         47.7         49.4           DTT         33         107.50.5         55.8           NAL         52         50.0         48.9           TRI         39         59.8         49.1           DOC         32         63.6         55.8           DAL         50         40.8         45.7           SNALES         41.4         7.0           SHALES         41.4         4.0.8	AGE         WT. KOR         P.V. ML/KORM         BOV ML/KORM           EL         27         64.5         44.8         39.7           ED         32         57.5         41.9         34.4           ME         26         75.0         39.7         28.4           OD         31         76.8         41.4         36.1           AOE         71.8         34.5         28.9         27.9           IOP         53         69.1         32.5         27.9           IOP         53         69.1         32.5         24.9           IOP         53         64.5         35.5         24.9           PR3         36         64.5         35.5         30.8           AW         60         47.7         49.4         32.5           PTT         35         107.5         30.3         26.4           TAL         32         50.0         48.9         30.2           MRI         59         59.8         49.1         39.0           DOC         32         65.6         55.8         31.4           DAL         50         40.8         45.7         40.6           SMALES () </td <td>AGE         WT. KOM         P.V. ML/KOM         ROV ML/KOM         TEV ML/KOM           EL         27         64.5         44.8         39.7         84.5           EE         27         64.5         44.8         39.7         84.5           EE         27         64.5         41.9         34.4         76.3           EE         26         75.0         39.7         28.4         68.1           OD         31         76.8         41.4         36.1         77.5           AO         60         71.8         34.5         28.9         65.4           IOP         35         69.1         32.5         27.9         60.4           IOP         35         69.1         32.5         21.7         74.2           TOC         37         73.6         35.5         24.9         58.2           FRI         36         64.5         35.5         30.8         66.3           AW         60         47.7         49.4         32.5         81.9           DTT         35         107.30.5         26.4         56.7           TAL         32         50.0         48.9         30.2         79.1</td> <td>AGE         WT. KONK         P.V. ML/KOM         ROV ML/KOM         TBV ML/KOM         HOT ML/KOM           EL         27         64.5         44.8         39.7         84.5         49.0           EE         32         57.5         41.9         34.4         76.5         47.0           ME         26         75.0         39.7         28.4         68.1         43.5           NOD         31         76.8         41.4         36.1         77.5         48.5           NOD         51         76.8         41.4         36.1         77.5         48.5           NOR         60         71.8         34.5         28.9         65.4         47.5           NOR         41         58.2         42.1         32.1         74.2         45.0           NOR         41         58.2         42.1         32.1         74.2         45.0           NOR         41.7         59.5         30.8         66.5         48.3           AM         60         47.7         49.4         32.5         81.9         41.3           STT         35         107.         30.3         26.4         56.7         48.5           &lt;</td> <td>AGE         WT.         P.V.         ROV         TEV         HOT         NO.           EL         27         64.5         44.6         39.7         84.5         49.0         *17         ELL           EL         27         64.5         44.6         39.7         84.5         49.0         *17         ELL           EL         27         64.5         44.6         36.1         43.5         47.0         *18         PAT           MEN         26         75.0         39.7         28.4         68.1         43.5         *19         OAM           NOD         31         76.8         41.4         36.1         77.5         48.5         *20         CAL           MOR         60         71.8         34.5         28.9         63.4         47.5         *21         DUP           MOR         41         58.2         42.1         32.1         74.2         45.0         *22         PAL           MOR         51.5         30.8         66.3         48.5         *25         SHA           MOR         41.7         49.4         32.5         81.9         41.3         *26         PAR           MOR</td> <td>AGE         WT, KOH         F.V. ML/KOH         ROV ML/KOH         TEV ML/KOH         HOT ML/KOH         HOT S         NO.         AGE           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29           EL         26         75.0         39.7         28.4         68.1         43.5         *19         0.M         36           OD         31         76.8         41.4         36.1         77.5         48.5         *20         CAL         41           IAO         60         71.8         34.5         28.9         65.4         47.5         *21         DUP         58           10P         35         69.1         32.5         27.9         60.4         48.0         *22         PAL         50           00R         41         58.2         42.1         32.1         74.2         45.0         *23         BIO         53           100F         35.5         50.5         30.8         66.3         48.3         *25         SHA<td>AGE         W.         F.V.         ROV         TEV         HOT         NO.         AGE         WT           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29         52.7           EE         52         57.5         41.9         34.4         76.5         47.0         *18         FAT         39         46.8           WEN         26         75.0         39.7         28.4         68.1         43.5         *19         0AM         36         48.2           VOD         51         76.8         41.4         36.1         77.5         48.5         *20         0AL         41         47.7           AG         0         71.8         34.5         28.9         65.4         47.5         *21         DUP         38         56.8           100F         35         69.1         32.5         27.9         60.4         48.0         *22         PAL         30         51.8           100F         35         59.5         30.8         66.5         48.3         *25         BIO         55         55.0           1005         77.6         35.5</td><td>AGE         WT, KOK         P.V. ML/KOH         ROV ML/KOH         TEV ML/KOH         HOT ML/KOH         NO.         AGE         WT KOK.         PV ML/KOH           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29         52.7         40.7           AGE         32         57.5         41.9         34.4         76.3         47.0         *18         PAT         39         46.8         44.4           AGE         75.0         39.7         28.4         68.1         45.5         *19 OAM         56         48.2         41.8           AGE         76.8         41.4         36.1         77.5         48.5         *20 CAL         41         47.7         42.4           AGE         60         71.8         34.5         28.9         65.4         47.5         *21 DUP         38         56.6         48.6           AGE         41.1         58.2         42.1         32.1         74.2         45.0         *25 BIO         51.8         37.5           AGE         54.5         35.5         30.8         66.3         48.5         *25 BIO         55.5         56.4           AG</td><td>AGE         MT.         F.V.         ROV         TEV         HOT         NO.         AGE         MT         PV         ROV           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29         52.7         40.7         24.9           ED         32         57.5         41.9         34.4         76.5         47.0         *18         PAT         39         46.8         44.4         23.9           ED         32         57.5         41.9         34.4         76.5         47.0         *18         PAT         39         46.8         44.4         23.9           ED         26         79.0         39.7         28.4         68.1         45.5         *19 OAM         36         48.2         41.8         26.1           000         31         76.8         41.4         56.1         77.5         48.5         *20 CAL         41         47.7         47.4         25.4         25.4         25.5         26.5         48.6         26.5         55.5         26.5         55.5         26.5         55.5         36.4         25.9         77.7         24.5         55.2         57.7</td><td>AGE         W.         B.V.         BOV         TEV         HOT         MO.         AGE         HT         PV         BOV         TEV           KL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29         52.7         40.7         24.9         65.6           KB         32         57.5         41.9         34.4         76.5         47.0         *18         PAT         59         46.6         44.4         25.9         68.5           KB         26         75.0         39.7         28.4         68.1         45.5         *19         0.M         56         48.2         41.8         26.1         67.9           VDD         31         76.8         41.4         36.1         77.5         48.5         *20         CAL         41         47.7         47.4         25.4         65.8           AGO         71.8         34.5         28.9         65.4         48.0         *22         PAL         50         35.6         25.1         56.7         56.8         57.5         56.8         57.6         57.8         57.4         56.7         57.4         57.4         57.5         &lt;</td></td>	AGE         WT. KOM         P.V. ML/KOM         ROV ML/KOM         TEV ML/KOM           EL         27         64.5         44.8         39.7         84.5           EE         27         64.5         44.8         39.7         84.5           EE         27         64.5         41.9         34.4         76.3           EE         26         75.0         39.7         28.4         68.1           OD         31         76.8         41.4         36.1         77.5           AO         60         71.8         34.5         28.9         65.4           IOP         35         69.1         32.5         27.9         60.4           IOP         35         69.1         32.5         21.7         74.2           TOC         37         73.6         35.5         24.9         58.2           FRI         36         64.5         35.5         30.8         66.3           AW         60         47.7         49.4         32.5         81.9           DTT         35         107.30.5         26.4         56.7           TAL         32         50.0         48.9         30.2         79.1	AGE         WT. KONK         P.V. ML/KOM         ROV ML/KOM         TBV ML/KOM         HOT ML/KOM           EL         27         64.5         44.8         39.7         84.5         49.0           EE         32         57.5         41.9         34.4         76.5         47.0           ME         26         75.0         39.7         28.4         68.1         43.5           NOD         31         76.8         41.4         36.1         77.5         48.5           NOD         51         76.8         41.4         36.1         77.5         48.5           NOR         60         71.8         34.5         28.9         65.4         47.5           NOR         41         58.2         42.1         32.1         74.2         45.0           NOR         41         58.2         42.1         32.1         74.2         45.0           NOR         41.7         59.5         30.8         66.5         48.3           AM         60         47.7         49.4         32.5         81.9         41.3           STT         35         107.         30.3         26.4         56.7         48.5           <	AGE         WT.         P.V.         ROV         TEV         HOT         NO.           EL         27         64.5         44.6         39.7         84.5         49.0         *17         ELL           EL         27         64.5         44.6         39.7         84.5         49.0         *17         ELL           EL         27         64.5         44.6         36.1         43.5         47.0         *18         PAT           MEN         26         75.0         39.7         28.4         68.1         43.5         *19         OAM           NOD         31         76.8         41.4         36.1         77.5         48.5         *20         CAL           MOR         60         71.8         34.5         28.9         63.4         47.5         *21         DUP           MOR         41         58.2         42.1         32.1         74.2         45.0         *22         PAL           MOR         51.5         30.8         66.3         48.5         *25         SHA           MOR         41.7         49.4         32.5         81.9         41.3         *26         PAR           MOR	AGE         WT, KOH         F.V. ML/KOH         ROV ML/KOH         TEV ML/KOH         HOT ML/KOH         HOT S         NO.         AGE           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29           EL         26         75.0         39.7         28.4         68.1         43.5         *19         0.M         36           OD         31         76.8         41.4         36.1         77.5         48.5         *20         CAL         41           IAO         60         71.8         34.5         28.9         65.4         47.5         *21         DUP         58           10P         35         69.1         32.5         27.9         60.4         48.0         *22         PAL         50           00R         41         58.2         42.1         32.1         74.2         45.0         *23         BIO         53           100F         35.5         50.5         30.8         66.3         48.3         *25         SHA <td>AGE         W.         F.V.         ROV         TEV         HOT         NO.         AGE         WT           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29         52.7           EE         52         57.5         41.9         34.4         76.5         47.0         *18         FAT         39         46.8           WEN         26         75.0         39.7         28.4         68.1         43.5         *19         0AM         36         48.2           VOD         51         76.8         41.4         36.1         77.5         48.5         *20         0AL         41         47.7           AG         0         71.8         34.5         28.9         65.4         47.5         *21         DUP         38         56.8           100F         35         69.1         32.5         27.9         60.4         48.0         *22         PAL         30         51.8           100F         35         59.5         30.8         66.5         48.3         *25         BIO         55         55.0           1005         77.6         35.5</td> <td>AGE         WT, KOK         P.V. ML/KOH         ROV ML/KOH         TEV ML/KOH         HOT ML/KOH         NO.         AGE         WT KOK.         PV ML/KOH           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29         52.7         40.7           AGE         32         57.5         41.9         34.4         76.3         47.0         *18         PAT         39         46.8         44.4           AGE         75.0         39.7         28.4         68.1         45.5         *19 OAM         56         48.2         41.8           AGE         76.8         41.4         36.1         77.5         48.5         *20 CAL         41         47.7         42.4           AGE         60         71.8         34.5         28.9         65.4         47.5         *21 DUP         38         56.6         48.6           AGE         41.1         58.2         42.1         32.1         74.2         45.0         *25 BIO         51.8         37.5           AGE         54.5         35.5         30.8         66.3         48.5         *25 BIO         55.5         56.4           AG</td> <td>AGE         MT.         F.V.         ROV         TEV         HOT         NO.         AGE         MT         PV         ROV           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29         52.7         40.7         24.9           ED         32         57.5         41.9         34.4         76.5         47.0         *18         PAT         39         46.8         44.4         23.9           ED         32         57.5         41.9         34.4         76.5         47.0         *18         PAT         39         46.8         44.4         23.9           ED         26         79.0         39.7         28.4         68.1         45.5         *19 OAM         36         48.2         41.8         26.1           000         31         76.8         41.4         56.1         77.5         48.5         *20 CAL         41         47.7         47.4         25.4         25.4         25.5         26.5         48.6         26.5         55.5         26.5         55.5         26.5         55.5         36.4         25.9         77.7         24.5         55.2         57.7</td> <td>AGE         W.         B.V.         BOV         TEV         HOT         MO.         AGE         HT         PV         BOV         TEV           KL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29         52.7         40.7         24.9         65.6           KB         32         57.5         41.9         34.4         76.5         47.0         *18         PAT         59         46.6         44.4         25.9         68.5           KB         26         75.0         39.7         28.4         68.1         45.5         *19         0.M         56         48.2         41.8         26.1         67.9           VDD         31         76.8         41.4         36.1         77.5         48.5         *20         CAL         41         47.7         47.4         25.4         65.8           AGO         71.8         34.5         28.9         65.4         48.0         *22         PAL         50         35.6         25.1         56.7         56.8         57.5         56.8         57.6         57.8         57.4         56.7         57.4         57.4         57.5         &lt;</td>	AGE         W.         F.V.         ROV         TEV         HOT         NO.         AGE         WT           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29         52.7           EE         52         57.5         41.9         34.4         76.5         47.0         *18         FAT         39         46.8           WEN         26         75.0         39.7         28.4         68.1         43.5         *19         0AM         36         48.2           VOD         51         76.8         41.4         36.1         77.5         48.5         *20         0AL         41         47.7           AG         0         71.8         34.5         28.9         65.4         47.5         *21         DUP         38         56.8           100F         35         69.1         32.5         27.9         60.4         48.0         *22         PAL         30         51.8           100F         35         59.5         30.8         66.5         48.3         *25         BIO         55         55.0           1005         77.6         35.5	AGE         WT, KOK         P.V. ML/KOH         ROV ML/KOH         TEV ML/KOH         HOT ML/KOH         NO.         AGE         WT KOK.         PV ML/KOH           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29         52.7         40.7           AGE         32         57.5         41.9         34.4         76.3         47.0         *18         PAT         39         46.8         44.4           AGE         75.0         39.7         28.4         68.1         45.5         *19 OAM         56         48.2         41.8           AGE         76.8         41.4         36.1         77.5         48.5         *20 CAL         41         47.7         42.4           AGE         60         71.8         34.5         28.9         65.4         47.5         *21 DUP         38         56.6         48.6           AGE         41.1         58.2         42.1         32.1         74.2         45.0         *25 BIO         51.8         37.5           AGE         54.5         35.5         30.8         66.3         48.5         *25 BIO         55.5         56.4           AG	AGE         MT.         F.V.         ROV         TEV         HOT         NO.         AGE         MT         PV         ROV           EL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29         52.7         40.7         24.9           ED         32         57.5         41.9         34.4         76.5         47.0         *18         PAT         39         46.8         44.4         23.9           ED         32         57.5         41.9         34.4         76.5         47.0         *18         PAT         39         46.8         44.4         23.9           ED         26         79.0         39.7         28.4         68.1         45.5         *19 OAM         36         48.2         41.8         26.1           000         31         76.8         41.4         56.1         77.5         48.5         *20 CAL         41         47.7         47.4         25.4         25.4         25.5         26.5         48.6         26.5         55.5         26.5         55.5         26.5         55.5         36.4         25.9         77.7         24.5         55.2         57.7	AGE         W.         B.V.         BOV         TEV         HOT         MO.         AGE         HT         PV         BOV         TEV           KL         27         64.5         44.8         39.7         84.5         49.0         *17         ELL         29         52.7         40.7         24.9         65.6           KB         32         57.5         41.9         34.4         76.5         47.0         *18         PAT         59         46.6         44.4         25.9         68.5           KB         26         75.0         39.7         28.4         68.1         45.5         *19         0.M         56         48.2         41.8         26.1         67.9           VDD         31         76.8         41.4         36.1         77.5         48.5         *20         CAL         41         47.7         47.4         25.4         65.8           AGO         71.8         34.5         28.9         65.4         48.0         *22         PAL         50         35.6         25.1         56.7         56.8         57.5         56.8         57.6         57.8         57.4         56.7         57.4         57.4         57.5         <

#### RIHSA BLOOD VOLUME FULAONARY TUBSROULOSIS (FRE-OFSRATIVE)

1

# TABLE 14

Pulmonary tuberculosis surgery. RIHSA blood volume in pre-operative patients. There is no statistically significant difference between the tuberculosis group averages and the normal group averages.



NO.	•	BLOOD LOSS RIHSA ESTIMATE	BLOOD LOSS TOTAL MEASURED	REPLACEMENT (BLOOD + PVP)	POST-OPERATIVE RIHSA TOTAL BLOOD VOLUME REPORT
1	tel	2370	1953	1550	TBV DECREASED 861 ML.
2	LEB	865	1461	1325	TEV INCREASED 73 ML.
3	gen	3258	2694	2165	TBV DECREASED 851 ML.
4	POD	1627	1847	1400	TEV INCREASED 92 ML.
5	KAC	5561	555 <b>4</b>	4517	TEV DECREASED 1231 ML.
6	HOP	2072	2091	1450	TEV DECREASED 568 ML.
7	FOR	2365	2185	1945	TEV DECREASED 568 ML.
8	TUC	1593	1491	1400	TBV DECREASED 462 ML.
9	Fre	727	954	500	TBV DECLEASED 135 ML.
17	₿LL‡	2306	2596	2175	TBV DECREASED 241 ML.
18	FAT*	1322	1534	1100	TBV DECREASED 426 ML.
19	CAH*	1136	709	636	TBV DECREASED 485 ML.
20	CAL*	1492	1697	1550	TBV DECREASED 494 ML.
21	DUP	2716	2639	2180	TEV DECREASED 1108 ML.
22	FAL*	1318	1217	1900	TEV INCREASED 316 ML.

# RIHSA ESTIMATE, MEASURED OPERATIVE BLOOD LOSS, REPLACEMENT AND POST-OFFRATIVE RIHSA TOTAL BLOOD VOLUME (PULMONARY TUBBROULOSIS)

SUND ARY :

POSTOFERATIVELY PATIENTS HAD AVERAGE NET DECREASE OF 436 ML. TOTAL BLOOD VOLUME RIMAA ESTIMATE AND TOTAL MEASURED LOSS VARIED 243 ML. ON THE AVERAGE. (MAXIMUM VARIATIONS WERE \$ 600 ML). PATENTS' MEASURED LOSS EXCEEDED REPLACEMENT BY 325 ML. (AVERAGE). VOLUME OF TRANSPUSION AND FVP ADMINISTERED COULD BE SATISFACTORILY ACCOUNTED FOR WHEN LOSS WAS MEASURED, REPLACEMENT NOTED AND RIMAA BLOOD VOLUME DETERMINATIONS FERFORMED BEFORE AND AFTER OPERATION. POSTOFERATIVE ELOOD VOLUME DEFICIT OF 1000 ML. IS AN INDICATION FOR TRANSPUSION.

### TABLE 15

Pulmonary tuberculosis surgery. Summary of blood volume changes associated with pulmonary tuberculosis surgery. RIHSA estimate and gravimetric measurement of operative loss correlate well. The post-operative RIHSA blood volume test indicates the adequacy of replacement of operative blood loss.



		POST OPERATIVE									
		OHANGE IN RIHSA TOTAL BLOOD VOLUME (FULMONARY TUBER									
390	•	AGE	OPERATION	FOST-OPERATIVE TBV (ML,)							
1	tel	27	L.U.L.	- 861							
2	LEB	32	L.U.L.	+ 73							
3	GEN	26	L.L.L. + D.	- 851							
4	POD	31	L.U.L.	+ 92							
5	KAO	60	R.U.L.	- 1231							
6	HOP	35	L.U.L.	- 568							
7	FOR	41	L.U.L.	- 568							
8	TUC	37	R.U. + L.L.	- 462							
9	PRE	56	Т.	- 133							
17	ELL*	· 29	, R.L.L.	- 241							
18	PAT*	39	R.P.	- 426							
19	САМФ	36	R.P.	- 485							
20	CAL#	41	R.U.L.	- 494							
21	DUP	<u>5</u> 8	L.U.L.	- 1108							
22	PAL*	<del>3</del> 0	R.U.L.	+ 316							

----

.

ł

AVERAGE NET OHANGE: 465 ML. DEFEOIT TRANSFUSION IN RECOVERY ROOM RECOMMENDED IN CASES 5 KAO and 21 DUP\* (5 KAO REMAINED NORMOTENSIVE; 21 DUP\* BECAME HIFOTENSIVE IN RECOVERY ROOM). OVER REPLACEMENT RECOGNIZED IN C.R. IN CASE 22 PAL\*. OPERATIVE AND FOUR HOUR FOST-OPERATIVE HIFOTENSICH - PROBABLY RELATED TO DIFFICULTY IN MAINTAINING PROFER VERTILATORY EXCHANGE.

# TABLE 16

Pulmonary tuberculosis surgery. Change in total blood volume associated with surgery. Post-operatively 15 subjects had an average deficit of 463 ml. .



### RIHSA ESTIMATENO OF OPERATIVE BLOOD LOSS

BASED ON COMPARISON OF FRE- AND POSTOPERATIVE BLOOD VOLUME DETERMINATIONS. (PULMONARY TUBEROULOSIS)

_					
NO	•	△ ROV (ML)	BLOOD TRANSFUSED	∆ wB	RIHSA ESTIMATE
1	TEL	- 594	1050	1520	2370
2	LEB	+ 207	1325	- 460	865
3	GEW	- 492	2165	1095	3258
4	POD	- 102	1400	227	1627
5	KAO	° - 920	\$517	2044	5561
6	HOF	- 260	1450	622	2072
7	FOR	- 639	945	1420	2565
8	TUO	- 87	1400	195	1595
9	PRE	- 327	NIL	727	727
17	<b>ELL</b> ●	- 79	2175	151	2306
18	PAT*	- 102	1100	227	1322
19	САМ#	- 225	636	500	1136
21	DUP+	- 466	1680	1056	2716
22	PAL*	+ 37	1400	- 82	1318
20	CA L®	- 199	1050	442	1492

★★ CALCULATION: RTH3A ESTIMATE EQUALS BLOOD TRANSFUSED FLUS NET GAIN OR LOSS OR WHOLE BLOOD (△ WB). △ WB IS CALCULATED FROM NET CHANGE IN RED CELL VOLUME (△ RCV). △RCV IS THE INCREASE IN POSTOPERATIVE ROV (PLUS △ RCV) OR DECREASE IN POSTOPERATIVE ROV (- △ RCV).

POR CALCULATION ASSUME:
500 ML. BLOOD TRANSFUSION REPRESENTS AN AVERAGE OF 225 ML. RED CELLS.
NET CHANGE (GAIN + OR LOSS-) OF 225 ML. OF RED CELL VOLUME (RCV) REPRESENTS A NET CHANGE OF 500 ML. OF WHOLE BLOOD (AWB). IF AWB IS AN INGREASE DUE TO OVERTRANSFUSION, SUBTRACT AWB FROM BLOOD TRANSFUSED; IF AWB IS A DEOREASE DUE TO UNDERTRANSFUSION, SUBTRACT AWB FROM BLOOD TRANSFUSED. ANSWER IS RIHSA ESTIMATE OF OPERATIVE BLOOD LOSS.

# TABLE 17

Pulmonary tuberculosis surgery. Estimate of operative blood loss as calculated from preand post-operative RIHSA blood volume measurements.



#### MEASURE : OF OPERATIVE BLOOD LOSS AND REPLACEMENT (FULHONARY TUBEROULOSIS)

-												
ю.		301	**	OPSILITION	SPONGES	DRJ. PES	SUCTION	CHEST TUBE	TOTAL	BLOOD	FVP	REFLICEVENT TOTAL
1	TEL	27	64.5	L.U. 10830708Y	1636	317			1955	1050	500	1550
2	LD	<u>52</u>	57.5	L.U. LOBECTORY	1224	87		150	1461	1325		1525
5 4	120	26	75.0	L.L. LOBECTON -DECORTI-	1797	197	300	400	2694	2165		2165
•	POD	51	76.8	L.U. LOBECTONT	1367	260		200	1847	1400		1400
5	<b>FA</b> 0	60	n.*	R.U. LOBSCTORT-THROUGH	4784	220	200	350	555A	3517	1000	4517
6	RO <b>P</b>	<del>5</del> 5	69.1	L.U. LOBEOTOKY	1480	211	200	200	2091	1450		1450
7	POR	41	58.2	L.U. LOBECTORY	1485	200	150	350	2185	945	1000	1945
8	100	57	73.6	R.U. AND L. LOBECTORY	1249	82	160		1491	1400		1400
9	PRE	36	64.5	THORACOPLASTI	797	102	5	50	9 <b>%</b>		500	500
17	ELL*	29	52.7	R.L. LOBECTORY	2211	85	100	200	2596	2175		2175
18	P1 T*	<del>5</del> 9	46.8	R. PREDNONECTORY	1184	550			1554	1100		1100
19	CAHP	35	48.2	R. FREMOKSOTONY	552	87	90		709	656		636
20	CA L®	41	47.7	R.U. LOBSCTORY	1557	110	30	200	1697	1050	500	1550
21	DUP•	<b>5</b> 8	<del>%</del> .8	L.U. LOBSCTORY	1689	565	185	200	2659	1680	500	2160
22	PAL®	<del>5</del> 0	51.8	R.U. LOBECTONT	972	165	60	20	1217	1400	500	1900

· POULE PATIENTS

AVERAGE BLOOD LOSS IN O.R. (SPONNES, DRAPES, SUCTION)

1-TROPACOPLASTY

1-THORACOPLASTY 904 KL. 2-NULLONGOTOKY 1121 KL. 11-LOSBOTOKY (EKOLUDING 5 KAO)1814 KL.

AVERAGE DISCHEPANOT BET-BEN TOTAL MEASURED LOSS AND REPLACEMENT :

REPLACEMENT AVERAGED 525 ML. LESS THAN LOSS.

### TABLE 18

Pulmonary tuberculosis surgery. Measurement of operative blood loss and replacement. Summary of 15 cases. These patients had replacement of blood loss averaging 325 ml. under-transfusion. Maximal blood losses were encountered when procedures such as lobectomy required extensive dissection.



	8 B	1000	VOLU	<u> </u>
_		_		

TULNOWART TUBERCULOSIS (\_POST-OPERATIVE\_)

0	408	47 KGM	FV HE_/LCH	NCV NL/LON	THV ML/KOM	NOT S	<b>NO</b>	ACE	Ŧ	PV NIL/KGN	NCV NL/KCN	TUV WL/KGM	NCT \$
1 - TEL	27	64.5	40.6	30.5	71.1	44.7	17 - ELL <sup>X</sup>	29	52.7	37.3	23.7	61.0	40.5
2 • LID	32	57.5	39.5	38.0	77.5	51.0	18 - PAT <sup>X</sup>	39	46.8	37.5	21.7	<b>99.</b> 2	36,2
)- OBH	26	75.0	34.9	21.9	56.8	40.2	19 - CAN <sup>X</sup>	36	48.2	36.4	21.4	57.8	<b>38.</b> 5
4 - 200	n	76.8	43.9	34.8	78.7	46.0	20 - CAL <sup>X</sup>	41	47.7	36.2	19.2	55.4	¥.9
5 - KAC	60	71.8	30.2	16.1	46.3	16.3	21 - DUP <sup>X</sup>	38	56.8	37.3	18.6	55.9	34.7
6 - 107	33	69.1	28.4	23.8	52.1	47.5	22 - PAL <sup>X</sup>	30	51.8	42.7	27.2	69.9	40.6
7 - FOR	4	58.2	43.4	21.0	64.4	34.0							
8 - TUC	37	73.6	28.2	23.7	51.9	47.6							
9 - <b>PNE</b>	36	64.5	38.5	25.7	64.2	42.7							
67-07 TBC				NCV	TBW	HDT#	POST-OP TE	c			RCV	TBV	HCTS
WALLES)			36.4	26.2	62.6	43.2	(6 FEMALES)			37.9	22.0	<b>59.9</b>	36.0
			- 5.9	- 6.6	- 11.0	÷ 5.3				- 2.4	- 3.2	- 5.3	÷ 2.
			41-4	31.9	73.3	45.4	798-0P			40.1	24.1	64.2	39.3
16 m(ms)			- 7.0	- 4.7	- 10.4	- 3.4	(16 FEMALES	)		- 5.5	- 2.6	- 7.1	÷ ).
COMMA L.			40.8	32.0	72.7	45.8	NORMAL AND AND A			43.5	27.2	70.7	40.
			• • •		1.4.4		ATERALE						

:

i

# TABLE 19

Pulmonary tuberculosis surgery. Post-operative blood volume studies. (Within four hours after operation).

•

1

i

. {

i

į

•





### FIGURE 8

Replacement of whole blood loss; blood volume changes associated with a major operative procedure. The pre-operative hematocrit (PCV%) of 34% was low due to a large plasma volume. Operative transfusion was adequate.







;

Replacement of whole blood loss in the surgical treatment of hemorrhage from a duodenal ulcer. Though the hematocrit (PCV%) on day 13 was normal there was a true anemia (red cell deficit).

. .




#### FIGURE 10

Replacement of red cell deficit. Packed red cells were given pre-operatively because of the large total blood volume and chronic anemia. Operative blood loss was minimal.





Expansion of plasma volume occurring during ACTH therapy. Hematocrit (PCV%) changes are shown and illustrate the genesis of a spurious anemia.

### CHART I

RIHSA BLOOD VOLUME DETERMINATIONS IN SURGICAL CONDITIONS

REQUIRING REPLACEMENT THERAPY:

File No.	Name	Age	Date	WT.	Diagnosis	PV-ML	RCV-ML	TB <b>V-ML</b>	PV	RCI
4-20	S.C.	77	9/25	78.6	Duodenal ulcer - massive hemorrhage	3112	1038	4150	39.6	13,
4-21	S.C.	77	9/26	78 <b>.</b> 6	Duodenal ulcer - massive hemorrhage	3333	1477	4810	42•4	18,
4-22	S.C.	77	9/26	78.6	Duodenal ulcer - massive hemorrhage	3357	2093	5450	42.7	26,
4 <del>-</del> 37	S.C.	77	10/7	78.6	Duedenal ulcer - massive hemorrhage	2178	1532	3710	27.7	19.
4=64	A.A.	76	11/30	69.8	CA. ascending colon - anemia	4290	1460	5750	61.5	20,
4-69	A.A.	76	12/1	69.8	CA. ascending colon - anemia	4560	1780	6340	65•5	25

# ASSOCIATED WITH: a) total blood volume deficit b) red cell volume deficit

- a) total blood volume expansion b) red cell volume expansion

7	TBV	HCT	Remarks
.2	52.8	26.0	Pale; pulse 92; actively bleeding
•8	61.2	32•0	1200 ML blood since yesterday; bleeding stopped
.6	69•3	40.0	1600 ML blood plus gastrectomy since last test. Immediate post-op.
•5	47.2	43•0	P.O. #11; eating poorly
•9	82.4	26.5	Hemorrhage 1 month ago; 1000 ML blood over past 48 hours
•5	91.0	<b>29</b> •0	500 ML packed cells yesterday
		,	

### CHART I

# RIHSA BLOOD VOLUME DETERMINATIONS IN SURGICAL CONDITIONS

# ASSOCIATED WITH: a) total blood volume deficit b) red cell volume deficit

File No.	Name	Age	Date	WT.	Diagnosis	PV-ML	RCV-ML	TB <b>V-ML</b>	PV	RCV	TBV	HCT	Remarks
<b>4-</b> 20	S.C.	77	9/25	78.6	Duodenal ulcer - massive hemorrhage	3112	1038	4150	39.6	13.2	52.8	<b>26</b> •0	Pale; pulse 92; actively bleeding
4-21	S.C.	77	9/26	78 <b>.</b> 6	Duodenal ulcer - massive hemorrhage	3333	1477	4810	42•4	18,8	61.2	32•0	1200 ML blood since yesterday; bleeding stopped
4+22	S.C.	77	9/26	78.6	Duodenal ulcer - massive hemorrhage	3357	2093	5 <b>45</b> 0	42.7	26.6	<del>69</del> •3	40.0	1600 ML blood plus gastrectomy since last test. Immediate post-op.
4-37	S.C.	77	10/7	78.6	Duedenal ulcer - massive hemorrhage	2178	1532	3710	27.7	19.5	47.2	43 <b>.</b> 0	P.O. #11; eating poorly
4=64	<b>A.A.</b>	76	11/30	<b>69</b> •8	CA. ascending colon - anemia	4290	1460	5750	61.5	20.9	82.4	26.5	Hemorrhage 1 month ago; 1000 ML blood over past 48 hours
<b>4-6</b> 9	Å.Å.	76	12/1	69 <b>.</b> 8	CA. ascending colon - anemia	4 <i>5</i> 60	1780	6340	65 <b>•</b> 5	25•5	91.0	29 <b>.</b> 0	500 ML packed cells yesterday
												( con	tinued, next page)

CHART I

.

REQUIRING REPLACEMENT THERAPY: a) total blood volume expansion b) red cell volume expansion

File No.	Name	Age	Date W	r.	Diagnosis	PV→ML	RCV-ML	TBV-ML	PV
<b>4-7</b> 2	A.A.	76	12/4	69.8	CA. ascending colon - anemia	3780	21.20	5900	54•3
5 <b>-1</b>	J <b>.</b> S.	55	5/9	55•5	CA. stomach - massive hemorrhage	3220	775	3995	58.0
5 <del>-</del> 55	W.S.	79	3/10	59.0	Gastric ulcer - massive hemorrhage	2700	1060	3760	45•'
5-45	C.P.X	68	3/7	57.2	CA. colon - anemia	2115	1320	3435	36.9
5 <b>-</b> 10	A.S.	74	1/31	81.0	Duodenal ulcer - massive hemorr-	3200	1300	4500	39•!

4 <del>-</del> 32	S₀G₀	61	10/1	73•4	Esophageal varices - bleeding	3030	1210	4240	41•3	16.5
4 <del>-</del> 35	S₀G.	61	10/4	73•4	Esophageal varices - bleeding	3900	1920	5820	53.2	26•2
5-3	R.H.	16	1/18	52.7	Esophageal varices - bleeding	2880	1560	4440	54•5	29.8

CHART I (continued)

TBV	HCT	Remarks
84•6	37•5	500 ML blood 12/1; Rt. hemicolectomy with 500 ML blood 12/2; P.0.#2
72 <b>.</b> 0	20.0	Has been transfused; actively bleeding
63 <b>•</b> 7	29•3	Has been transfused; actively bleeding
60.0	40 <b>.</b> 0	Has been transfused; pre-op hemicolectomy; HGB was 39% 3/1
55•5	30.2	Hemorr. 48 hours ago; 1500 ML blood since; choledocholithotomy 16 days ago
57.8	28.5	Has had: 7000 ML blood, 500 ML packed cells, 700 ML PVP
79•4	<b>33</b> •0	Has had: 1000 ML blood, 500 ML packed cells, developed heratic
84•3	36.6	failure, died
		Hemorrhage 2 weeks ago; Has had 2000 ML blood

RCV

30•4

14.0

18.0

23.1

16**.**0

54•3

58.0

45•7

36.9

39•5

File No.	Name	Age	Date WT.	Diagnosis	PV-ML	RCV-ML	TBV-ML	PV	RCV	TBV
4=34	L.R.x	32	10/4 50.0	Esophageal varices	3104	2450	5570	62.1	49.0	101.1
4 <b>-</b> 36	L.R.X	32	10/5 50.0	Esophageal varices	2489	1563	4052	49.8	31.2	81.0
<b>4-</b> 38	L.R.x	32	10/7 50.0	Esophageal varices	1993	1027	3020	38.9	20•5	60•4
∕→ 5=19	M.R. <sup>x</sup>	29	2/8 54.5	Ulcerative Colitis - bleeding	3240	1570	<b>49</b> 10	59•5	28.8	₿8 <b>•</b> 3
<b>∖4-41</b>	L.R.X	32	10/8 50.0	Esophageal varices	2246	1264	3510	44.9	13.3	<b>70</b> •2
5-25	M.R.X	29	2/14 54.5	Ulcerative colitis - bleeding	2410	1770	4180	44•3	32•4	76•7
5 <b>-</b> 5	<b>▲</b> .H.	39	1/21 52.7	Post-gastrectomy bleeding	4360	810	5170	82.7	15.4	98.1
4-74	<b>▲</b> ₀B₀	64	12/4 44.5	CA. stomach	2075	1015	3090	46.6	22.8	69•4
4 <b>-</b> 76	<b>A</b> .B.	64	12/6 44.5	CA. stomach	2130	1 <b>75</b> 0	3880	47.9	39•3	87.2
4-81	<b>A</b> .B.	64	12/2 44.5	Câ. stomach	1925	1575	3500	43•3	35•4	78 <b>.</b> 7
5/B	J.D.	70	5/19 65.9	Post-prostatectomy hemorrhage	3820	1730	5550	58.0	26.3	84•2

CHART I (continued)

- 177 -

HCT	Kemarks
44.0	Hemorrhage 1 month ago; now pre-op
<b>38</b> •5	Post-op; shunt impossible; 3500 ML blood in OR (hemorrhage)
34•0	P.O.#2; wound bleeding; has had 1000 ML blood since 10/5
<b>34.</b> 0	Pre-op
36.0	P.O.#3; 500 ML blood yesterday
44.0	Post-op colectomy plus trans- fusion
16.3	Operation 1949, HGB 10% 1/20 before 1000 ML blood plus 75 ML packed cells
44.0	Pre-op
47.3	Had 1000 ML blood over 48 hours pre-op
47.0	Post-op <sub>•</sub> ; laparotomy (non-resectable)
32•5	Hemorrhage; massive transfusion; cardiac failure

File No.	Name	Age	Date	WT.	Diagnosis	PV-ML	RCV-ML	TB <b>V-ML</b>	PV	RCV	TBV	H
5-14	E.S.X	65	2/5	79.3	Post-cholecystectomy hemorrhage	2680	1080	3760	33•7	13.7	47•4	
5-15	E.S.X	65	2/6	79.3	Post-cholecystectomy hemorrhage	2560	1410	3970	32•3	17.8	50.1	
5 <del>-</del> 18	E.S.X	65	2/7	79•3	Post-cholecystectomy hemorrhage	2620	1730	4350	33.1	21.8	54•9	,
<b>5-</b> 24	R.S.X	44	2/14	71.8	Ulcerative colitis - acute	2160	2416	4576	30.1	33 <b>.</b> 6	63•7	
4 <del>~</del> 50	M.R.	61	10/28	69 <b>.</b> 0	CA. Stomach - post-op	2720	3330	6050	39•4	48 <b>•</b> 2	87.6	
4-51	M.R.	61	10/29	69.0	Ca. stomach - post-op	1900	2910	4810	27.5	42.2	69 <b>•</b> 7	
5 <b>-</b> 55	J.L.X	44	2/17	70.8	Post-op abdomino-perineal resection	2645	1715	43 <b>68</b>	37•4	24•2	61 <u>.</u> 6	
5-26	G <b>₀V</b> ₀ <sup>X</sup>	50	2/14	57.2	Post-colectomy hypotension	2250	1770	40.20	<b>3</b> 9•3	30•9	70 <b>.</b> 2	
5-C	<b>E</b> ₊C₊	78	3/14	90.7	Duodenal ulcer - massive hemorrhage	2660	880	3540	29.7	9•7	39•4	

•

(continued maxt page)

CHART I (continued)

CT	Remarks
30•0	Bleeding 72 hours; transfused; pale
37.0	Has had 1300 ML blood since 2/5; continues to bleed
41.5	Has had 500 ML blood since 2/6; bleeding stopped
55•0	P.O.#3 laparotomy; had 1000 ML blood in OR; now bleed- ing. Died 2/6 gangrene of colon
55.0	Esophagogastrectomy today ; hemorr. and 3500 ML blood in OR; in pulmonary edema
60•5	Phlebotomy 300 ML 10/28; congestive failure; hypotension. Hied.
4 <b>1.</b> 0	Unstable B.P. (100/); pulse 120. Stablized after 1000 ML blood
46•0	BP 96/64; P. 120, P.0.#1; 1000 ML blood in OR
26•0	1720 hours. bleeding act- ively. 5000 ML blood after this study

File No.	Name	Age	Date	WT.	Diagnosis	PV-ML	RCV-ML	TBV-ML	PV	RCV	TBV	HCT	Remarks
5 <b>-</b> D	E.C.	78	3/14	90 <b>.</b> 7	Duodenal ulcer - massive hemorr- hage	3140	1100	4240	34•6	12.1	46.7	27.0	2110 Hrs. given 7000 ML blood after this; operation
5-E	E₊C₊	78	3/14	90 <b><sub>0</sub>7</b>	Duodenal ulcer - massive hemorr- hage	3620	1355	49 <b>75</b>	39.9	14.9	54•8	<b>3</b> 0 <b>•</b> 7	2400 hrs. post-op given 1500 ML blood more. Bled again. Died 3/15-0330
5 <b>-</b> F	E.E.	53	3/22	75.7	Post-op hypotension (neosynephrine used) internal mammary transplant	2000	1630	3630	26•4	21.4	47.8	46•8	P.O.#1 400 ML blood in OR; 500 ML blood today. Nec- synephrine maintain in GBP 120/80
5 <b>-</b> G	E₊E₊	53	3/23	75•7	Post-op hypotension (neosynephrine used) internal mammary transplant	2190	1635	38 <b>25</b>	29.0	21.6	50.6	44•5	P.0.#2 decreasing neosyne- phrine. skin cold, pale, clammy since 3/22
5/H	E.E.	53	3/24	75.7	Post-op hypotension (neosynephrine used) internal mammary transplant	2720	1600	4320	35•9	21.1	57.0	38.7	P.0.#3 Warm, dry. Urine S.G. 1.027
5 <b>-</b> I	E.E.	53	3/25	75.7	Post-op hypotension (neosynephrine used) internal mammary transplant	2700	16 <b>30</b>	4330	35.7	21.5	57.2	<b>3</b> 9 <b>.</b> 0	P.O.#4 Warm, dry
5 <b>-</b> J	E.E.	53	3/26	75.7	Post-op hypotension (neosynephrine used) internal mammary transplant	2840	1640	4480	37.5	21.7	59•2	38.3	P.O. #5 Warm, dry
5 <b>-</b> K	E.E.	53	3/28	75•7	Post-op hypotension (neosynephrine used) internal mammary transplant	2760	1640	4400	36•4	21 <b>.</b> 0	58.0	38.7	P.O. #7 normotensive; no vaso constriction (total Il31 used approximately 50 JC.
5 <b>-</b> L	C.P.	<b>*</b> 29	5/28	58.2	Mitral stenosis	21.21	1364	3485	36•4	23.5	59•9	39.0	Pre-op study. Commissurotomy done 6/6: 750 ML loss; 500 ML blood given

- 179 -

CHART I (continued)

(continued next page)

.

- 180 -

File No.	Name	Age	Date	WT	Diagnosis	PV-ML	RCV-ML	TBV-ML	PV	RCV	TBV	HCT	Remarks
5 <b>∽</b> M	G <sub>●</sub> P <sub>●</sub> <sup>≭</sup>	29	6/6	58•2	Post-op wound hemorrhage	1500	860	2360	25.8	14.7	40.5	37.0	Bled 1200 ML into chest bottle; BP 80/ ; given 1000 ML before study, 1000 ML blood after study
5 <b></b> N	M₀R₀ <sup>X</sup>	60	3/28	<b>7</b> 0•5	Strangulated hernia	23 <b>3</b> 0	2520	4850	33.1	35.7	68.8	52 <b>₀</b> 0	50% of small bowel strangulat rehydrated and given 1000 ML plasma pre-op
<b>5</b> 0	M.R.X	60	3/28	70 <b>。</b> 5	Strangulated hernia	3140	2090	5230	44•5	29.6	74.1	40.0	Before this study: bowel re- section; 1000 ML blood; 500 ML PVP, Died 3/29
4-73	D <sub>●</sub> B <sub>●</sub> <sup>≭</sup>	45	11/2	48 <b>.</b> 0	Post-op radical mastectomy	1755	1122	2877	36•6	24•3	59•9	41.0	P.O. #1 was transfused in OR
4 <b>-</b> 79	s.c. <sup>x</sup>	19	12/10	46•2	Post-op ligation P.D.A.	1720	1110	2830	37.2	24.0	61.2	40 <b>.7</b>	P.O. #4 was transfused less than loss measured in OR
5-P	D.I.X	34	5/55	51.8	Post-op pulmonary resection	2130	1110	3240	41.1	21.4	62•5	35•6	Immediate post-op hypotensive 3500 ML blood in OR
4 <b>**</b> 19	H <b>₀A</b> •	58	9/24	54•5	Cå. sigmoid	3494	1223	4717	64.1	22•4	86•5	27.0	Pre-op before transfusion
5=27	B <b>₀</b> T <b>,</b> <sup>X</sup>	3 1/4	2/16	14.3	10% burn (1/1 ) operative hypotension ( 2/15 )	538	349	887	37.6	24•4	62.0	41.0	Post-op study. Had 250 ML blood for hypotension at time of grafting
5-9	<b>▲</b> .₽.	63	5/15	57.6	Duodenal ulcer. Hemorrhage	2230	1000	3230	38 <b>•</b> 7	17•4	56.1	32•4	500 cc hematemesis 8 hours ago; transfused; pre-op

CHART I (continued)

.

File No.	Name	Åge	Date	WT	Diagnosis	PV-ML	RCV-ML	TBV-ML	PV	RCV	TBV	HCT	]
			•										
<b>4-</b> 75	D <sub>●</sub> R <sub>●</sub>	77	12/4	45.5	Duodenal ulcer - chronic obstruct- ion, bleeding	3980	1540	55 <b>2</b> 0	87•5	33•8	121.3	29•2	]
4-77	D.R.	77	12/7	45•5	Duodenal ulcer - chronic obstruct- ion, bleeding	3205	1755	4960	70•4	38.6	109.0	36.8	]

CHART I (continued)

- 181 -

.

### Remarks

Pre-op. lost 36 pounds in 3 years

٠

Pre-op had 500 ML packed cells 500 ML blood since 12/4

#### CHART II

RIHSA BLOOD VOLUME DETERMINATIONS

File No.	Name	Åge	Date	WT.	Diagnosis	PV-ML	RCV-ML	TBV-ML	PV	RCV	TBV	H
4-43	<b>▲</b> .K.	. <b>59</b>	10/9	75.0	Spontaneous rupture of esophagus; Lt. hydrothoray	2180	2820	5000	29.1	37.6	66 <b>.</b> 7	5
4-44	<b>▲</b> .K.	59	10/11	<b>75</b> •0	Spontaneous rupture of esophagus; Lt. hydrothoray	3140	2900	6040	41.8	<u>3</u> 8•7	80,5	4
5-34	J.L.	59	3/5	75.0	20% burn ( 2/4 )	3070	1850	4920	41.0	24.5	65•5	3
<del>5-</del> 50	J.L.	59	3/10	75•0	20% burn ( 2/4 )	2690	2080	4770	35•8	27.7	63•5	4
5-53	J.L.	59	3/12	2 75.0	20% burn ( 2/4 )	2640	1900	4540	35•3	25•3	60.6	4
5 <b>-4</b> 4	J.L.	59	4/6	75.0	20% burn ( 2/4 )	2830	1690	4520	37.7	<b>22.</b> 6	60,3	3
4-66	J.L.	34	12/1	58.6	Ulcerative colitis; took ACTH 6 weeks	3190	2060	5250	54•5	35.0	89•5	4

CHART II

Conditions associated with abnormalities of body water and electrolyte metabolism in geriatric and poor-risk patients.

CT %	Remarks
6.5	Hypotensive; oliguric; poor skin turgor rehydration begun
8•0	Chest drainage plus 500 ML blood $10/9$ ; normal urine output and $B_{\bullet}P_{\bullet}$
9.1	Given 1000 ML blood after this
5•4	Poor skin turgor; disorientation; given tube feeding
4•2	Intermittently disoriented; burn healing
9•0	Skin graft 4/1 plus 500 ML blood; normal hydration; improved affect
1.0	Pre-op (no ACTH-2 weeks); diuresia and 31 pound weight loss-3 weeks

File No.	Name	Åge	Date	WT.	Diagnosis	PV-ML	RCV-ML	TBV-ML	PV	RCV	TBV	HCT%	Remarks
4-78	J•₽	34	12/7	58.6	Ulcerative colitis; took ACTH 6 weeks	2930	1970	<b>49</b> 00	50 <b>.</b> 0	33.6	83.6	41.7	Post-op. 2500 ML blood in OR (all volumes calculated on 58.6 KGM dry weight)
4-80	J₊L₊	34	12/14	58.6	Ulcerative colitis; took ACTH 6 weeks	40 <b>60</b>	<b>190</b> 0	5960	69.3	32•4	101.7	33 <b>.</b> 0	P.O.#7; ACTH being given; gained 4 pounds since 12/1; 500 ML blood started
4 <b>-</b> 83	J.L.	34	12/16	58.6	Ulcerative colitis; took ACTH 6 weeks	4320	2040	6360	73 <b>•7</b>	34•8	108.5	33•3	P.O. <b>#9; Na 132; K 2.7; CL 96;</b> CO <sub>2</sub> 27.2; continues weight gain and <b>A</b> CTH
5 <b>-A</b> B	J <b>∙</b> I∙⁰	34	3/12	58.6	Ulcerative colitis; took ACTH 6 weeks	4320	2000	6320	73•7	34.1	107.8	33.0	ACTH has been stopped; had 1500 ML blood since last test; has lost weight over past two month:
5 <b>-3</b> 8	J₊B₊	73	3/5	61.4	Pemphigus; hydrocortone q.d. 6 months	2930	2270	5200	<b>47</b> •7	37.0	84.7	45•5	650 MGM hydrocortone q.d.; losin weight
5 <b>-</b> ≜C	J.B.	73	3/22	61.4	Pemphigus; hydrocortone q.d. 6 months	3020	2010	50 <b>3</b> 0	49•2	32•7	81.9	41.7	Decreasing hydrocortone; lost 10 pounds, 17 days
5 <b>-≜</b> D	S.D.	74	3/20	52•5	Pneumonia; paralytic ileus	1150	1460	2610	21.6	27.6	49.2	56.0	Oligoric; poor skin turgor; HGB 118%; NPN 118; Na 128; being hydrated
5 <b>-AE</b>	S.D.X	74	3/22	52•5	Pneumonia; paralytic ileus	1520	1410	2930	29.0	26.8	55.8	50.0	Somnolent; fair skin turgor; urine output 1300 ML 3/21
5 <b>-</b> AF	S.D.X	74	3/24	52.5	Pmeumonia; paralytic ileus	1780	1180	2960	33•9	22•5	56•4	41.6	Had 500 ML plasma for hypotensic 3/23; 500 ML blood started now

- 183 -

File No.	Name	Åg€	Date	WT.	Diagnosis	PV-ML	RCV-ML	TBV-ML	PV	RCV	TBV	HCT%
5 <b>-A</b> G	S.D.X	74	3/27	52•5	Pneumonia; paralytic ileus	1715	1395	3110	32.6	<b>26.</b> 6	59•3	46.8
5- <b>A</b> H	S.D.X	74	4/7	52•5	Pneumonia; paralytic ileus	1620	1300	2920	30.6	24•7	55.6	46.
<b>4-</b> 65	P <sub>o</sub> L <sub>•</sub> X	87	11/30	36.4	CA. ampulla of vater	1670	1244	2914	45•9	34•2	80.1	44.
5-16	x B <sub>e</sub> R <sub>o</sub>	65	2/6	46•5	Perforated duodenal ulcer	1685	2375	4060	36.2	51.2	87•4	60.0
5-17	B <sub>•</sub> R <sub>•</sub> <sup>x</sup>	65	2/7	46.5	Perforated duodenal ulcer	2460	2240	4700	52 <b>.</b> 9	48.1	101.0	49•1
5-21	<b>x</b> B•R•	65	2/9	<b>\$</b> 6•5	Perforated duodenal ulcer	2185	2240	4430	47•4	48.1	95•3	52.7
5- <b>A</b> I	G₀M₀	55	4/1	84•2	Acute renal failure-post-op.	3260	1950	5210	38.7	23•2	61.9	39.0
5 <b>-AJ</b>	B.P.X	69	3/25	61.4	Post-op Rt. hemicolectomy	3110	1350	4460	50.7	21.9	70 <b>.</b> 6	31.
5 <b>-A</b> K	<b>≭</b> B <b>•₩</b> •	62	4/24	40.0	Post-op abdomino-perineal resection	1855	1520	3375	45.8	37•5	83.3	47.0
5- <b>&amp;</b> L	B <b>.₩.<sup>≭</sup></b>	62	4/27	40 <b>.</b> 0	Post-op abdomino-perineal resection	2020	1550	3570	49•9	38 <b>.</b> 3	87.2	45.2

1

CHART II (continued)

- 184 -

.

CT%	Remarks
5 <b>.</b> 8	Was unconscious 2 days; now alert; K falling
5.5	Hypotension (70/44) reversed with 325 ML plasma, oliguric. Died
4.5	P.O.#3 cholecystjejunostomy letaargi icteric. Na 120; NPN 50
0.0	P.O.#1 Plication of perforation; dehydrated Na = 119; oliguric; transfused in OR
9.7	Had 500 ML 3% NaCL; better hydration Na-131; adequate urine output
2.7	NPN 24; Na 137; put of oxygen tent
9.0	Post-op colostomy; psuedomyxoma peritone 11
L•5	P.O.#1; dyhydration; olicuria
7•0	P.O.#3; dehydration; poor skin turgo Na-126; 500 ML blood given; rehydrat
5.2	P.O.#6; better skin turgor; Na-130; Bleeding from G-I tract

File No.	Name	Age	Date	WT.	Diagnosis	PV-ML	RCV-ML	TBV-ML	PV	RCV	TBV	HCT%
5-12	C.	60	2/1	50.0	Post-op prostatectomy	2440	1130	3570	48•2	22.6	71.4	33•5
5 <b>-A</b> M	H.S.	60	4/11	74.1	Appendectomy 4/6	2000	2100	4100	27.0	28•3	55 <b>•3</b>	53•5
5-4N	H.S.	60	4/17	74.1	Appendectomy 4/6	3570	1800	5370	48.2	24.3	72•5	35.0
5 <b>-A</b> 0	H.S.	60	4/18	74.1	Appendectomy 4/6	4160	2330	6490	56.1	31.4	87.5	37.5
5 <b>-≜</b> P	I.L.	57	4/27	39•5	Gastrostomy 4/23 - CA	2340	1345	3685	59•2	34•1	93•3	38.0
<del>5-</del> 9	B.R.	33	1/27	48.6	Mitral stenosis; congestive failure (therapy:digitoxin, diuretics, phleb- otomy; surgery: mitral commissurotomy total RIHSA dose: less than 80 UC over 60 days).	3240 7	2260	5500	70•3	49•2	119.8	43•0
5-13	B₀R•	33	2/4	<b>4</b> 6•4	Mitral stenosis; congestive failure (therapy: digitoxin, diuretics, phleb- otomy; surgery: mitral commissurotomy total RIHSA dose: less than 80 UC over 60 days).	3070 7	2270	5340	66 <b>.9</b>	49.5	116.3	42.5
5-20	B.R.	33	2/9	45•4	Mitral stenosis; congestive failure (therapy: digitoxin, diuretics, phleb- otomy; surgery: mitral commissurotomy total RIHSA dose: less than 80 JC over 60 days).	2840 7	2040	4880	61.9	44 <b>4</b>	106.3	43•5

(continued next page)

#### Remarks

Na 97.5 on 1/31; rehydrated since then. Died 2/3. Renal failure

Hypotensive; oliguric; Na 146.5; Given 1000 ML plasma later

Better hydrated; NPN 139; oliguric

Poor skin turgor; transfused. Died. ? Renal failure

Dehydrated; poor skin turgor; cachectic

Failure: dyspnea; pulmonary congestion; distended neck veins

Essentially similar to 1/27. Enlarged TBV. (volumes calculated on basis of dry weight 45/KGM)

Phlebotomy 350 ML 2/6

File No.	Name	Age	Date	WT	Diagnosis	PA-WT	RCV-ML	TB <b>V-ML</b>	PV	RCV	TBV	HCT%	Remarks
5-23	B.R.	33	2/13	45.0	Mitral stenosis; congestive failure (therapy: digitoxin, diuretics, phleb- otomy; surgery: mitral commissurotomy; Total RIHSA dose: less than 80 UC over 60 days).	2950	1730	4680	64•3	37.7	102.0	38.6	Phlebotomy 350 ML 2/11. Clinically improved
5-31	B•R•	33	3/3	45 <b>•9</b>	Mitral stenosis; congestive failure (therapy: digitoxin, diuretics, phleb- ctomy; surgery: mitral commissurotomy; total RIHSA dose: less than 80 UC over 60 days).	3450	1680	5130	75.2	36 <u>.</u> 6	111.8	37•9	Plasma volume enlarged; weight gain; diuretics give 3/4
5 <b>-</b> 48	B.R.	33	3/9	45•9	Mitral stenosis; congestive failure (therapy: digitoxin, diuretics, phleb- otomy; surgery: mitral commissurotomy; total RIHSA dose: less than 80 UC over 60 days).	2790	1870	4660	60,8	40 <b>.</b> 7	10 <b>1.</b> 5	41.7	Commissurotomy 3/7,750 ML measured loss; 750 ML blood 3/7; 250 ML blood 3/9
5 <b>-A</b> P	B <b>₀</b> R₀	33	3/14	45•4	Mitral stenosis; congestive failure (therapy: digitoxin, diuretics, phleb- otomy; surgeryL mitral commissurotomy; total RIHSA dose: less than 80 UC over 60 days).	3030	1810	4840	66.0	39•4	105.4	<i>3</i> 9∎0	P.0.#7; NPN-59 3/9 (P.0.#2 NPN-28 3/17 (P.0.#10), norm post-op course
5 <b>-A</b> R	B₂R₅	33	3/30	44.1	Mitral stenosis; congestive failure (therapy: digitoxin, diuretics, phleb- otomy; surgery: mitral commissurotomy; total RIHSA dose: less than 80 UC over 60 days).	2670	1530	4200	55 <b>•2</b>	33 <b>.</b> 3	91.5	<b>38.</b> 0	P.O.#23; discharged from hospital; no signs of fail ure; digitoxin maintenance

.

CHART II (continued)

1

•

•••

÷

## CHART III

# RIHSA BLOOD VOLUME DETERMINATIONS IN MISCELLANEOUS SURGICAL CONDITIONS

File No.	Name	Ag●	Date	WT.	Diagnosis	P <b>V-ML/</b> KGM	RCV-ML/KGM	TBV-ML/KGM	HCT %	Remarks
5-7	J.F.	27	1/25	65 <b>.</b> 8	Fracture Rt. Femur	45•4	24.0	69•4	<b>36</b> •0	Fracture few hours ago; 500 ML blood given pre-op
5 <del>-</del> 35	L.L.	70	3/5	70•5	Fracture Lt. Humerus and Leg	36.1	20.2	56.3	37•5	Fractures 3/4; casts applied
4 <b>-</b> 58	H <b>.₩.</b>	53	11/25	71.1	CA. stomach	43•1	26.9	70.0	40.0	Lost 30 pounds - 8 weeks; pre-op, transfused after test
4 <del>-</del> 23	₩.P.	<b>5</b> 6	9/29	51.0	Gastric ulcer	67•0	33•2	100.0	34•6	Pre=op
4 <b>-</b> 13	V.L.X	51	9/17	75•5	Duodenal ulcer	35•8	18.3	56.1	34•0	Obese, no weight change; pre-op
4-12	E.C.	57	9/17	77.3	Duodenal ulcer	36.1	26.4	62.5	44•0	Pre-op; slightly obese
4-3	J.M.	52	9/15	71.0	Duodenal ulcer	38.1	27.8	65 <b>•9</b>	44•0	Medical regime - 3 weeks treat- ment before test
5 <b>~3</b> 9	H.T.	65	3/5	88•7	Duodenal ulcer	34•7	29.7	64•4	48 <b>.</b> 0	Obese, pre-op
5-B1	K.G. <sup>x</sup>	41	<b>3/</b> 23	61.4	Acute cholecystitis	41.4	24.8	66.2	<b>3</b> 9.0	Also has mitral stenosis
5 <b>-</b> 46	L.G.	53	3/9	65 <b>•9</b>	CA. cecum	41.8	25.1	66.9	39•0	Pre-op

. \_\_\_\_\_CHART III

•

.

File No.	Name	Age	Date	WT.	Diagnosis	PV-ML/KGM	RCV-ML/KGM	TBV-ML/KGM	HCT %	Remarks
5 <del>~</del> 30	L.B.X	52	2/18	62.2	CA. rectum	61.8	34•6	95.8	37.5	Lost 25 pounds - one year
4-24	A.L.	69	9/29	68.2	ABD, aneurysm	55•4	24•9	80 <b>•4</b>	36.0	Lost 30 pounds - 3 months
<b>4-2</b> 8	U.R.X	3 <b>7</b>	9/29	51.0	Hyperthyroidism	51.0	32.8	83•8	40.0	BMR minus 32; on medi- cation 6 months
5 <del>-</del> 32	E.L.	39	3/4	51.4	Mitral stenosis	56.7	31.1	87.8	37.0	6 months pregnant
5-29	A.L.	46	2/17	63 <b>.</b> 6	Mitral stenosis	39•5	38.1	77.4	51.0	Pre-op commissurotomy
5-36	F.N.	67	3/5	91.0	Fracture Lt. Rt. legs	36•7	24.6	61.3	41.8	Fracture 12/13; in casts; bed rest
4 <del>-</del> 52	<b>A</b> •D• <b>X</b>	49	11/18	34•0	Ca. hypopharynx	62•3	40.0	102•3	45.0	Cachectic; post- gastrostomy
5 <b>-</b> 40	J.M.	63	3/5	77.2	CA. stomach	51.8	29•5	81.3	37.8	Post-gastrostomy and transfusion
4-10	$L_{\bullet}D_{\bullet}$	50	9/17	61.4	Duodenal ulcer	34•2	31.6	65•8	50.0	P.O. #2 Gastrectomy
4-2	$\mathbf{L}_{\bullet}\mathbf{H}_{\bullet}$	24	9/15	55 <b>•5</b>	Duodenai ulcer	47•3	32.0	79•3	42.0	<b>P.O.</b> #12 Plication of perforation

•

.

**、**...

.

CHART III (continued)

-									
	File No.	Name	Age	Date	WT.	Diagnosis	PV-ML/KGM	RCV-ML/KCM	TBV-ML/KGM
_	<del>5-</del> 6	J.V.	54	1/21	67•7	Duodenal ulcer	50.8	14.9	65 <b>.7</b>
	<del>5-</del> 8	J <b>.</b> V.	54	1/24	67.7	Duodenal ulcer	<b>47</b> •0	16.1	63.1
	5 <b>-</b> 11	J.V.	54	1/31	67•7	Duodenal ulcer	51.8	23•4	75•2
	5-22	J₊V₊	54	2/10	67.1	Duodenal ulcer	54.1	22.8	76.9
	5 <b>-</b> 45	J.V.	54	3/9	67.1	Duodenal ulcer	50•4	28.0	78.4
	<b>4-7</b> 0	Y.M.	31	11/2	57.0	Hypotension post-op	38.1	34•8	72.9
	4 <del>-</del> 6	T.B. ≭	48	9/16	69.0	Wound infection	28.9	20.8	49•5
	4-29	T.B. <sup>x</sup>	<b>4</b> 8	9/29	69.0	Wound infection	53.6	23•4	77.0
	5 <b>-</b> B2	M.L.X	41	4/4	142.	Wound hematoma	34•2	19.0	53.2
	4-1	J.M. <sup>x</sup>	69	9/14	55 <b>•0</b>	CA. signoid	41.2	29.8	71.0

(continued next page)

CHART III (continued)

•

. -

# HCT % Remarks

23.8	P.O.#28 gastrectomy; disruption of duodenal stump; transfused
26.6	P.O.#31, transfused since last test. melena
32•5	P.O.#38 given 1000 ML blood since last test
33.0	P.O.#48 Given 1500 ML blood since last test; entero-cutaneous fistula
<b>3</b> 7.0	Developed bowel obstru- ction today; pre-op
<b>49</b> •0	P.O.#1 cholecystectomy; transfused; ECG showed ? myocardial infarct
42.0	P.O.#6 cholecystectomy; pale
30•5	P.0. #19
37.3	Marked obesity

42.0 P.O.#3 sigmoid resection

File No.	Name	Åge	Date	WT.	Diagnosis	PV-ML/KGM	RCV-ML/KGM	TBV-ML/KGM
5 <b>-</b> B3	P.S. <sup>x</sup>	70	3/16	89•5	CA rectum	25.9	20.6	46.5
5 <b>-</b> B4	P.S. <sup>x</sup>	<b>7</b> 0	3/18	89 <b>•</b> 5	CA rectum	29.6	20•4	50.0
4-8	I.G.X	54	9/16	35•6	Bowel obstruction	61.1	21.6	82.7
5-43	G.K.X	70	3/6	45 <b>•9</b>	Bowel obstruction	47•9	25•5	73•4
5 <del>-</del> 2	F.F.X	60	1/18	67 <b>•7</b>	Hypersplenism	38.4	19.6	58.0
5-41	E.A.X	74	3/6	51.0	Varicose veins	45.1	20.6	65.7
5 <del>-</del> B5	E.R. X	46	5/9	68.2	Lymphoma.	45•4	28.7	74.1
5-4	H.M.	64	<b>1/</b> 18	70.0	Emphysema	39.6	32.6	72.2
4 <del>-</del> 9	B.K.X	40	9/16	64.0	Cå. breast	47.6	21.4	69.0

•

CHART III (continued)

HCT 发	Remarks
46.0	P.O.#1 A-P resection; marked obesity
41.0	P.0.#3 not transfused
<b>26.</b> 0	Adhesions; P.O.#2; extremely thin; CA colon, 1948
36.3	P.O.#10; Richter's femoral hernia; CA rectum, 1947
33.8	P.O.#5 Splenectomy
32•5	Diabetic; undergoing skin grafting
40 <b>•5</b>	Pre-op
47.0	11 +
31.0	Post-op mastectomy

### CHART IV

( PRE- AND POST-OPERATIVE ) RIHSA BLOOD VOLUME DETERMINATIONS

-				· · · · · · · · · · · · · · · · · · ·									
	File No.	Åge	Date	Diagnosis	PV∞ML	RCV-ML	TBV-ML	PV	RCV	TBV	HCT%	WT.	Remark
	1-HT	58X	3/27	Parotid Tumor	2250	1650	3900	34•4	25.2	59.6	44.0	65 <b>•5</b>	Pre-op
	2-HT	58 <b>x</b>	3/28	Parotid tumor	1880	1430	3310	28 <b>.</b> 7	21.8	50•5	<b>45</b> •0	65.5	Post-oj neck <b>di</b> 2500 bi
	<b>3-</b> HT	58 <del>x</del>	3/29	Parotid tumor	1745	1655	3400	26.6	25•3	51.9	50•7	65.5	P.O.#1 study
	4-HT	58 <b>x</b>	4/4	Parotid tumor	2560	1710	4270	39.1	26.1	65.2	41.7	62.0	P.0.#7
	1-#F	68 <b>x</b>	9/28	CA - colon (ascending)	2364	1210	3574	47•6	24•2	71.8	34•0	49•8	Pre-op years
	2-MP	68x	<b>9/3</b> 0	CA - colon (ascending)	1977	1163	3140	3 <b>9.</b> 6	23•4	63.0	37.0	49.8	Post-oj fusion
	3-MF	68x	10/7	CA - colon (ascending)	1877	843	2720	37.7	16.9	54•6	31.0	54•3	P.0. #
	1-ES	42 <b>x</b>	4/6	Mediastinal tumor	2295	1205	3500	34.8	18.3	53.1	35.8	66.0	Pre-op
	2 <b>-ES</b>	42x	4/7	Mediastinal tumor	1950	1100	3050	29.6	16.4	45.2	37.6	<del>6</del> 6.0	Post-o

CHART IV

. '

#### ks

#### Ď

op excision-parotid tumor, radical issection; 2385 gravimetric loss; blood replacement

1 had 500 ML blood before this

p; diabetic; lost 80 pounds-several

op. Rt. hemicolectomy; no transn in OR

#### #7

p; not transfused

Post-op thoracotomy and excision of tumor; 500 blood in OR; BP-98, unstable; given 1250 ML blood; BP-120; 500 blood given 4/8

File No.	Age	Date	Diagnosis	PV-ML	RCV-ML	TBV-ML	PV	RCV	tbv	HCT%	WT.	Ren
1-AM	42 <b>x</b>	11/28	Mitral stenosis	2150	1830	3980	33•4	28.4	61.8	48.0	64.5	Pre-c
2-4M	42 <b>x</b>	11/29	Mitral stenosis	2040	1710	3750	31.6	26.5	58.1	47.5	64•5	Post-
1⇒FT	59	10/7	Unresolved pneumonia	2050	1460	3510	37•3	26.5	63 <b>.8</b>	41.5	55.0	Pre-0 10/7
2 <b>-</b> FT	59	10/7	Unresolved pneumonia	2006	1514	3520	36.5	27.5	64.0	<b>43</b> •0	55.0	Post
3 <b>-</b> FT	59	10/3	Unresolved pneumonia	2510	1860	4370	45•7	33.8	79.5	42.5	55.0	P.0.
1-IM	35 <b>x</b>	11/23	Bowel obstruction (SA. ceruix)	2110	1660	3770	33.8	26.6	60•4	46.0	62.5	Pre-c
2-IM	<b>35x</b>	11/23	Bowel obstruction (CA. ceruix)	2360	1690	4050	37.8	27.0	64.8	43 <b>•5</b>	62.5	Post- loss.
1-LC	32	5/16	Mitral stenosis	<b>26</b> 00	2070	4670	46 <b>.2</b>	36.8	83.0	46.3	56.3	Pre-c
2-LC	32	5/18	Mitral stenosis	1880	1576	3456	33•4	28.0	61.4	47•5	56.3	Post- blood
<b>1-S</b> H	<b>19x</b> -	5/31	Bronchiectasis (Rt. M.L. and Rt. L.L.)	2018	1180	3198	48.0	28.1	76.1	38.5	42 <b>•</b> 0	Pre-c
2 <b>-</b> SH	19x	6/1	Bronchiectasis (Rt. M.L. and Rt. L.L.)	1761	965	2726	41.9	23.0	64.9	36.9	42.0	Post-
1-PN	67 <b>x</b>	4/9	Jaundice-obstructive (P.O. hepat	itis) 2470	1540	4010	39•4	24.5	63 <b>.</b> 9	40.0	62.7	Pre-0 4/10

CHART IV (continued)

#### Remarks

e-op; commissurotomy 11/29 st-op. 100 blood given in OR e-op wedge resection Lt. upper lobe /7. Post-op 500 blood in OR ost-op 500 blood in OR 0. #5 e-op colostomy st-op (no blood in OR) minimal blood 38. e-op commissorotomy 5/18 st-op 888 gravimetric loss; 500 ood in OR e-op R.M.L. and R.L.L. segmental 6/1 st-op 1500 blood given in OR e-op choledochotomy, liver biopsy

Åge	Date	Diagnosis	PV-MI.	RCV-ML	TBV-ML	PV	RCV	<b>t</b> b <b>v</b>	HCT%	WT.	Rei
67 <b>x</b>	4/10	Janndice-obstructive (P.O. hepatitis)	1650	1310	2960	26.3	20•9	47.2	46•2	62.7	Por
67 <b>x</b>	4/11	Jaundice≕obstructive (P.O. hepatitis)	2095	1755	3850	33•4	27.9	61.3	47.5	62.7	P.( stu
68	9/20	CA-ampulla vater	3704	1841	5545	53.6	26.6	80.2	33.5	69.1	Pre
68	9/21	CA-ampulla vater	2992	2019	5011	43•3	29•2	72.5	42.0	69 <b>.</b> 1	Pos (si
68	9/22	CA-ampulla vater	2802	2013	4815	40.5	29.2	69.7	43.5	69.1	P.
68	9/24	Cå-ampulla vater	3475	1759	5234	50.3	25•4	75.7	35.0	69.1	P.
62	3/16	Peptic esophagitis (stricture)	<b>2</b> 7 <b>3</b> 0	1880	<b>461</b> 0	42.1	28.9	71.0	<b>43</b> •0	64.8	Pro
62	3/24	Peptic esophagitis (stricture)	3335	1915	5250	51.4	29•4	80.8	37.9	65.0	Pre
6 <b>2</b>	3/25	Peptic esophagitis (stricture)	2740	1870	4610	42.1	28.7	71.0	42.2	65.0	Pos ML
62	<b>3/</b> 26	Peptic esophagitis (stricture)	2510	1960	4480	38.6	30.1	68.7	45•7	65.0	P.(
62	3/27	Peptic esophagitis (stricture)	3095	1945	5040	47.6	29•9	77•5	40.8	65.0	P.
62	3/28	Peptic esophagitis (stricture)	3180	1760	4940	48.8	27.1	75.9	37•2	65.0	P.
62	4/7	Peptic esophagitis (stricture)	3025	1735	4760	46•6	26.7	73.5	37.9	60 <b>•9</b>	P.
	▲g• 67x 67x 68 68 68 68 62 62 62 62 62 62 62 62 62	Age Date   67x 4/10   67x 4/11   68 9/20   68 9/21   68 9/22   68 9/22   68 9/24   62 3/16   62 3/24   62 3/25   62 3/26   62 3/27   62 3/28   63 4/7	AgeDateDiagnosis67x4/10Jaundice-obstructive (P.O. hepatitis)67x4/11Jaundice-obstructive (P.O. hepatitis)689/20CA-ampulla vater689/21CA-ampulla vater689/22CA-ampulla vater689/24CA-ampulla vater689/24CA-ampulla vater623/16Peptic esophagitis (stricture)623/24623/25639/25643/26659/27663/276723/28683/28634/7644/7654/7664/7	AgeDateDiagnosisFV-ML67x4/10Janndice-obstructive (P.0. hepatitis)165067x4/11Jaundice-obstructive (P.0. hepatitis)2095689/20CA-ampulla vater3704689/21CA-ampulla vater2992689/22CA-ampulla vater2802689/22CA-ampulla vater2802689/24CA-ampulla vater2802689/24CA-ampulla vater2730623/16Peptic esophagitis (stricture)2730623/24Peptic esophagitis (stricture)2335623/25Peptic esophagitis (stricture)2510623/26Peptic esophagitis (stricture)3095623/28Peptic esophagitis (stricture)3180634/7Peptic esophagitis (stricture)3025	Age   Date   Diagnosis   FV-ML   RCV-ML     67x   4/10   Janndice-obstructive (P.0.   1650   1310     67x   4/11   Jaundice-obstructive (P.0.   2095   1755     68   9/20   CA-ampulla vater   3704   1841     68   9/21   CA-ampulla vater   2992   2019     68   9/22   CA-ampulla vater   2802   2013     68   9/22   CA-ampulla vater   2802   2013     68   9/24   CA-ampulla vater   2802   2013     68   9/24   CA-ampulla vater   2802   2013     62   3/16   Peptic esophagitis (stricture)   2730   1880     62   3/24   Peptic esophagitis (stricture)   2740   1870     62   3/25   Peptic esophagitis (stricture)   2740   1870     62   3/26   Peptic esophagitis (stricture)   3095   1945     62   3/26   Peptic esophagitis (stricture)   3095   1945	Age   Date   Diagnosis   PV-ML   RCV-ML   TEV-ML     67x   4/10   Jaundice-obstructive (P.0. hepatitis)   1650   1310   2960     67x   4/11   Jaundice-obstructive (P.0. hepatitis)   2095   1755   3850     68   9/20   CA-ampulla vater   3704   1841   5545     68   9/21   CA-ampulla vater   2992   2019   5011     68   9/22   CA-ampulla vater   2802   2013   4815     68   9/24   CA-ampulla vater   2802   2013   4815     68   9/24   CA-ampulla vater   2802   2013   4815     68   9/24   CA-ampulla vater   3475   1759   5234     62   3/16   Peptic esophagitis (stricture)   3335   1915   5250     62   3/25   Peptic esophagitis (stricture)   2740   1870   4610     62   3/26   Peptic esophagitis (stricture)   3095   1945   5040     62 <td>Age   Date   Diagnosis   FV-ML   RCV-ML   TEV-ML   PV     67x   4/10   Jaundice-obstructive (P.0. hepatitis)   1650   1310   2960   26.3     67x   4/11   Jaundice-obstructive (P.0. hepatitis)   2095   1755   3850   33.4     68   9/20   CA-ampulla vater   3704   1841   5545   53.6     68   9/21   CA-ampulla vater   2992   2019   5011   43.3     68   9/22   CA-ampulla vater   2802   2013   4815   40.5     68   9/22   CA-ampulla vater   3475   1759   5234   50.3     68   9/24   CA-ampulla vater   3475   1759   5234   50.3     62   3/16   Peptic esophagitis (stricture)   3335   1915   5250   51.4     62   3/24   Peptic esophagitis (stricture)   2510   1860   4480   38.6     62   3/26   Peptic esophagitis (stricture)   3095   1945</td> <td>Age   Date   Diagnosis   FV-ML   RCV-ML   TEV-ML   PV   RCV     67x   4/10   Jaundice=obstructive (P.0. hepatitis)   1650   1310   2960   26.3   20.9     67x   4/11   Jaundice=obstructive (P.0. hepatitis)   2095   1755   3850   33.4   27.9     68   9/20   CA=ampulla vater   3704   1841   5545   53.6   26.6     68   9/21   CA=ampulla vater   2992   2019   5011   43.3   29.2     68   9/22   CA=ampulla vater   2802   2013   4815   40.5   29.2     68   9/24   CA=ampulla vater   2802   2013   4815   40.5   29.2     68   9/24   CA=ampulla vater   3475   1759   5234   50.3   25.4     62   3/16   Peptic esophagitis (stricture)   2730   1880   4610   42.1   28.9     62   3/24   Peptic esophagitis (stricture)   2335   1915</td> <td>Age   Date   Diagnosis   FV-ML   RCV-ML   TBV-ML   FV   RCV   TBV     67x   4/10   Jaundice-obstructive (P.0. hepatitis)   1650   1310   2960   26.3   20.9   47.2     67x   4/11   Jaundice-obstructive (P.0. hepatitis)   2095   1755   3850   33.4   27.9   61.3     68   9/20   CM-ampulla vater   3704   1841   5545   53.6   26.6   80.2     68   9/21   CM-ampulla vater   2992   2019   5011   43.3   29.2   72.5     68   9/22   CM-ampulla vater   2802   2013   4815   40.5   29.2   69.7     68   9/22   CM-ampulla vater   3475   1759   5234   50.3   25.4   75.7     62   3/16   Peptic esophagitis (stricture)   3335   1915   5250   51.4   29.4   80.8     62   3/24   Peptic esophagitis (stricture)   2740   1870   4610   <t< td=""><td>AgeDateDiagnosisFV-MLRCV-MLTEV-MLFVRCVTEVHCTS<math>67x</math><math>4/10</math>Jaundice=obstructive (P.0. hepatitis)16501310296026.320.947.246.2<math>67x</math><math>4/11</math>Jaundice=obstructive (P.0. hepatitis)20951755385033.427.961.347.5<math>68</math><math>9/20</math>CA=ampulla vater37041841554553.626.680.233.5<math>68</math><math>9/20</math>CA=ampulla vater29922019501143.329.272.542.0<math>68</math><math>9/22</math>CA=ampulla vater28022013481540.529.269.743.5<math>68</math><math>9/22</math>CA=ampulla vater28022013481540.529.269.743.5<math>68</math><math>9/24</math>CA=ampulla vater34751759523450.325.475.735.0<math>62</math><math>3/16</math>Peptic esophagitis (stricture)27301880461042.128.971.043.0<math>62</math><math>3/24</math>Peptic esophagitis (stricture)23351915525051.429.480.837.9<math>62</math><math>3/26</math>Peptic esophagitis (stricture)25101960448038.630.168.745.7<math>62</math><math>3/27</math>Peptic esophagitis (stricture)30951945504047.629.977.540.8<math>62</math><math>3/28</math>Peptic esophagitis (stricture)318017604</td><td>Age   Date   Diagnosis   FV-ML   RCV-ML   TEV-ML   PV   RCV   TEV   HCT\$   WT.     67x   4/10   Jaundice-obstructive (P.O. hepatitis)   1650   1310   2960   26.3   20.9   47.2   46.2   62.7     67x   4/11   Jaundice-obstructive (P.O. hepatitis)   2095   1755   3850   33.4   27.9   61.3   47.5   62.7     68   9/20   CA-ampulla vater   3704   1841   5545   53.6   26.6   80.2   33.5   69.1     68   9/20   CA-ampulla vater   2992   2019   5011   43.3   29.2   72.5   42.0   69.1     68   9/22   CA-ampulla vater   2802   2013   4815   40.5   29.2   69.7   43.5   69.1     62   3/16   Peptic esophagitis (stricture)   2730   1880   4610   42.1   28.9   71.0   43.0   64.8     62   3/24   Peptic esophagitis (stricture)<!--</td--></td></t<></td>	Age   Date   Diagnosis   FV-ML   RCV-ML   TEV-ML   PV     67x   4/10   Jaundice-obstructive (P.0. hepatitis)   1650   1310   2960   26.3     67x   4/11   Jaundice-obstructive (P.0. hepatitis)   2095   1755   3850   33.4     68   9/20   CA-ampulla vater   3704   1841   5545   53.6     68   9/21   CA-ampulla vater   2992   2019   5011   43.3     68   9/22   CA-ampulla vater   2802   2013   4815   40.5     68   9/22   CA-ampulla vater   3475   1759   5234   50.3     68   9/24   CA-ampulla vater   3475   1759   5234   50.3     62   3/16   Peptic esophagitis (stricture)   3335   1915   5250   51.4     62   3/24   Peptic esophagitis (stricture)   2510   1860   4480   38.6     62   3/26   Peptic esophagitis (stricture)   3095   1945	Age   Date   Diagnosis   FV-ML   RCV-ML   TEV-ML   PV   RCV     67x   4/10   Jaundice=obstructive (P.0. hepatitis)   1650   1310   2960   26.3   20.9     67x   4/11   Jaundice=obstructive (P.0. hepatitis)   2095   1755   3850   33.4   27.9     68   9/20   CA=ampulla vater   3704   1841   5545   53.6   26.6     68   9/21   CA=ampulla vater   2992   2019   5011   43.3   29.2     68   9/22   CA=ampulla vater   2802   2013   4815   40.5   29.2     68   9/24   CA=ampulla vater   2802   2013   4815   40.5   29.2     68   9/24   CA=ampulla vater   3475   1759   5234   50.3   25.4     62   3/16   Peptic esophagitis (stricture)   2730   1880   4610   42.1   28.9     62   3/24   Peptic esophagitis (stricture)   2335   1915	Age   Date   Diagnosis   FV-ML   RCV-ML   TBV-ML   FV   RCV   TBV     67x   4/10   Jaundice-obstructive (P.0. hepatitis)   1650   1310   2960   26.3   20.9   47.2     67x   4/11   Jaundice-obstructive (P.0. hepatitis)   2095   1755   3850   33.4   27.9   61.3     68   9/20   CM-ampulla vater   3704   1841   5545   53.6   26.6   80.2     68   9/21   CM-ampulla vater   2992   2019   5011   43.3   29.2   72.5     68   9/22   CM-ampulla vater   2802   2013   4815   40.5   29.2   69.7     68   9/22   CM-ampulla vater   3475   1759   5234   50.3   25.4   75.7     62   3/16   Peptic esophagitis (stricture)   3335   1915   5250   51.4   29.4   80.8     62   3/24   Peptic esophagitis (stricture)   2740   1870   4610 <t< td=""><td>AgeDateDiagnosisFV-MLRCV-MLTEV-MLFVRCVTEVHCTS<math>67x</math><math>4/10</math>Jaundice=obstructive (P.0. hepatitis)16501310296026.320.947.246.2<math>67x</math><math>4/11</math>Jaundice=obstructive (P.0. hepatitis)20951755385033.427.961.347.5<math>68</math><math>9/20</math>CA=ampulla vater37041841554553.626.680.233.5<math>68</math><math>9/20</math>CA=ampulla vater29922019501143.329.272.542.0<math>68</math><math>9/22</math>CA=ampulla vater28022013481540.529.269.743.5<math>68</math><math>9/22</math>CA=ampulla vater28022013481540.529.269.743.5<math>68</math><math>9/24</math>CA=ampulla vater34751759523450.325.475.735.0<math>62</math><math>3/16</math>Peptic esophagitis (stricture)27301880461042.128.971.043.0<math>62</math><math>3/24</math>Peptic esophagitis (stricture)23351915525051.429.480.837.9<math>62</math><math>3/26</math>Peptic esophagitis (stricture)25101960448038.630.168.745.7<math>62</math><math>3/27</math>Peptic esophagitis (stricture)30951945504047.629.977.540.8<math>62</math><math>3/28</math>Peptic esophagitis (stricture)318017604</td><td>Age   Date   Diagnosis   FV-ML   RCV-ML   TEV-ML   PV   RCV   TEV   HCT\$   WT.     67x   4/10   Jaundice-obstructive (P.O. hepatitis)   1650   1310   2960   26.3   20.9   47.2   46.2   62.7     67x   4/11   Jaundice-obstructive (P.O. hepatitis)   2095   1755   3850   33.4   27.9   61.3   47.5   62.7     68   9/20   CA-ampulla vater   3704   1841   5545   53.6   26.6   80.2   33.5   69.1     68   9/20   CA-ampulla vater   2992   2019   5011   43.3   29.2   72.5   42.0   69.1     68   9/22   CA-ampulla vater   2802   2013   4815   40.5   29.2   69.7   43.5   69.1     62   3/16   Peptic esophagitis (stricture)   2730   1880   4610   42.1   28.9   71.0   43.0   64.8     62   3/24   Peptic esophagitis (stricture)<!--</td--></td></t<>	AgeDateDiagnosisFV-MLRCV-MLTEV-MLFVRCVTEVHCTS $67x$ $4/10$ Jaundice=obstructive (P.0. hepatitis)16501310296026.320.947.246.2 $67x$ $4/11$ Jaundice=obstructive (P.0. hepatitis)20951755385033.427.961.347.5 $68$ $9/20$ CA=ampulla vater37041841554553.626.680.233.5 $68$ $9/20$ CA=ampulla vater29922019501143.329.272.542.0 $68$ $9/22$ CA=ampulla vater28022013481540.529.269.743.5 $68$ $9/22$ CA=ampulla vater28022013481540.529.269.743.5 $68$ $9/24$ CA=ampulla vater34751759523450.325.475.735.0 $62$ $3/16$ Peptic esophagitis (stricture)27301880461042.128.971.043.0 $62$ $3/24$ Peptic esophagitis (stricture)23351915525051.429.480.837.9 $62$ $3/26$ Peptic esophagitis (stricture)25101960448038.630.168.745.7 $62$ $3/27$ Peptic esophagitis (stricture)30951945504047.629.977.540.8 $62$ $3/28$ Peptic esophagitis (stricture)318017604	Age   Date   Diagnosis   FV-ML   RCV-ML   TEV-ML   PV   RCV   TEV   HCT\$   WT.     67x   4/10   Jaundice-obstructive (P.O. hepatitis)   1650   1310   2960   26.3   20.9   47.2   46.2   62.7     67x   4/11   Jaundice-obstructive (P.O. hepatitis)   2095   1755   3850   33.4   27.9   61.3   47.5   62.7     68   9/20   CA-ampulla vater   3704   1841   5545   53.6   26.6   80.2   33.5   69.1     68   9/20   CA-ampulla vater   2992   2019   5011   43.3   29.2   72.5   42.0   69.1     68   9/22   CA-ampulla vater   2802   2013   4815   40.5   29.2   69.7   43.5   69.1     62   3/16   Peptic esophagitis (stricture)   2730   1880   4610   42.1   28.9   71.0   43.0   64.8     62   3/24   Peptic esophagitis (stricture) </td

CHART IV (continued)

•

#### marks

ost-op; transfused in O.R. O. #1 Had 1500 ML blood since 4/10 budy re-op whipple procedure 9/21 ost-op 2500 ML estimated loss surgeon); 2300 ML blood in OR O. #1 O. #1 O.#3 slightly dehydrated re-op thoraco-abdominal esophagoastrectomy 3/25 re-op ost-op 2764 gravimetric loss; 4000 L blood in OR (2700 donor blood) O.#1 O.#2 O. #3 Mild icterus-skin O.#13 No post-op transfusions

File No.	Åge	Date	Diagnosis	PV-ML	RCV-ML	TBVML	PV	RCV	TBV	HCT%	WT.
<b>1∽M</b> H	45	3/25	Varicose veins	3660	2950	6610	36.6	29.5	66.1	46.5	100.
2-MH	45	3/25	Varisose veins	3530	2960	6490	35•3	29.6	64.9	47•5	100.
l-TF	57	9/28	CA esophagus	3480	1590	5070	72.2	33.0	105.2	37.0	48.2
2-TF	57	10/13	CA esophagus	2820	2610	5430	58 <b>•5</b>	54 <b>•2</b>	112.7	48.0	4 <sup>8</sup> •2

.

.

CHART\_IV (continued)

· .

Remarks

Pre-op bilateral vein stripping

Post-op minimal blood loss

Pre-op gastrostomy 10/13 cachectic; lost 16 pounds in 3 months

Post-op transfused pre-op; 1500 ML blood

#### PART V DISCUSSION OF RESULTS

<u>A - RESULTS IN NORMAL SUBJECTS:</u> (Tables 1 to 5)

Although there is a tendency for the

total blood volume of children to be larger and of the normal female adults to be smaller in ml./Kgm. than the total blood volume of normal male adults, no statistically significant difference of two standard deviations is seen between the group means. The normal males had a higher average hematocrit than the normal female adults and normal children accounting for the slightly higher red cell volume in ml./Kgm. in the normal male adults. Total blood volume results expressed as milliliters per square meter of surface area, however, show that children have a smaller blood volume than the adult males and females. (Statistically significant difference is seen in comparison of the children with the adult males). This latter fact was pointed out by Rowntree, Brown and Roth (144) in their red dye studies reported in 1929 and later by Robinow (143). Inspection of the

results of Ely and Sutow (52) shows that with T-1824 blood volume studies, larger children have relatively larger total blood volumes expressed as milliliters per square meter of surface area. The wide range of normal values is noted in our series as in the other reported series when results are expressed as M1./Kgm. The children's group is more homogenous than the adult groups as can be ascertained by the standard deviation of 6.1 for a total blood volume of 78.3 ML./Kgm. Our values for adults agree well with those reported by Storaasli (166) and Brady (27). No normal RIHSA values have appeared in the literature for children. Our values for children's total blood volume is markedly different from Robinow's (143) value of 90 ML./Kgm. which Dingman (44), for example, has accepted. Because children have a larger body surface area to height relationship then adults, it would appear to be more satisfactory to use weight as a basis of prediction of blood volume in children. Ely and Sutow (52) and Inkley (91) found weight and surface area to be satisfactory in the prediction of blood volume in children (52) and adults (91).

# <u>B</u> - <u>TECHNIQUE</u> AND <u>COUNTER</u> <u>STANDARDIZATION</u>: (Tables 6 to 13)

Serial RIHSA blood volume determinations by the method described in the section on Materials and Methods shows a reproducibility of plus or minus 2% (Table 6). This is acceptable for a biological measurement and agrees with the findings of Brady (27) who also used RIHSA.

Five ml. of dilute RIHSA could be delivered with a variation of much less than 1% (Table 7); counter variation was less than 1% (Table 8); replicate plasma samples were counted with a variation of less than 1% when counting rates were greater than ten times background (Table 9). Geometrical relationships of sample to counter were satisfactory when 2 ml. samples were counted (Tables 10 and 11).

Variations of voltage, pulse height selector and attenuator settings were made (Tables 12 and 13) so as to establish optimal counting conditions.

#### C - PULMONARY TUBERCULOSIS SERIES: (Tables 14 to 19)

Pre-operatively the pulmonary tuberculosis patients had approximately the same average hematocrit values as the normal groups of adults, with lower values for females than for males. The variation between the RIHSA estimate of operative blood loss and the gravimetric method of measuring operative blood loss averaged plus or minus 250 ml. in the 15 cases studied with a maximum variation of 600 ml. in two cases (Table 15). RIHSA blood volume studies and gravimetric measurement of operative loss serve complementary functions as laboratory aids in maintaining patients in a state of blood volume equilibrium. Pre-operatively a RIHSA blood volume study will help to uncover unsuspected blood volume deficits correctable by transfusion. This may be helpful in poor-risk patients. During operation the measurement of blood loss by the gravimetric means is simple, practical and permits contemporaneous replacement of blood loss, minimizing the dangers of

hemorrhagic hypotension or circulatory overload and cardiac failure. This is useful where large blood loss is anticipated. Large operative blood loss may occur when lobectomy is done in individuals who have had previous collapse procedures or empyema and may be expected to have numerous vascular adhesions and require protracted dissection. Postoperatively a RIHSA blood volume study is of value in ascertaining the adequacy of replacement of operative blood loss and in the estimation of the degree of abnormality of the blood volume. This information is useful in the differential diagnosis of post-operative hypotension and in guiding transfusion therapy for the prevention of hemorrhagic hypotension.

Familiarity with the information which the RIHSA blood volume determination and the gravimetric measurement potentially offer, will suggest many instances in which either test or both in combination may be of great value in selected patients. The ability to account for blood loss and transfusion replacement within 250 ml. on the average is highly suggestive that sequestration of blood does not occur under the conditions of our experiments.

In battle casualties large areas of soft tissue damage may contain blood which is extravascular but not extracorporeal. Artz, Howard and Prentice (8) in studies of battle casualties have noted an inability to measure accurately by blood volume techniques the expected increment due to large volumes of transfused blood. This has resulted in their emphasis on sequestration of blood occurring in individuals who require massive transfusion for restoration of normal hemodynamics after injury.

Our findings are of particular interest in connection with recent application of blood volume studies to patients with pulmonary tuberculosis. Berlin (19), Kehne (93) and Albritten (2) have reported the occurrence of blood volume deficits in patients awaiting surgery of pulmonary tuberculosis. The suggestion is made by these authors that transfusion to normal blood volume at least for present weight be done pre-operatively. Our findings corroborate the lack of correlation of the hematocrit with blood volume findings in pulmonary tuberculosis as reported by these authors.

The decision as to what constitutes a significant deficit in blood volume cannot be made without reference to statistical considerations nor can it be made purely on the grounds of statistics. Clinically a total blood volume deficit of 15 ML/Kgm

(12 times standard deviation 10) is probably of importance. This would represent a discrepancy from normal average blood volume of about 1050 ml. in the 70 Kgm, male of average physique. Weighing the risk of transfusion against the risk of failure of compensation of circulating dynamics during a major operative procedure when blood loss may amount to more than 1000 ml. and not be replaced contemporaneously, causes us to favor such an arbitrary figure as the limit of pre-operative deficit. It must be recognized that the expression of blood volume in ml/Kgm. has limitations that affect the interpretation of results. Specifically, obesity affects the percentage of body weight represented by the active metabolic mass, to which blood volume is probably most closely related. Wide physiological variations in blood volume occur so that normal values may not be rigidly applied to individuals. Conversely the blood volume determinations plus clinical evaluation of the extent of the patient's disease, magnitude of operation procedure contemplated, ability to contemporaneously replace operative blood loss by forming an accurate estimate of loss during the operative procedure - these factors will influence the credence placed in a single pre-operative blood volume determination.

Routine pre-operative transfusion of pulmonary tuberculosis patients is as unwarranted as routine failure to transfuse. Normal concentration indices (hemoglobin, red cell count, hematocrit) are not helpful in the selection of patients for preoperative transfusion. Clinical estimate based on recent weight change, duration of disease and sanitarium care and roentgenologic estimate of the extent of disease, may at times be misleading. Blood volume determinations may help and at times are extremely useful when related to the clinical picture, especially when performed serially as a means of following changes in blood volume consequent to pre-operative transfusion.

Berlin (19) noted that 2 out of 26 cases studied apparently had a secondary polycythemia due to pulmonary fibrosis. Our results indicate the same findings in some of the male patients. If routine transfusions were given pre-operatively these patients may have developed circulatory overload. Even though the polycythemia may be compensatory for an abnormal pulmonary alveolar-capillary gradient of diffusion of oxygen due to fibrosis of the lung parenchyma, there is no positive reason for administering transfusion which will only increase the polycythemia.

The female patients did have a normal average hematocrit (39%). Among the female patients there were no instances of hypervolemia and they had lower blood volumes on the average than the male patients. - 204 -

Transfusion might be considered more frequently in the female patients pre-operatively.

Where facilities for blood volume determinations are not available and a large volume of pulmonary tuberculosis surgery is performed, the occurrence of significant pre-operative deficits in certain patients will not be recognized preoperatively. This emphasizes the necessity for careful estimate of operative blood loss and contemporaneous replacement. Where practical, routine gravimetric measurement of blood loss should be employed in pulmonary tuberculosis surgery. At least, the measurement of operative blood loss should be conducted on those cases recognized clinically as poor risks. A period of two to three weeks trial of the method is educational to surgeons, anaesthetists, operating room nurses and blood bank personnel responsible for supplying properly cross-matched blood for use during operation. Such a trial of the method is an instructive discipline for surgeons who are completely confident of their ability to judge operative blood loss. Placing the sponges on a rack after weighing permits a valuable correlation between the reported measurement and the visual image of the number and saturation of the gauze sponges used. Improved operative technique prompted by a desire for economy in blood loss may ultimately benefit the patient.

The largest pre-operative deficit of total blood volume was found in male patient #11. Although he had a hematocrit of 48.4%, his pre-operative total blood volume was 22% less than expected. Clinically he was judged a poor risk, having poor pulmonary function studies, a large cyst in the left upper lobe and an immobile emphysematous chest. Following left upper lobectomy (transfusion 1450 cc.; blood loss 2000 cc.) his blood volume was further decreased 550 ml. His post-operative blood volume was 30% sub-normal. Post-operatively this patient was not hypotensive but did have markedly low hemoglobin and hematocrit determinations. From the hemodilution one may infer
rapid re-expansion of the plasma volume by translocation of extracellular fluid. This mechanism for expanding the blood volume would practically explain the absence of oligemic hypotension post-operatively.

## <u>D</u> - <u>RESULTS OF SINGLE AND SERIAL STUDIES</u> <u>PRESENTED IN CHARTS 1 TO 4</u>:

Determinations were performed

in poor-risk patients with blood volume deficits (Chart 1), electrolyte abnormalities (Chart II), miscellaneous surgical conditions (Chart III), and in patients before and after operation (Chart IV). These studies showed the practicability of the RIHSA blood volume as applied to the problems of surgical patients. Correlation of the laboratory data with the clinical condition of the patient helped to define and elucidate abnormalities of blood homeostasis and fluid balance. The rapid differentiation of plasma volume, red cell volume, and total blood volume deficits was of considerable practical importance in many cases of hemorrhage, dehydration and hypotension in poor-risk patients. In surgical centers to which complicated surgical problems are referred for treatment, maintenance of a blood volume laboratory with scintillation counting equipment for RIHSA blood volume studies

- 207 -

may be compared with maintenance of a metabolism laboratory with flame photometry apparatus for serum cation analysis. The rapid, accurate measurement of blood volume and the rapid, accurate measurement of serum cations may both be indicated in problems of pre- and post-operative management, especially of poor-risk patients or patients subjected to major operative procedures. The interpretation of tests of serum cation analysis and blood volume are best made by an individual who understands the limitations of the laboratory tests and appreciates the relationship of the tests to the clinical conditions of the patient. The interpretation of blood volume tests should ideally be done by the clinician responsible for the surgical management. However the advice of a consultant trained in metabolism, especially as related to surgical problems, and in physiology as related to circulatory dynamics would be of great value to the individuals assigned the responsibility for the pre- and post-operative care of poor risk surgical patients.

Examination of the data of Charts I to 4 effectively demonstrates the lack of correlation of the hematocrit percent with the total blood volume in ml./Kgm. Most of the authorities on the subject of blood volume from Rowntree (144) in 1929 to Berlin (17) in 1952 have made this observation. However with the data of a recent blood volume study, physical examination of the patient with respect to general state of health and state of hydration and history of fluid intake, state of nutrition, history of transfusions or blood loss and the hematocrit percent or other concentration indices of the blood have some value in ascertaining blood volume excesses or deficits in surgical patients. In a surgical patient, when there is an abnormality of blood volume sufficient to interfere with the maintenance of normal hemodynamics, a rapid blood volume test such as the RIHSA test, is a source of more meaningful information than is an index of concentration such as the homatocrit percent.

Figures 8 to 11 illustrate diagrammatically typical surgical cases in which blood volume studies correlate well with the clinical course of the patient and are more useful than hematocrit determinations.

# E - INTERPRETATION OF BLOOD VOLUME DETERMINATIONS; ESTIMATE OF VOLUME DEFICITS:

It has been noted that there is a

good general agreement as to normal values of the currently used (i.e. T/1824, RIHSA, P<sup>32</sup> and Cr<sup>51</sup> tagged red cell) methods of plasma volume or red cell volume determination and that the methods are clinically satisfactory (74, 135, 136), for determination of total blood volume when used with the venous hematocrit over an average range of 30-50%. However, it has been pointed out that average normal values may not be rigidly applied to individuals because of the wide range of normal values which are included in the average normal value (136). Hence the statistical limitations and the clinical applicability of values must be reconciled in some way. The wide range of average values when expressed as ml/Kgm. probably arises to a great extent from the differences in body density or proportion of lean body mass to body weight in different individuals (68). However, expression of results as ml./Kgm is the most convenient and not the most

inexact way of expressing blood volume (136). When an extreme of body type is encountered (i.e. marked obesity or marked leanness) one must realize the probably effect of body type on the number of ML. of blood per Kgm and then compare the findings in the particular individual with the findings in the average normal. Applying a statistical rule of considering a variation of two standard deviations from the mean as significant, some obese normals will be considered not significantly different from the normal. In our series of 23 male patients: PV = 40.8 plus or minus 6.0; RCV = 32.0 plus or minus 3.4; TBV = 72.7 plus or minus 8.5. The range of values is: PV 32.9 - 52.9; RCV 25.4 - 37.2; TBV 58.8 - 90.2. Hence it can be seen that there is a wide range of normal. Repeated sampling since 1915 (94) with dilution methods of blood volume determination has not succeeded in narrowing the ranges when results are expressed as ml./Kgm. In our series of normal males, one standard deviation represents the following percent of the mean: PV - 14.7%; RCV - 10.6%; TBV - 11.7%. Hence it is quite obvious that, from a statistical point

of view, deviations of 10% from the average are not significant in an isolated determination. (The variation of 10% between successive determinations would probably be significant statistically as well as clinically since the coefficient of variation between serial determinations with RIHSA is of the order of 2 to 3%). Before major surgical procedures the finding of a red cell volume deficit of at least 15% or a total blood volume deficit of at least 15% in a patient who is not extremely obese would suggest that transfusion might be adventageous. (These arbitrary limits are based on approximately  $l^{\frac{1}{2}}$  times the standard deviation for red cell volume and  $l_2^{\frac{1}{2}}$  times the standard deviation for total blood volume). Since neither transfusion nor pre-operative anemia are innocuous, the problem must be solved on a basis of an evaluation of the risk of unnecessary transfusion (inconpatibility, allergic reaction, septicemia, circulatory overload, hemosiderosis with multipe transfusions) as opposed to the risk of omitting necessary transfusion (decreased oxygen carrying capacity of blood, hypovolemia

rendering the patient more susceptible to decompensation of circulatory dynamics with anaesthesia and operative blood loss, hypoproteinemia). From the point of view of circulatory dynamics it has been shown that patients with normal blood volume tolerate transfusion well (47), thus transfusion of a patient who had a normal blood volume but a laboratory report of "10% deficit" would not necessarily cause the patient to suffer from an over-expansion of his blood volume. Thus for clinical purposes we are inclined to categorically state that these deficits are not necessarily clinically significant: red cell volume less than 15% below normal, total blood volume less than 15% below normal. Deficits in plasma volume of the order of 15% in a patient with history of extracellular fluid loss or internal redistribution of fluid after mechanical or thermal trauma may suggest the use of plasma or plasma expanders as well as rehydration (salt and water replacement). As applied to a 70 Kgm male, 15% deficits would amount to: PV - 430 cc.; RCV - 330 cc.; TBV - 760 cc. Following such a rule

will prevent the administration of transfusion solutions to patients who may not require transfusion. However, if a patient had a larger blood volume in ml./Kgm than average, lost some of the volume, and a laboratory report of "10% deficit" was made, the patient may have gone from a 115% to a 90% average volume and be in need of transfusion, i.e., he would have lost 22% (22, 115) of his original blood volume. This instance applies particulary to those individuals with whole blood loss. Hence, in a thin individual a 10% volume deficit of total blood should be corrected to average normal for weight by whole blood transfusion. The problem of what constitutes a deficit can probably best be solved by some means of readily relating the volume of blood to the active metabolic mass of the patient, but no practical, simple means of doing this is at hand.

### PART VI SUMMARY

A review of the literature of clinical

blood volume studies has been made with reference to applic\_ation of a rapid, reliable, simple method to surgical patients. Problems bearing on the precision and accuracy of blood volume methods have been discussed. The relationship of blood volume to circulatory dynamics and alterations of blood volume in states of health and disease have been mentioned.

The RIHSA method of blood volume determination was chosen as being satisfactory for the purpose of routine clinical blood volume study in surgical patients and as a basis for the establishment of a Blood Volume Laboratory in the Royal Victoria Hospital. A method of using the RIHSA for these purposes was evolved and tested over a period of one year commencing in July, 1954. The technique and counting equipment were standardized. Over 300 determinations performed in human subjects demonstrated the practicability and utility of the method. Normal values were established for adults and children. A group of patients with pulmonary tuberculosis were studied before, during and after surgery with measurements being made of pre- and post-operative RIHSA blood volume and of operative blood loss. Correlation was made of directly measured operative blood loss and the estimate of operative blood loss made from pre- and post-operative RIHSA blood volume.

Single and serial RIHSA blood volume determinations were performed in poor risk surgical patients, patients subjected to operative procedures and patients who had abnormalities of fluid and electrolyte metabolism.

### PART VII CONCLUSIONS

1. - The RIHSA blood volume method is a rapid, simple, reliable method of estimating blood volume, particularly suitable for use in surgical patients.

2. - A Blood Volume Laboratory was inaugurated in the Royal Victoria Hospital and over 300 determinations performed in human subjects.

3. - A modification of the RIHSA blood volume was developed and described for use in the Blood Volume Laboratory of the Royal Victoria Hospital.

4. - The RIHSA blood volume method described was found to give serially reproducible results with plus or minus 2.2% variation.

5. - Normal values in ml./Kgm. were obtained for: (continued pg. 219)

	Plasma	Red <sup>C</sup> ell	Total Blo	od Hematocrit
	volume	volume	Volume	X
Adult males	40•8	32.0	72.7	45•8
	± 6•0	±3.4	±8.5	±3•0
Adult females	43•5	27.2	70.7	40.3
	± 7•3	± 3.7	±10.2	±3.3
Children	49•6	28.7	78.3	38.2
	14•5	±2.4	±6.1	±1.9

6. - Children were found to have a smaller blood volume
per square meter of body surface than adults (27 children;
11 adult females; 13 adult males):

	Ml. Total	Bloo	d Volume	per	square	meter	of
	surface as	rea.					
Children	197	14 =	186				
Female adults	25]	<u>.</u> 8 ±	295				
Male adults	278	38 ±	253				

7. - The mean blood volume of pulmonary tuberculosis patients (32 subjects) was not significantly different from the mean blood volume of the normal subjects.

8. - Routine blood transfusion before surgery for pulmonary tuberculosis is discussed but not recommended.

9. - Gravimetric measurement of operative blood loss during pulmonary tuberculosis surgery (15 patients) agreed well with the estimate made from pre- and post-operative RIHSA blood volume studies. Average variation was 243 ml. and maximum variations were plus or minus 600 ml.

10. - The RIHSA blood volume method provides laboratory data which is of value in the management of problems of water and electrolyte metabolism occurring in surgical patients.

#### BIBLIOGRAPHY

- Adolph, E.F., Gerbasi, M.J. and Lepore, M.J. Rate of entrance of fluid into blood in hemorrhage. Amer. J. Physiol. <u>104</u>:502, 1953.
- 2. Albritten, F.F., Lipshutz, H., Miller, B.J. and Gibbon, J.H., Jr. Blood volume changes in tuberculosis patients treated by thoracoplasty. J. Thoracic Surg. <u>19</u>:71, 1950
- 3. Allen, J.G., Clark, D.E., Thornton, T.F.Jr., and Adams, W.E. The transfusion of massive volumes of citrated whole blood and plasma in man: Clinical evidence of its safety. Surgery <u>15</u>:824, 1944.
- Allen, T.H., Pallavicini, C. and Gregersen, M.I. Simultaneous measurement of plasma volume with hemoglobin and with T-1824.
   Amer. J. Physiol. <u>175:</u>236, 1953.
- 5. Allen, T.H. and Reeve, E.B. Distribution of "extra plasma" in the blood of some tissues in the dog as measured with P<sup>32</sup> and T-1824. Amer. J. Physiol. <u>175</u>:218, 1953.
- 6. Arnold, H.R., Carrier, E.B., Smith, H.P. and Whipple, G.H. Blood volume studies: V. The carbon monoxide method --its accuracy and limitations. Amer. J. Physiol. <u>56</u>:313, 1921.

- 7. Artz, C.P. and Howard, J.M. Initial care of the severely wounded. J.A.M.A. <u>156</u>:488, 1954.
- 8. Artz, C.P., Howard, J.M., Sake, Y., Bronwell, A.W. and Prentice, T. Clinical experience in the early management of the most severely wounded battle casualties. Ann. Surg. <u>141</u>:285, 1955.
- 9. Ashby, W. Blood volume. I. A method for determining whole blood volume based on the circulating corpuscle volume. Arch. Int. Med. <u>35</u>:516, 1925.
- 10. Aust, J.B., Chou, S.N., Marvin, J.F., Brackney, E.L. and Moore, G.E. A rapid method for clinical total blood volume determination using radioactive iodinated human serum albumin (RIHSA). Proc. Exper. Biol. and Med. <u>77</u>:514, 1951.
- 11. Aust, J.B., Chou, J.N., Marvin, J.F., Brackney, E.L. and Moore, G.E. The use of radioactive iodinated human serum albumin (RIHSA) for clinical total blood volume studies. Surgical Forum, Amer. Coll. Surg., Philadelphia, W.B. Saunders and Company, 1952.
- 12. Barnes, D.W.H., Loutit, J.F. and Reeve, E.B. A comparison of estimates of circulating red blood cell volume given by the Ashby marked red cell method and the T-1824 hematocrit method in man. Clin. Sc. <u>1</u>:135, 1948.

- 13. Baronofsky, I.D., Treloar, A.E. and Wangensteen, O.H. Blood loss in operations. A statistical comparison of losses as determined by the gravimetric and colorimetric methods. Surgery 20:761, 1946.
- 14. Bazett, H.C. In MacLeod's Physiology in Modern Medicine. St. Louis, Mo., C.V. Mosby Company.
- Beling, C.A., Bosch, D.T. and Morton, T.V. Blood volume determinations in surgery. Surg., Gyn. & Obst. <u>90</u>:686, 1950.
- Berlin, N.I., Hyde, G.M., Parsons, R.J. Lawrence, J.H. and Post, S. Blood volume of normal female as determined with P<sup>32</sup> labelled red cells. Proc. Soc. Exper. Biol. and Med. <u>76</u>:831, 1951.
- Berlin, N.I., Hyde, G.M., Parsons, R.J., Lawrence, J.H. and Port, S. The blood volume in various medical and surgical conditions. New. Eng. J. Med. <u>247</u>:675, 1952.
- Berlin, N.I., Lawrence, J.H. and Gartland, J. Blood volume in chronic leucemia as determined by P<sup>32</sup> labelled red cells. J. Lab, and Clin. Med. <u>36</u>:435, 1950.
- 19. Berlin, N.I., Rowles, D.F., Hyde, G.M. Parsons, R.J., Lawrence, J.H. and Post, S. Blood volume in pulmonary tuberculosis. A.M.A. Arch. Int. Med. <u>88</u>:17, 1951.

- 20. Berlin, N.I., Rowles, D.F., Hyde, G.M., Parsons, R.J., Samson, P.C. and Post, S. The blood volume and blood turnover in thoracic surgery as determined by P<sup>32</sup> labelled red blood cells. Surg., Gyn. & Obst. <u>92</u>:712, 1951.
- 21. Berson, S. and Yalow, R. The use of K<sup>42</sup> or P<sup>32</sup> labelled erythrocytes and Il31 tagged human serum in simultaneous blood volume determinations. J. Clin. Invest. <u>31</u>:572, 1952.
- 22. Berson, S.A., Yalow, R.S., Schreiber, S.S. and Post, J. Tracer experiments with I<sup>131</sup> labelled human serum albumin: distribution and degradation studies. J. Clin. Invest. <u>32</u>:746, 1953.
- 23. Bischoff, T.L.W. Quoted from Welcker. Ztschr. f. rat. med. <u>4</u>:145, 1858.
- 24. Blum Quoted by Watson-Jones, R. (op. cit.)
- 25. Blundell, J. A successful case of transfusion. Lancet <u>1</u>:431, 1829.

7

26. Bonica, J.J. and Lyter, C.S. Measurement of blood loss during surgical operations. Amer. J. Surg. 81:496, 1951.

- Brady, L.W., Cooper, D.Y., Colodzin, M. McClenathan, J.E., King, E.R., and Williams, R. Blood volume studies in normal humans. Surg. Gyn. & Obst. <u>97</u>:25, 1953.
- Carbone, J.V., Furth, F.W., Scott, R., Jr. and Crosby, W.H. An hemostatic defect associated with dextran infusion. Proc. Soc. Exper. Biol. and Med. <u>85</u>:101, 1954.
- 29. Chanutin, A., Smith, A.H. and Mendel, L.B. Factors concerned in blood volume regulation. Amer. J. Physiol. <u>68</u>:444, 1924.
- 30. Chaplin, H., Jr., and Mollison, P.L. Correction for plasma trapped in the red cell column of the hematocrit. Blood 7:1227, 1952.
- 31. Chaplin, H., Jr., and Mollison, P.L. The body - venous hematocrit ratio: its constancy over a wide hematocrit range. J. Clin. Invest. <u>32</u>:1309, 1953.
- 32. Churchill, E.D. Quoted by Ravdin, I.S. and Ravdin, R.G. (op. cit.)
- 33. Clark, J.H., Nelson, W., Lyons, C., Mayerson, H.S. and DeCamp, P. Chronic shock: the problem of reduced blood volume in the chronically ill patient. I. Concept of chronic shock. II. Hemoglobin and red cell deficits in chronic shock. III. Quantitative aspects of the anemia associated with malignant tumors. Ann. Surg. <u>125</u>:618, 1947.

- 34. Chou, S.N., Aust, J.B., Moore, G.E. and Peyton, W.E. Radioactive iodinated human serum albumin as tracer agent for diagnosing and localizing intracranial lesions. Proc. Soc. Exper. Biol. and Med. 77:193, 1951.
- 35. Chou, S.N., Aust, J.B., Peyton, W.B. and Moore, G.E. Radioactive isotopes in localization of intracranial lesions. Arch. Surg. <u>63</u>:554, 1951.
- 36. Coller, F.A., Crook, C.E. and Iob, V. Blood loss in surgical operations. J.A.M.J. <u>126</u>:1, 1944.
- 37. Comroe, J.H., Jr. The location and function of the chemorecptors of the aorta. Amer. J. Physiol. <u>127</u>:176, 1939.
- 38. Comroe, J.H., Jr. and Schmidt, C.F. Carotid body reflexes and regulation of respiration. Amer. J. Physiol. <u>121</u>:75, 1938.
- 39. Crehan, J.P. The value of blood volume determinations in the poor-risk patient. Surg. Clin. North America. <u>34</u>:605, 1954.
- 40. Crispill, K.R., Porter, B. and Nieset, R.T. Studies of plasma volume using human serum albumin tagged with radioactive iodine I<sup>131</sup>. J. Clin. Invest. <u>29</u>:513, 1950.

- 226 -

- 41. Crosby, W.H. The hemolytic states. Bull. N.Y. Acad. Med. <u>30</u>:27, 1954.
- 42. Crosby, W.H. and Akeroyd, J. The limit of hemoglobin synthesis in hereditaty hemolytic anemia. Amer. J. Med. <u>13</u>:273, 1952.
- 43. Cruickshank, E.W.H. and Whitfield, I.C. The behavior of T-1824 (Evans blue) in circulating blood and a modified method for the estimation of plasma volume. J. Physiol. <u>104</u>:52, 1945.
- 44. Dingman, R.O., Ricker, O.L. and Iob, V. Blood loss in ingant cleft lip and cleft palate surgery. Plastic and Reconstructive Surgery, <u>4</u>:NO.4, July, 1949.
- 45. Dunbar, H.S. and Ray, B.S.
  Localization of brain tumors and other intracranial
  lesions with radioactive iodinated human serum albumin.
  Surg. Gyn.& Obst. <u>98</u>:433, 1954.
- 46. Ebert, R.V. and Stead, E.A. Demonstration that the cell-plasma ratio of blood contained in minute vessels is lower than that of venous blood. J. Clin. Invest. <u>20</u>:317, 1941.
- 47. Ebert, R.V., Stead, E.A. and Gibson, J.G. Response of normal subjects to acute blood loss, with special reference to the mechanism of restoration of blood volmue. Arch. Int. Med. <u>68</u>:578, 1941.

- 48. Edelman, I.S., Olney, J.M., James, A.H., Brooks, L. and Moore, F.D.
  Body composition: Studies in the human being by the dilution principle. Science <u>115</u>:447, 1952.
- 49. Editorial. Plasma volume expanders. Canad. Serv. Med. J; <u>10</u>:389, 1954.
- 50. Elkinton, J.R. in Fulton's Textbook of Physiology. Philadelphia, W.B. Saunders and Company, 1949.
- 51. Elkinton, J.R. and Taffel, M. The apparent volume of distribution of sulfocyanate and of sulfanilamide in the dog. Amer. J. Physiol. <u>138</u>:126, 1942.
- 52. Ely, R.S. and Sutow, W.W. Growth of thiocyanate space in infancy and childhood. Pediatrics <u>10</u>:115, 1952.
- 53. Emerson, C.P. and Ebert, R.V. Reduced blood volume: A study of shock in battle casualties. Ann. Surg. <u>122:745</u>, 1943.
- 54. Evans, E.I., Hoover, M.J., James, G.W. and Alm, T. Blood volume changes in traumatic shock. Ann. Surg. <u>119</u>:64, 1944.
- 55. Fahraeus, R. The suspension stability of blood. Physiol. Rev. 9:241, 1929.

- 56. Farmer, T.W., Lanz, H., McCall, M.S., Morgan, C., Nicholl, W. and Clayton, R. Use of radioactive iodinated human serum albumin as tracer agent in the study of cerebral disorders. Proc. Soc. Exper. Biol. and Med., <u>81</u>:33, 1952.
- 57. Fields, T., Kaplan, E. and Terril, M. A simplified technique for blood volume determinations using I ----HSA.
   J. Lab. and Clin. Med. 43:332, 1954.
- 58. Fine, J. and Seligman, A.M. Traumatic shock: IV. A study of the problem of "lost plasma" in hemorrhagic shock by the use of radioactive plasma protein. J. Clin. Invest. 22:285, 1943.
- 59. Finley, R.K., Jr., Templeton, J.Y., III, Holland, R.H. and Gibbon, J.H., Jr. Changes in urine and serum electrolytes and plasma volume after major intrathoracic operations. J. Thoracic Surg. <u>22</u>:219, 1951.
- 60. Fox, C.L. Jr., and Lasker, S.E. Fluid therapy in surgical emergencies including hemorrhage, loss of gastrointestinal fluids and thermal burns. Surg. Clin. N. Amer. <u>35</u>:335, 1955.
- 61. Fox, C.L.Jr., Lasker, S.E., Winfield, J.M. and Mersheimer, W.L. Albumin, K, Na, and Cl redistribution and erythrocyte loss after surgical trauma and extensive burns. Ann. Surg. 140:524, 1954.

- 62. Frank, H. and Gray, S.J. The determination of plasma volume in man with chronic chloride. J. Clin. Invest. <u>32</u>:1000, 1953.
- 63. Freinkel, N., Schreiber, G.E. and Athens, J.W. Simultaneous distribution of T-1824 and I<sup>131</sup> labelled human serum albumin in man. J. Clin. Invest. <u>32</u>:138, 1953.
- 64. Gatch, W.D. and Little, W.D.
  Amount of blood loss during some of the more common operations.
  J.A.M.A. <u>83</u>:1075, 1924.
- 65. Gibson, J.G.
  Clinical studies of the blood volume: VI. Changes in the blood volume in pernicious anemia in relation to the hematopoietic response to intramuscular liver extract therapy.
  J. Clin. Invest. <u>18</u>:401, 1939.
- 66. Gibson, J.G.
  Clinical studies of the blood volume. Blood volume in anemias and polycythemia.
  J. Clin. Invest. <u>18</u>:621, 1939.
- 67. Gibson, J.G., 2nd, and Evans, W.A., Jr.
  Clinical studies of the blood volume.
  I. Clinical application of a method employing the azo dye "Evans Blue" and the spectrophotometer.
  J. Clin. Invest. <u>16</u>:301, 1937.
- 68. Gibson, J.G., 2nd and Evans, W.A., Jr. Clinical studies of the blood volume. II. The relation of plasma and total blood volume to venous pressure, blood velocity rate, physical measurements, age and sex in ninety normal humans. J. Clin. Invest. <u>16</u>:317, 1937.

- 69. Gibson, J.G., 2nd and Evelyn, K.A. Clinical studies of the blood volume. IV. Adaptation of the method to the photoelectric micro colorimeter. J. Clin. Invest. <u>17</u>:153, 1938.
- 70. Gibson, J.G., Peacock, W.C., Seligman, A.M. and Sack, T. Circulating red cell volume measured simultaneously by the radioactive iron and dye methods. J. Clin. Invest. 25:838, 1946.
- 71. Grant, R.K. and Reeves, E.B.
  Observations on the general effect of injury in man.
  Medical Research Council. Special Report No. 217.
  London, His Majesty's Stationary Office, 1951.
- 72. Gray, S.J. and Frank, H. The simultaneous determination of red cell mass and plasma volume in man with radioactive sodium chromate and chronic chloride. J. Clin. Invest. <u>32</u>:1000, 1953.
- 73. Green, H.D. Vascular architecture, structures and components. Presented October 5th, 1953 to the Symposium on Circulation and Hemostasis. Army Medical Service Graduate School. Walter Reed Army Medical Center, Washington, D.C.
- 74. Gregersen, M.I. Blood volume. Ann. Rev. Physiol. <u>13</u>:397, 1951.

1

75. Gregersen, M.I.
Effect of circulatory states on determinations of blood volume.
Amer. J. Med. <u>15</u>:785, 1953.

- 76. Gregersen, M.I. and Nickersen, J.L. Relation of blood volume and cardiac output to body type. J. Applied Physiol. <u>3</u>:329, 1950.
- 77. Gregersen, M.I., Boyden, A.A., and Allison, J.B. Direct comparison in dogs with plasma volume measured with T-1824 and with antigens. Amer. J. Physiol. <u>163</u>:517, 1950.
- 78. Gregersen, M.I., Cezik, L.J. and Allen, T.H. Proportion of "extra plasma" in the eviscerate dog. Amer. J. Physiol. <u>175</u>:224, 1953.
- 79. Hahn, P.F., Balfour, W.M., Ross, J.R. Ball, W.F. and Whipple, G.H. Red cell volume, circulating and total, as determined by radio iron. Science, <u>93</u>:87, 1941.
- 80. Hammond, J.F. Editorial Department, J.A.M.J. Personal communication, 1955.
- 81. Heller, W. and Paul, J. Evaporated exalate as an anticoagulant for small blood samples.
  J. Lab. and Clin. Med. <u>19</u>:777, 1934.
- 82. Hemingway, A., Scott, F.H. and Wright, H.N. The kinetics of the elimination of the dye water blue from dog plasma after intravenous injection. Amer. J. Physiol. <u>112</u>:56, 1935.

- 83. Hevesy, G. and Zerahn, K. Determination of the red corpuscle content. Acta Physiol. Scand. <u>4</u>:376, 1942.
- 84. Hevesy, G., Koster, K.H., Sorenson, G., Warburg, E. and Zerahn, K. The red corpuscle content of the circulating blood determined by labelling the erythrocytes with radio-phosphorus. Acta Med. Scand. 116:561, 1944.
- 85. Hopper, J., Jr., Elkinton, J.R. and Winkler, A.W. Plasma volume in dogs in dehydration, with and without salt loss. J. Clin. Invest. <u>23</u>:111, 1944.
- 86. Howard, J.M. Current status of thinking regarding shock. Presented October 9th, 1953 to the Symposium on Circulation and Hemostasis. Army Medical Service Graduate School. Walter Reed Army Medical Center, Washington, D.C.
- 87. Howard, J.M. Experiences with shock in the Korean theater. in Shock and Circulatory Homeostasis. Green, H.G., editor. New York, Josiah Macy, Jr. Foundation, 1954.
- 88. Howard, J.M., Artz, C.P. and Stahl, R.R. The hypertensive response to injury. Ann. Surg. <u>141</u>:327, 1955.
- 89. Howarth, S. and Sharpey-Schafer, E.P. Low blood pressure phases following hemorrhage. Lancet, <u>1</u>:18, 1947.

- 90. Hughes, W.L., Jr. and Straessle, R. Preparation and properties of serum and plasma proteins.
  XXIV Iodination of human serum albumin. J. Amer. Chem. Soc. <u>72</u>:452, 1950.
- 91. Inkley, S.R., Brooks, L. and Krieger, H. A study of methods for the prediciton of plasma volume. J. Lab. and Clin. Med. <u>45</u>:841, 1955.
- 92. Jackson, D.P., and Krevans, J.R. A hemorrhagic state following multiple whole blood transfusions. Presented at the annual meeting of the American Society for Clinical Investigation, May, 1955.
- 93. Kehne, J.H. Veteran's Administration Hospital, Memphis, Tennessee. Personal communication, 1955.
- 94. Keith, M.N., Rowntree, L.G. and Geraghty, J.T. A method for the determination of plasma and blood volume.
  Arch. Int. Med. <u>16</u>:547, 1915.
- 95. Klotz, I.M. and Walker, F.M. The binding of organic ions by proteins. Charge and pH effects.
  J. Amer. Chem. Soc. <u>69</u>:1609, 1947.
- 96. Krieger, H., Holden, W.D., Hubay, C.A. Scott, M.W., Storaasli, J.P. and Friedell, H.L. Appearance of protein tagged with radioactive iodine in thoracic duct lymph. Proc. Soc. Exper. Biol. and Med. 73:124, 1950.

- 97. Krogh, A. The Anatomy and Physiology of Capillaries. New Haven, Yale University Press, 1929.
- 98. Ladd, W.R. and Gross, R.E. Abdominal Surgery of Infancy and Childhood. Philadelphia, W.B. Saunders Company, 1941.
- 99. Lands, A.M. and Johnson, W.H. Distribution of body water following hemorrhage. Proc. Soc. Exper. Biol. and Med. <u>49</u>:123, 1942.
- 100. Lawson, H. and Rehm, W.S. Efficacy of gelatin solutions and other cell-free fluids in reversing effects of nearly complete exsanguination. Amer. J. Physiol. <u>144</u>:217, 1945.
- 101. Loutit, J.F., Mollison, M.D. and Van der Walt Venous pressure during venesection and blood transfusion. Brit. Med. J. 2:658, 1942.
- 102. MacKenzie, D.W., Jr., Whipple, A.O. and Wintersteimer, M.P. Direct observations on the circulation of blood in transilluminated mammalian spleens. Proc. Soc. Exper. Biol. and Med. <u>44</u>:139, 1940.
- 103. Madden, S.C., Kattus, A.A., Jr., Carter, J.R. Miller, L.L. and Whipple, G.H. Plasma protein production as influenced by parenteral protein digests, very high protein feeding and red blood cell catabolism. J. Exper. Med. <u>82</u>:181, 1945.

- 104. McInnes, G.F., Bodansky, O. and Brunschwig, A. Blood volume and blood biochemical studies in patients undergoing radical surgery. Surg. Gyn. & Obst. <u>90</u>:686, 1950.
- 105. McLain, P.L., Ruhe, C.H.W. and Kruse, T.K. Concurrent estimates of blood volume in animals by bleeding and dye methods. Amer. J. Physiol. <u>164</u>:611, 1951.
- 106. Miller, B.J., Gibbon, J.H., Jr. and Albritten, F.F., Jr. Blood volume and extracellular fluid changes during thoracic operations. J. Thoracic surgery. 18:605, 1949.
- 107. Mollison, P.L. Blood <sup>T</sup>ransfusion in Clinical Medicine. Oxford., Blackwell Scientific Publications, 1951.
- 108. Mollison, P.L., Veall, N. and Cutbush, M. Red cell volume and plasma volume in newborn infants. Arch. Dis. Child. 25:252, 1950.
- 109. Moore, F.D. The conquest of space - by the red blood cell. Ann. Surg. <u>135</u>:143 1952.
- 110. Moyer, J.H., Morris, G. and Beazley, H.L. Renal hemodynamic response to vasopressor agents in the treatment of shock. Circulation <u>12</u>:96, 1955.

- 111. Nachman, H.M., James, G.W., Moore, S.W., and Evans, E.I. A comparative study of red cell volumes in human subjects with radioactive phosphorus tagged cells and T-1824 dye. J. Clin. Invest. <u>29</u>:258, 1950.
- 112. Nesbit, R.M. and Conger, K.B. Studies of blood loss during transurethral prostatic resection. J. Urol. <u>46</u>:713, 1941.
- 113. Nicholson, M.J. and Jensen, F.G. Importance of blood volume studies in management of surgical patients. Current Res. in Anaesth. and Analg. <u>31</u>:27, 1952.
- 114. Nickerson, J.L., Sear, H. and Reeve, E.B. Simultaneous measurements of cell volume with Fe<sup>55</sup> and P<sup>32</sup> in splenectomized dogs. Amer. J. Physiol. <u>175</u>:230, 1953.
- 115. Noble, R.P. and Gregersen, M.I. Blood volume in clinical shock; mixing time and disappearance rate of T-1824 in normal subjects and in patients in shock; determination of plasma volume in man from 10-minute sample. J. Clin. Invest. 25:158, 1946.
- 116. Noble, R.P. and Gregersen, M.I. Blood volume in clinical shock: II. The extent and cause of blood volume reduction in traumatic, hemorrhagic and burn shock. J. Clin. Invest. <u>25</u>:172, 1946.

- 117. Nylin, G. and Scott-Baker, J.C. Quoted by Mollison, P.L. (op. cit.) Personal communication, 1950.
- 118. Ohike, R.F. and Scales, J.J.
  Plasma augmenters in clinical surgery.
  C.M.A.J. 68:260, 1953.
- 119. Owen, C.A., Jr., and Power, M.H. Intercellular plasma of centrifuged human erythrocytes as measured by means of iodo I<sup>131</sup> albumin. J. Applied Physiol. <u>5</u>:323, 1953.
- 120. Parsons, W.H., Williams, W.T. and Forsythe, L.J. The clinical significance of blood volume determinations. Ann. Surgery. <u>135</u>:791, 1952.
- 121. Paquin, A.J., Jr., Marshall, V.F. and Nathanson, B. Studies on a practical method for the determination of operative blood loss. Ann. Surg. <u>141</u>:53, 1955.
- 122. Perera, G.A. The effect of significant weight change on the predicted plasma volume. J. Clin. Invest. <u>25</u>:401, 1946.
- 123. Peters, J.P.
  Some remarks on diabetic acidosis.
  Yale J. Biol. and Med. <u>27</u>:152, 1954.

- 124. Peters, J.P. Personal communications, 1954.
- 125. Petersdorf, R.G. and Welt, L.G. The effect of an infusion of hyperoncotic albumin on the excretion of water and solutes. J. Clin. Invest. <u>32</u>:283, 1953.
- 126. Peyton, W.T., Moore, G.E., French, L.A. and Chou, S.N. Localization of intracranial lesions by radioactive isotopes. J. Neurosurgery <u>9</u>:432, 1952.
- 127. Pilcher, F. and Sheard, C. Measurements on the loss of blood during transurethral prostatic resection and other surgical procedures determined by spectrophotometric and photometric methods. Proc. Staff Meetings, Mayo Clinic, 12:213, 1937.
- 128. Plentl, A.D. and Gelfand, M.M. A modific ation of the dye-dilution method for serial estimations of the plasma volume. Surg. Gyn. & Obst. <u>98</u>:485, 1954.
- 129. Prentice, T.C. Circulation and blood volume problems in the seriously wounded casualty. Presented October 9th, 1953 to the Symposium on Circulation and Homeostasis. Army Medical Service Graduate School. Walter Reed Army Medical Center, Washington, D.C.
- 130. Prentice, T.C., Olney, J.M., Jr., Artz, C.P., and Howard, J.M. Studies of blood volume and transfusion therapy in Korean battle casuality. Surg. Gyn. & Obst. <u>99</u>:542, 1954.

- 131. Price, P.B. Blood volume in health and disease. J.A.M.A. <u>145</u>:781, 1951.
- 132. Price, B.P., Hanlon, C.R., Longmire, W.P. and Metcalf, W. Experimental shock; effects of a cute hemorrhage in healthy dogs. Bull. John Hopkins Hospital <u>69</u>:327, 1941.
- 133. Randall, H.T. Water and electrolyte balance in surgery. Surg. Clin. N. Amer. <u>32</u>:1, 1952.
- 134. Ravdin, I.S. and Ravdin, R.G.
  Collective review: shock, fluid and electrolytes, 1905-1955.
  International Abstracts of Surgery, <u>100</u>:101, 1955.
- 135. Ravdin, I.S., Walker, J.M. and Rhodes, J.A. Blood volume maintenance and regulation. Ann. Rev. Physiol. <u>15</u>:165, 1953.
- 136. Reeve, E.B. Methods of estimating plasma and total red cell volume. Nutrition Abstracts and Rev. <u>17</u>:811, 1948.
- 137. Reeve, E.B. Use of radioactive phosphorus for the measurement of red cell and blood volume. Brit. Med. Bull. <u>8</u>:181, 1952.
- 138. Reeve, E.B., Gregersen, M.I., Allen, T.H. Sear, H. and Walcott, W.W. Effects of alteration in blood volume and venous hematocrit in splenectomized dogs and in the estimates of total blood volume with P<sup>32</sup> and T-1824. Amer. J. Physiol. <u>175</u>:204, 1953.

- 139. Reeve, E.B., Gregersen, M.I., Allen, T.H., Sear, H. and Walcott, W.W. Validity of cell and blood volume measurements in the bled splenectomized dog. Amer. J. Physiol. <u>175</u>:211, 1953.
- 140. Reeve, E.B., and Beall, N. A simplified method for the determination of circulating red cell volume with radioactive phosphorus. J. Physiol. <u>108</u>:12, 1949.
- 141. RISA. Iodinated (I<sup>131</sup>) serum albumin (human). Pamphlet published by Abbott Laboratories. North Chicago, Illinois, 1953.
- 142. Roberts, L.N., Smiley, J.R., Sears, C.A. and Manning, G.W. Plasma volume measured by iodinated albumin and T-1824. C.M.A.J. <u>69</u>:510, 1953.
- 143. Robinow, M. and Hamilton, W.F. Blood volume and extracellular fluid volume of infants and children. Amer. J. Dis. Child. <u>60</u>:827, 1940.
- 144. Rowntree, L.G., Brown, G.E. and Roth, G.M. The Volume of the Blood and Plasma in Health and Disease. Philadelphia, W.B.Saunders Company, 1929.
- 145. Royster, H.P., Pendergrass, H.P., Walker, J.M. and Barnes, M. The value of blood volume determinations in radical operations for cancer of the head and neck, including measurements of operative blood loss. Ann. Surg. 133:830, 1951.
- 146. Russell, S.J.M. Blood volume studies in healthy children. Arch. Dis. Child. 24:88, 1949.
- 147. Rydin, H. and Verney, E.B. The inhibition of water diuresis by emotional strain and by muscular exercise. Quart. J. Exper. Physiol. 27:343, 1938.
- 148. Sayen, J.J., Sheldon, W.F., Kuo, P.T., Zinsser, H.F., Horwitz, O. and Sumen, A.F. Favorable effects of L-Norepinephrine on experimental localized ischemia of the myocardium. J. Clin. Invest. <u>31</u>:658, 1952.
- 149. Schlenker, F.S. and Noll, J. On the determination of packed cell volume. Jour. Lab. & Clin. Med. <u>39</u>:582, 1952.
- 150. Schreiber, S.S., Bauman, A., Yalow, R.S., and Berson, S.A. Blood volume alterations in congestive heart failure. J. Clin. Invest. <u>33</u>:578, 1954.
- 151. Schultz, A.L., Hammarsten, J.F., Hiller, B.I., and Ebert, R.V. A critical comparison of the T-1824 and iodinated albumin methods for plasma volume measurement. J. Clin. Invest. <u>32</u>:107, 1953.
- 152. Sear, H., Allen, T.H. and Gregersen, M.I. Simultaneous measurement in dogs of plasma volume with I<sup>131</sup> human albumin and T-1824 with comparison of their long term disappearance from the plasma. Amer. J. Physiol. <u>175</u>:240, 1953.

- 153. Seeley, S.F. and Pulaski, E.J. The plasma substitutes: progress report. Amer. J. Surg. <u>85</u>:382, 1953.
- 154. Seeves, J.F. and Latchem, C.W. A table for determination of blood loss during transurethral prostatic resection. Proc. Staff Meeting, Mayo Clinic <u>20</u>:151, 1945.
- 155. Sheldon, W.H., Stevens, S.S. and Tucker, W.B. The Varieties of Human Physique. New York, Harper, 1940.
- 156. Sibley, W.L. and Lundy, J.S. Blood volume and hemoglobin after transfusion. Surg. Gyn. & Obst. <u>67</u>:490, 1938.
- 157. Siler, V.E. and Fultz, C.T. Evaluation of blood volume determination in severe hemorrhage using radioactive iodinated human serum albumin. Fundamental Forum, Amer. Coll. of Surgeons, 1953.
- 158. Smith, D.W. Specific transfusion therapy. Surgery <u>33</u>:525, 1953.
- 159. Smith, H.P., Arnold, H.R. and Whipple, G.H. Blood volume studies. VII. Comparative values of Welcker, carbon monoxide and dye methods for blood volume determinations. Accurate estimates of absolute blood volume. Amer. J. Physiol. <u>56</u>:337, 1921.

160. Squire, J.R., Bull, J.P., Maycok, W.d'A. and Ricketts, C.R. Dextran: Its Properties and Use in Medicine. Oxford, Blackwell Scientific Publications, 1955.

161. Sterling, K. The turnover rate of serum albumin in man as measured by Il31-tagged albumin. J. Clin. Invest. <u>30</u>:1228, 1951.

- 162. Sterling, K. Serum albumin turnover in Laennec's cirrhosis as measured by I<sup>131</sup> -tagged albumin. J. Clin. Invest. <u>30</u>:1238, 1951.
- 163. Sterling, K. and Gray, S.J. Determinations of the circulating red cell volume in man by radioactive chromium. J. Clin. Invest. <u>29</u>:1614, 1950.
- 164. Stewart, J.D. and Rourke, G.M. Intracellular fluid loss in hemorrhage. J. Clin. Invest. <u>15</u>:697, 1936.
- 165. Stirrett, L.A., Yuhl, E.T. and Libby, R.L. A new technique for the diagnosis of carcinoma metastatic to the liver. Surg. Gyn. & Obst. <u>96</u>:210, 1953.
- 166. Storaasli, J.P., Krieger, H., Friedell, H.L. and Holden, W.D. The use of radioactive iodinated plasma protein in the study of blood volume. Surg. Gny. & Obst. <u>91</u>:458, 1950.

- 167. Strumin, M.M., Blake, A.D. and Wicks, W.A. Preservation of whole blood. J. Clin. Invest. <u>26</u>:667, 1947.
- 168. Talbot, T.R., Jr. Blood transfusions. Surg., Gyn. & Obst. <u>93</u>:411, 1951.
- 169. Taylor, H.L., Erickson, L., Henschel, A. and Keys, A. The effect of bed rest on the blood volume of normal young men. Amer. J. Physiol. <u>144</u>:227, 1945.
- 170. Thomas, L.B., Adams, W.E. and Thornton, T.F., Jr. Alterations of the blood following intrathoracic operations. Surgery <u>20</u>:38, 1946.
- 171. Thompson, W.O., Thompson, P.K. and Dailey, M.E. The effect of posture upon the composition and volume of the blood in man. J. Clin. Invest. <u>5</u>:573, 1927.
- 172. Turner, F.P., Butler, B.C., Smith, M.E. and Scudder, J. Dextran; an experimental plasma substitute. Surgery, Gyn. & Obst. <u>88</u>:661, 1949.
- 173. Tyer, M.P., Aikawa, J.K. and Cayer, D. Measurements of the disappearance of radioactive tagged albumin from serum and the excretion of I 131 in the urine of patients with cirrhosis. Gastroenterology, <u>21</u>:79, 1952.

- 174. Vazquez, O.N., Newerly, K., Yalow, R.S. and Berson, S.A. Determination of trapped plasma in the centrifuged erythrocyte volume of normal human blood with radio-iodinated (I<sup>131</sup>) human serum albumin and radio-sodium (Na<sup>24</sup>). J. Lab. and Clin. Med. <u>39</u>:595, 1952.
- 175. Verney, E.B. Absorption and excretion of water; the antidiuretic hormone. Lancet 2:739, 1946.
- 176. Verney, E.B. The antidiuretic hormone and the factors which determine its release. Proc. Roy. Soc. <u>B 135</u>:25, 1947.
- 177. Walcott, W.W. Blood volume in shock. Amer. J. Physiol. <u>143</u>:247, 1945.
- 178. Wallace, J. and Sharpey-Schafer, E.P. Blood changes following controlled hemorrhage in man. Lancet <u>2</u>:393, 1941.
- 179. Walters, S. Inactivity as a factor in erythrocyte and hemoglobin variations. Amer. J. Physiol. <u>105</u>:96, 1933.
- 180. Wangensteen, O.H. The controlled administration of fluid to surgical patients: including description of gravimetric methods of determining status of hydration and blood loss during operation. Minnesota Med. <u>25</u>:783, 1942.

181.	Warren, J.V., Merrill, A.J., and
	Stead, E.H., Jr.
	The role of extracellular fluid in the main-
	tenance of a normal plasma volume.
	J. Clin. Invest. <u>22</u> :635, 1943.

- 182. Wasserman, K. and Mayerson, H.S. Exchange of albumin between plasma and lymph. Amer. J. Physiol. <u>165</u>:15, 1951.
- 183. Watson-Jones, R. Factures and Joint Injuries, Volume I. Edinburgh and London, E. & F. Livingstone, 1952.
- 184. Weil, P.G. and Baldry, R.E. Plasma expanders in surgical shock. Canad. Serv. Med. Jour. <u>10</u>:293, 1954.
- 185. Whipple, A.O. Halsted's New York period. Surgery <u>32</u>:542, 1942.
- 186. Whipple, G.H. and Madden, S.C. Hemoglobin, plasma protein and cell protein: their interchange and construction in emergencies. Medicine 23:215, 1944.
- 187. White, M.L., Jr. and Buxton, R.W. Blood loss in thoracic operations. J. Thoracic Surg. 12:198, 1942.
- 188. Whiting, J.A. and Hotz, R. An evaluation of the Evans blue dye T-1824 method for studying the circulating blood volume. Surg. Gyn.& Obst. <u>97</u>:709, 1953.

- 189. Widdowson, E.M. and McCance, R.A. The effect of rest in bed on blood volume as indicated by hemoglobin and hematocrit values. Lancet <u>1</u>:539, 1950.
- 190. Wiggers, C.J. Physiology of Shock. New York, The Commonwealth Fund, 1950.
- 191. Wilson, W.C. Blood volume in surgical disorders. Edin. Med. J. <u>57</u>:30, 1950.
- 192. Wintrobe, M.M. Clinical Hematology. Philadelphia. Lea and Febiger, 1946.
- 193. Wish, L., Furth, J. and Storey, R.H. Direct determinations of plasma, cell and organ-blood volumes in normal and hypervolemic mice. Proc. Soc. Exper. Biol. and Med. <u>74</u>:644, 1950.
- 194. Yuhl, E.T., Stirrett, L.A. and Libby, R.L. A comparative study of the use of diiodofluorescein and iodinated human serum albumin for the diagnosis and localization of intracranial neoplasms. Ann. Surg. <u>137</u>:184, 1953.